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Abstract 
Chronic kidney disease globally affects 10% of the population with fibrosis being one of the 
hallmarks of disease progression. Renal fibrosis is characterised by a change in the extracellular 
matrix (ECM) that can lead to tissue remodelling and organ loss. Throughout this process the 
kidney is exposed to damaging cytokines and growth factors. Heparan Sulfate (HS) proteoglycans 
present on the ECM and cell membranes play a crucial role in protecting, storing and presenting 
these cytokines and growth factors to the surrounding cells. This study focuses on HS sulfation and 
the enzymes modulating it, particularly HS 3-O-sulfotransferases (HS3ST), in the context of renal 
fibrosis.   
Initially, this work used an in vivo murine model of renal fibrosis to assess changes in HS sulfation 
during disease progression. The amount of HS total O-sulfation and particularly 2-O-sulfation were 
increased. HS 3-O-sulfation was localised on the basal membrane of tubules and more intensively 
on blood vessels and the glomerulus. In this model, the level of mRNA encoding HS3ST1, 
Sulfatase 1 and HS2ST1 was increased, whilst HS3ST3A was decreased. Amongst all enzymes 
studied, HS3ST1 displayed the strongest correlation with collagen deposition during fibrosis. The 
generation of renal epithelial cells overexpressing HS3ST1 enabled the identification of a 
differential signalling pattern of Heparin Binding Epidermal Growth Factor like growth factor (HB-
EGF) in cells with higher HS 3-O-sulfation.  Additionally, this project found that pro-fibrotic 
factors downregulated HS3ST1 expression in human renal epithelial cells and rat renal fibroblasts.  
Finally, this project attempted to generate competing peptides and peptoids for Fibroblast Growth 
Factor 2 (FGF2) binding to renal epithelial cells. Although peptides and peptoids were found to 
bind to heparin by isothermal titration calorimetry, no binding competition was observed in vitro. 
However, the peptides and peptoids studied did emphasise the importance of secondary structure 
in the binding of HS to protein.  
Overall this highlights the complexity of HS modification during fibrosis. This work emphasises 
the need to study HS3ST in inflammation as it seems to be a potential marker of fibrosis. 
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1.1 Rationale for this study 
Healing processes allow the body to repair and regenerate itself in a well-orchestrated and 
coordinated manner involving actions of pro- and anti-inflammatory molecules. The extracellular 
matrix which surrounds and supports the cells within a tissue is in a dynamic equilibrium between 
synthesis and degradation. This balance is challenged during inflammation which can lead to the 
uncontrolled accumulation of extracellular matrix within an organ if unresolved. This process, 
called fibrosis, can develop in most organs and drive organ failure. To date, it is irreversible.  
Renal fibrosis is one of the main features in chronic kidney diseases (CKD) and chronic graft 
rejection. Understanding and targeting it has therefore become one of the biggest challenges in 
modern medicine.  Glycosaminoglycans (GAGs) which are carbohydrate molecules that are found 
on all cells membranes and matrices are important in cell to cell and cell-matrix interaction. 
Heparan Sulfate (HS) is a GAG that plays a pivotal role in the initiation of inflammation and 
fibrosis with the ability to trigger leukocyte attraction, chemokine and growth factor binding and 
signalling. The science of studying GAGs is complex and still emerging with the development of 
new analytical tools. This study was designed to improve understanding of the changes in HS in 
fibrosis and their potential use in therapy. The following introduction highlights first the basics 
about kidney structure/function and the development and management of CKD. Second, GAG 
synthesis and involvement in renal homeostasis is described with a focus on HS. 
 
1.2 Renal homeostasis 
1.2.1 Kidney: origin and structure  
In human development, the urogenital system originates from the intermediate mesoderm. Kidney 
formation starts with two primitive forms, the pronephros and the mesonephros that develop in 
early stages, around day 22 and day 25 of gestation but regress later on (Gilbert, 2000). While the 
mesonephros degenerates completely in female, some parts of the male reproductive system are 
derived from mesonephric tubules (Michos, 2009). The metanephros represents the third and 
final stage of kidney development. It requires the interaction between the epithelial ureteric bud 
and the metanephric mesenchyme. Together they induce cell survival, specification and spatial 
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organisation. The metanephric mesenchyme will become the nephron while the ureteric bud will 
become the collecting duct (Lechner and Dressler, 1997). In utero, fetal kidneys become 
functional at about 14 weeks and produce 90% of the amniotic fluid after 20 weeks (Vanderheyden 
et al., 2003).  
Each kidney is surrounded by a fibrous capsule and adipose tissue for protection. Blood supply 
comes into the kidney via the abdominal aorta and leaves it via the inferior vena cava. The kidney 
is composed of 3 regions, the renal cortex which is the outer and darker area (due to increased 
perfusion representing 90% of renal blood flow), the renal medulla, composed of striated pyramids, 
and finally the renal pelvis where urine is collected and directed to the ureter. The renal structure 
is displayed Figure 1-1. 
 
Figure 1-1: Kidney structure 
Figure created using Servier Medical art. 
 
1.2.2 Kidney function  
Kidneys are responsible for urine production, fluid and electrolyte homeostasis. The functional 
unit of the kidney is called nephron. It is composed of the glomerulus and Bowman’s capsule which 
plays a role in filtration and a renal tubule to collect and concentrate urine (see Figure 1-2). On 
General introduction 
 
3 
average, there are approximately 1 million nephrons per kidney but this number can vary up to 10 
times between individuals (Bertram et al., 2011). Blood reaches the nephron via the afferent 
arteriole. The arteriole subdivides into small capillaries where a permeable fenestrated endothelium 
initiates the filtration process. The glomerular epithelial cells are specialised cells named podocytes 
because of their elongated foot look like cytoplasm. The endothelial cells and podocytes share a 
basement membrane rich in fibers and proteoglycans (Haraldsson et al., 2008). The glycocalyx on 
both cell types has been suggested to play a role in the filtration process. The efferent arteriole 
leaves the glomerulus but stays close to the nephron to reabsorb ions and water from the filtrate 
(vasa recta).   
 
Figure 1-2: Glomerular structure 
The glomerulus is the filtration unit of the kidney. Blood is reaching the glomerulus’ capillaries 
via the afferent arteriole and leaves via efferent arterioles. Blood is filtered through a fenestred 
endothelium, reaches the Bowman’s space and is further processed through the tubules. The 
endothelium and the glomerular epithelial cells, the podocytes, share the same basemement 
membrane enriched in proteoglycans and fibers.  
Additionally, kidneys are in control of blood pressure, acid-base balance and vitamin D 
metabolism. They are responsible for the production and release of renin and erythropoietin which 
impact blood pressure and haematocrit respectively (Lote, 2013). The blood flow is important for 
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the glomerular filtration rate and is detected by specialised cells named juxtaglomerular cells. 
These cells secrete renin when blood flow is too low which leads to the activation of the Renin-
Angiotensin system to regulate blood pressure. 
 
1.2.3 Renal diseases 
Kidney diseases can be acute or chronic depending on their duration. Even though Acute Kidney 
Injuries (AKI) can sometimes lead to the development of chronic diseases, AKI can be reversible 
if the cause of the damage is identified and treated. As seen Figure 1-3 it can start from diseases 
that are not initially related to the kidney.  
  
Figure 1-3: Acute kidney injury causes and examples  
Acute kidney injuries can be due to prerenal injuries as a consequence of a change in renal blood 
flow, due to postrenal injury with an obstructed urinary tract or due to intrarenal injury. Figure 
created using Servier Medical art. 
 
Pre-renal injuries are caused by the obstruction or alteration of renal blood flow by hypovolemia 
(loss of fluid), impaired cardiac output and vascular damages. Post-renal injuries originates from 
the obstruction of the urinary tract by benign prostate hyperplasia, renal stones and intra-abdominal 
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tumors (Thadhani et al., 1996; Basile et al., 2012). Pre and post renal injuries can all lead to the 
development of intra kidney inflammation. Intrarenal injuries including glomerulonephritis, 
tubular necrosis, interstitial nephritis represent 35-70% of AKI and can be due to direct damage, 
inflammation, infection, drugs and auto immune diseases (Basile et al., 2012). 
On a cellular level, kidney injuries trigger cell stress and differentiation. Pathologies related to 
podocyte dysfunction can be observed by podocyte deficiency, foot process effacement, or 
podocyte dysfunction (Wiggins, 2007). Additionally, renal function correlates best to tubular 
integrity and the extent of tubulointerstitial fibrosis (Hewitson and Becker, 1995). Following an 
injury, tubular cells can undergo necrosis, apoptosis or an epithelial to mesenchymal transition-like 
process. The tubular epithelial cells proliferate migrate and contribute to disease progression (Liu, 
2004). Furthermore, resident fibroblasts can transform into myofibroblasts and secrete pro fibrotic 
ECM components. Activated myofibroblast are a marker of disease progression (López-Novoa et 
al., 2011). 
 
1.2.4 Diagnosis and factors of risk 
Early stage renal diseases are asymptomatic which makes them difficult to detect before late stages. 
The clinical signs only emerge when nephron function is lost, the glomerular filtration rate has 
dropped and urine outpout decreased. The body retains waste with an increase of urea in the blood 
(uremia) and there is protein loss in the urine (proteinuria). 
A marker of reduced filtration is the presence of waste molecules in the blood such as creatinine, 
a molecule made during muscle activity. Additionally a good indicator of kidney function is the 
presence of essential molecules in the urine such as albumin, a protein found in the serum and 
essential for blood osmotic pressure (Baker, 1998). A screening programme would include a 
metabolic profile assessment, calculating glomerular filtration rate, and urinalysis (Woodhouse et 
al., 2006). Kidney diseases can be classified by glomerular filtration rate (see Table 1-1) and 
urinary albumin to creatinine ratio. 
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Table 1-1: Classification of AKI and CKD  
From (Chawla et al., 2014). A more accurate classification would include the urinary albumin to 
creatinine ratio. GFR: glomerular filtration rate. 
Diabetes and hypertension are leading causes of end stage renal disease (Ghaderian et al., 2015). 
Patients with hypertension have thicker vessels with a decreased luminal volume that diminish 
kidney blood flow. A reduced blood flow to the kidney leads to the activation of the renin 
angiotensin system which further increases hypertension. The resulting deprivation of blood supply 
to the kidney leads to a decrease in nutrients and oxygen and can generate ischemic injuries. As 
seen previously, ischemia is one of the main cause of intrarenal injuries. During renal injury, pro 
fibrotic growth factors such as Transforming Growth Factor β1 (TGFβ1) are secreted (Bobik, 2004) 
and stimulate production of extracellular matrix which generates scar tissue and causes 
tubulointerstitial fibrosis and glomerulosclerosis that diminish nephron function.  
In diabetic patients, hyperglycemia and oxidative stress induce vascular remodelling and podocyte 
apoptosis (Susztak et al., 2006). Furthermore, hyperglycemia generates advanced glycation end 
products which can alter the diabetic vessel wall composition and cause endothelial dysfunction. 
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These structural and cellular change can induce kidneys hypoperfusion and altered renal recovery 
from ischemia and can cause intrarenal damage (Spinetti et al., 2008). Additionally, in the late 
1990s smoking was found associated with high risks of early stage renal disease (ESRD) (Klag et 
al., 1996). 
Complications of CKD involve cardiovascular disorder mainly due to the development of 
hypertension and electrolytes abnormalities such as hyperkalemia which can cause cardiac 
arrhythmias. Furthermore, patients can develop hypocalcemia and have weak bones due to less 
activation of vitamin D (Nigwekar et al., 2014). Toxin accumulation and anemia as CKD reduces 
erythropoietin synthesis can also be observed (Bello et al., 2017). 
 
1.3 Management of chronic kidney diseases 
1.3.1 Early stages of chronic kidney diseases 
For patients with hypertension, blood pressure and proteinuria can be controlled by anti-
hypertensive drugs such as angiotensin-converting enzyme inhibitors, angiotensin receptors 
blockers or a change in diet. Overall, a change in  patients life style can be recommended with a 
low protein diet, less salt, smoking cessation, more exercise and a moderate consumption of alcohol 
(Saweirs and Goddard, 2007). Furthermore, the control of glycaemia levels in diabetic patients and 
lipid-lowering therapy for patients that have not started dialysis are potential therapies (Kaysen, 
2017). For patients with anemia, erythropoiesis-stimulating agents can be used. Unbalanced 
electrolytes such as phosphate can be overcome with the use of phosphate binders or a controlled 
diet. 
 
1.3.2 Renal failure: dialysis and transplantation 
Treatments of end stage renal disease, also called renal failure, are limited. Patients can undergo 
dialysis or kidney transplant. It was in 1944 that the first machine capable of blood filtration was 
created by Willem J. Kolff. There are now two types of dialysis, Hemodialysis and peritoneal 
dialysis (Queeley and Campbell, 2018). Even though patients’ survival is increased with dialysis, 
there are lots of side effects and limitations to it. It is time consuming, tiring, associated with 
infections and cardiovascular disease.  
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The second option, renal transplantation, is generally accepted as the best option for better life 
quality with early graft survival improving over the last decades. The first successful kidney 
transplantation in animals were performed by Emerich Ullmann in 1902, Vienna with a dog 
autotransplant and a dog-to-goat xenograft (Ullman, 1914). It was 4 years later that the first 
transplantation in human was performed by Mathieu Jaboulay in Lyon with a pig and a goat kidney 
being grafted into the patients’ fold of elbow (Jenkins, 1906). However, the grafts survived for only 
hours or few days and patients died quickly after. The development of our knowledge of 
immunology and rejection, with the first successful transplant performed in the mid-20th century, 
between twins and the introduction of immunosuppressive drug therapy were major advances and 
improved patients survival (Murray et al., 1955, 1984).  
In the UK, renal graft survival is 85-95% at one year, falling to 70-80% after 5 years. Improving 
long term graft survival is now the major challenge with survival only 50-60% after 15 years. In 
fact, ten years after transplantation, more than 50% of patients have progressive chronic renal graft 
dysfunction (Nankivell et al., 2003). Due to graft rejection, it is not unusual for patients to need 
more than one transplant during their life. Despite the decrease in waiting time for patients in need 
of a transplant, there are still hundreds of patients dying while waiting (NHS Blood and 
transplantation data 2017). Preserving the donor kidney’s integrity and limiting damage during 
transplantation would increase the patients’ quality of life and help decrease the shortage in organs. 
New techniques to better assess kidney function and increase organ quality prior to transplant are 
being developed such as normothermic perfusion, a technique being explored at Newcastle 
University. This could allow more organs to be transplanted with potentially less complications 
(Hosgood et al., 2018). 
 
1.3.3 Origins of graft injury after transplantation 
Integrity of the transplant organ depends firstly on the donor’s health status and age. Additionally, 
surgical procedures can generate cellular stress. Damage from the time of retrieval, time outside 
the body, temperature, ischemia reperfusion injury and surgical complications are factors 
contributing to graft dysfunction. After transplantation, the kidney is still subject to injury from 
hemodynamic changes that lead to glomerular hypertension, urinary infection and drug toxicity all 
of which could impair kidney function. For example, the use of calcineurin inhibitors is pro-
fibrotic. The recipient immune system is also a source of organ damage. Vascular insufficiency 
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can be caused by immune mediated injury due to reactivity against human leukocyte antigen (HLA) 
and non-HLA antigens on endothelial cells. Patients with anti-HLA antibodies are more likely to 
develop chronic rejection compared to renal transplant recipients without these antibodies 
(McKenna et al., 2000; Süsal and Opelz, 2002). 
 
1.3.4 Early events in transplantation 
Organ retrieval triggers different types of stress in the kidney. First the kidney is subjected to 
ischemia as soon as the surgeon clamps the arterial blood supply. The decrease in oxygen and 
nutrients induces a decrease in the energy supplied to the cells and an increase in Reactive Oxygen 
Species (ROS). The activation of hypoxia induced factor mediates endothelial damages which can 
lead to cell death (Situmorang and Sheerin, 2018). Second, the organ is subjected to mechanical 
injuries during manipulation. These injuries generate an inflammatory response. Additionally, 
when the organ is transplanted, reperfusion which allows blood flow to go through the kidney 
generates an increase in Reactive Nitrogen Species (RNS) and ROS and opening of mitochondrial 
pore leading to cell death.  
Therefore, when the graft is in place, the organ has been through a lot of physiological stresses and 
cytokines and growth factors that trigger inflammation have been released. They create a 
chemotactic environment and induce cell recruitment (Sherwood and Toliver-Kinsky, 2004). The 
first leukocytes to be recruited to the graft are neutrophils (de Oliveira et al., 2016). They are the 
most abundant leukocytes in the blood and infiltrate injured area very quickly, followed by 
monocytes, which differentiate to become macrophages that start wound repair (Koh and DiPietro, 
2011). 
Multiple tissue remodeling factors (proteases, growth factors, matrix metalloproteinases), vascular 
mediators (prostaglandins) and cytokines are secreted by macrophages and contribute to wound 
repair by triggering cell infiltration, remodeling, and extracellular matrix (ECM) accumulation 
(Koh and DiPietro, 2011). Numerous cells, such as T cells, macrophages and mast cells, secrete 
pro-fibrotic factors (Meng et al., 2014). Increased cell division can be observed in renal healing 
(Hewitson and Becker, 1995) that can be explained by the proliferation of fibroblasts inside the 
tissue to provide ECM proteins. This is called fibrogenesis and it takes place as long as the 
fibroblasts are present. If the inflammation is not stopped tissue destruction and scar tissue 
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accumulation will continue, leading to organ dysfunction and loss. The presence of inflammatory 
stimuli, pro-fibrotic factors, the continuous infiltration and/or the persistence of inflammatory cells 
prevent the termination of inflammation. What was an attempt from the body to heal transforms 
into an uncontrolled process leading to disruption of structure and function. 
 
1.3.5 Acute and Chronic Rejection 
The follow up after a transplantation needs to assess kidney function by analysing glomerular 
filtration rate (Kasiske et al., 2002). Following transplantation, a biopsy of the organ provides 
histological information about vascular, tubular and glomerular inflammation, tubular atrophy and 
lymphocyte infiltration. The Banff classification can help determine the state of the organ. It is an 
international classification for renal transplant histology that looks at the evolution of graft 
inflammation. Since 2007 there are 5 categories (Table 1-2). 
The new organ is seen as foreign material by the body and to prevent acute rejection, patients 
receive immunosuppressive treatment that target cytokine-mediated T cell and antigen presenting 
cell activation and proliferation; First, corticosteroids down-regulate IL2 and IL2 receptor 
expression in T cells (Daynes and Araneo, 1989; Paliogianni et al., 1993) and IL1β, IL6 and TNFα 
expression in monocytes and macrophages (Breuninger et al., 1993; Linden and Brattsand, 1994; 
Steer et al., 1997). Calcineurin inhibitor and antiproliferative drugs are responsible for T cell 
inhibition.  
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1 normal No rejection detected 
2 Antibody mediated rejection Antibody mediated graft injury with C4d staining in the 
glomerulus and peri-tubular capillaries. Associated with 
capillary vascular or glomerular inflammation, acute 
tubular necrosis or chronic injury (including IFTA). 
3 Borderline changes Interstitial lymphocyte infiltrates with minor tubulitis 
and no intimal arteritis 
4 T cell mediated rejection Significant interstitial, tubular inflammation and/or 
intimal inflammation. Chronic arteriopathy also 
included. 
5 Interstitial fibrosis and 
tubular atrophy  
In the absence of another pathology. Grade I mild 25% 
of cortical area, Grade II 26 to 50% cortical area and 
grade III when more of 50% of cortical area is affected. 
6 Other Changes that are not caused by rejection 
 
Table 1-2: Classification of renal allograft rejection 
From (Ferreras et al., 2015) and (Solez et al., 2008). 
 
1.4 The Extracellular Matrix 
The extracellular matrix (ECM) is acellular and functions as a mechanical support to all tissues. 
The composition and proportion of fibrous proteins and proteoglycans in the ECM determine its 
structure and is unique to every tissue (Frantz et al., 2010). The body has to maintain a healthy 
balance between degradation and synthesis of the ECM components mediated by the activity of 
matrix metalloproteinases and their inhibitors. An abnormal overproduction of ECM leads to a stiff 
tissue that can lose its function (Figure 1-4). As mentioned previously, this process is called fibrosis 
and can affect almost all organs. In western countries, chronic fibro-proliferative diseases are 
responsible for about 45% of all deaths (Wynn, 2007). The main components that will be described 
in this section are collagens, elastin, glycoproteins and proteoglycans. 
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Figure 1-4: Matrix Remodelling during fibrosis 
The process of fibrosis leads to the overproduction of ECM components such as fibrous proteins 
and HSPG generating a stiff environment within the organ. Dilated and/or atrophic tubules can be 
observed. Fibroblasts play an important role by becoming activated into myofibroblasts and 
secreting pro-fibrotic growth factors such as FGF2. Figure created using Servier Medical art. 
 
1.4.1 Collagens and elastin 
Collagens are the major fibrous glycoproteins with a characteristic triple helix representing 10 to 
96% of their structure (Ricard-Blum, 2011). So far 28 types have been discovered. They can be 
classified as fibril-forming collagens (I, II, III, V, XI, XXIV, XXVII), fibril-associated collagens 
with interrupted triple helices (IX, XII, XIV, XVI, XIX, XX, XXI, XXII), network-forming 
collagens (IV, VIII, X) membrane collagens (XIII, XVII, XXIII, XXV), multiplexins (XV, XVIII) 
and collagen VI, VII, XXVI, XXVIII. In tissues the predominant collagen is fibrillary. Collagen is 
not only important for tissue structure but also for cell migration, differentiation and receptors 
activation (Hynes, 2009). Type IV collagen is the main component of the GBM (Miner, 1999). 
Urinary concentration of collagen IV is associated with kidney function in type 1 and type 2 
diabetes (Okonogi et al., 2001; Morita et al., 2011). Furthermore collagen IV immunostaining is 
increased in chronic transplant nephropathy (Kawase et al., 2001). The kidney interstitial ECM is 
mainly composed of collagen I, III, V, VI, VII and XV and the abnormal accumulation of collagen 
in the interstitium is one characteristic of renal fibrosis (Farris and Colvin, 2012) which will be 
further described later.  
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The ECM elasticity is mainly regulated by the presence of elastin, a protein synthesised and 
secreted as protoelastin and later cross-linked by lysyl oxidase to forms elastic fibers. In a uremic 
mouse model of CKD, elastin degradation was implicated in vascular calcification (Pai et al., 2011) 
but these observations were not found in human patients (Schlieper et al., 2010). 
 
1.4.2 Glycoproteins and Proteoglycans 
Glycoproteins are proteins bound to oligosaccharides. One important glycoprotein located in the 
ECM is fibronectin. It binds to collagen, heparin and cells receptors and is therefore important for 
cell migration (Yue, 2014). Fibronectin is secreted during the development of renal fibrosis and 
contributes to disease progression (Liu, 2015). Inhibiting fibronectin deposition has been shown to 
improve liver function in a murine model of liver fibrosis (Altrock et al., 2015). Hence, fibronectin 
is a promising target for fibrosis treatment.  
Proteoglycans (PG) are composed of a core protein covalently bound to glycosaminoglycans 
(GAGs).  GAGs are linear polysaccharides made of repeating blocks (Esko et al., 2009). PGs are 
considered as the reservoir of the ECM due to their ability to bind growth factors. They can create 
gradients and act as coreceptors which make them ideal targets for drug development. PGs can be 
divided into three groups: membrane bound, secreted and intracellular PGs.  
Membrane-bound PGs include syndecans, Cluster of Differentiation CD44v3, CD47, betaglycan, 
neuropillin1, glypicans, Protein Tyrosine Phosphatase, thrombomodulin, neuron-glial antigen 2 
and synaptic Vesicle protein 2. Secreted PGs include the aggrecan family, Small Leucine-Rich 
Proteoglycan family, collagen type IX, 2 chain, perlecan, agrin, collagen XVIII. Finally, 
intracellular PGs include serglycin which are found in granules of hematopoietic cells and can be 
secreted  (Lindahl et al., 2015). PGs generated from the binding of a core protein to Heparan Sulfate 
and their functions is shown Table 1-3. 
PGs have multiple functions. They can facilitate the binding of FGF family members to receptors, 
bind to chemokines, enable cell adhesion and cell spreading (Iozzo, 2001; Ferreras et al., 2015; 
Iozzo and Schaefer, 2015). They are also involved in the clearance of lipoproteins. Additionally, 
Proteoglycans can be internalised by endocytosis and degraded in the lysosome. This degradation 
is essential to maintain homeostasis. A lack of degrading enzymes can lead to diseases such as 
mucopolysaccharidosis. 
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PGs turnover happens by cleavage of the core protein through the activity of metalloproteases, by 
cleavage of HS by heparanase or membrane endosulfatases and by endocytosis. Most of the 
resulting glycans will be further degraded in lysosomes. It is hypothesised that heparanase and 
metalloprotease activities are implicated in ECM remodelling (Lindahl et al., 2015).   
The GAGs composing PGs are essential for their activities as they provide negative charges that 
are essential for protein binding. It is noteworthy that not all GAGs are bound to a protein.  
 
HSPG type localisation function 
Perlecan S basement membranes, other ECM, 
cartilage 
ECM assembly, cell migration, binds growth factors 
Agrin S basement membranes, brain, 
neuromuscular junctions 
neuromuscular junction, ligand 
Collagen 
XVIII 
S basement membrane basement membrane function 
Syndecan (1-
4) 
M most cells cell adhesion, migration cytoskeletal organisation, 
ligand clearance 
Betaglycan M fibroblasts coreceptor, TGFß1 signalling 
Glypican (1-6) M epithelial, mesenchymal cells, brain coreceptor 
CD44 M most cells hyaluronan and growth factor receptor 
Serglycin I mast cells, leukocytes, endothelial cells coagulation, wound repair, granule formation, support 
protease activity 
 
Table 1-3: HSPGs localisation and function 
Adapted from (Esko et al., 2009) S: secreted, M: membrane, I: intracellular 
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1.5 Glycosaminoglycans 
There are 6 different groups of GAGs, which are mostly linear and negatively charged. They are 
classified according to the monosaccharides composing their repeating disaccharides (Figure 1-5). 
It was in the early 20th century that Karl Meyer discovered hyaluronan (previously called 
hyaluronic acid) (Meyer and Palmer, 1934), dermatan sulfate (Meyer and Chaffee, 1941), keratan 
sulfate (Meyer et al., 1953) and some forms of chondroitin sulfate (Meyer et al., 1956) while Jorpes 
and Gardell identified heparin and heparan sulfate structures (Jorpes and Gardell, 1948). In the 
middle of the 20th century, isolation and analysis methods for proteoglycans allowed scientists to 
discover that proteoglycans are found in the ECM, inside the cell and on cell surfaces. GAGs are 
synthesised in the ER-Golgi system, except hyaluronan which is made at the plasma membrane. 
Even though the protein core of PG regulates localisation, quantity and time of expression, the 
presence of GAGs bearing negative charges is important for ligand interaction.  
 
Figure 1-5: GAGs structure and features 
From (Prestegard et al., 2015) Iduronic acid (IdoA), N-acetylglucosamine (GlcNAc), N-
acetylgalactosamine (GalNAc), Galactose (Gal), Glucuronic acid (GlcA). 
 
 
1.5.1 Hyaluronan 
Hyaluronan (previously named hyaluronic acid) was originally isolated from bovine vitreous 
(hualos glass in greek). Hyaluronan (HA) can be present in two forms, hyaluronic acid or as sodium 
hyaluronate in physiological conditions hence the new termination (Balazs et al., 1986). 
Remarkably, amongst all GAGs, HA is the simplest of all with no sulfation, no core protein 
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attached and not being synthesised in the Golgi apparatus (Fraser et al., 1997; Stern, 2004). HA 
binds to other components of the ECM or to cell surface receptor such as CD44. HA is mainly 
found in skin, synovial fluid, vitreous body, and muscles. 
Three different hyaluronan synthase enzymes (HAS1, 2, 3) can independently synthesise 
hyaluronan at the plasma membrane and excrete it in the extracellular space, with HAS2 generating 
the largest hyaluronan molecules (Itano and Kimata, 2002). HA is composed of 250 to 25,000 
repeating units of N-acetylglucosamine and D-glucuronic acid linked together with alternating 
glycosidic bonds GlcNAc-β-(1→4)-GlcA-β-(1→3). HA has a quick turnover with a half-life 
ranging from hours to several days (Fraser et al., 1997). Its degradation occurs by endocytosis and 
lysosomal degradation via the activity of hyaluronidases (Stern, 2004). Because of its lengths and 
structure, hyaluronan is highly hydrophilic and lubricious and confers tissue hydration. 
Interestingly, when cells are exposed to stress they can secrete an unusual ECM structure with thick 
chains of HA (de La Motte et al., 2003; Selbi et al., 2006). This phenomenon is hypothesized to 
mediate leukocyte binding (Majors et al., 2003; Petrey and de la Motte, 2014). Despite its 
simplicity, HA is involved in many physiological processes such as maintaining tissue 
hydration/integrity, wound healing (Monslow et al., 2009), leukocyte trafficking and inflammation 
(Mack et al., 2012). HA function depends on the polymer’s length. High molecular weight HA has 
anti-inflammatory properties (Nakamura et al., 2004) while during inflammation, HA 
fragmentation generates debris which have pro-inflammatory activity (Petrey and de la Motte, 
2014). 
HA is widely used in dermatology as a soft tissue-filler (Cohen et al., 2013). In general, the use of 
HA in the clinic has many benefits. HA is non-immunogenic as it does not contain a core protein 
and it can be degraded by hyaluronidase (Hirsch et al., 2007). HA injections to patients suffering 
from osteoarthritis provides pain relief and improved walking (Petrella and Wakeford, 2015). 
Regarding HA in kidney disease, hyaluronan was found in rejected human kidneys (Wells et al., 
1990), with an increased staining within the cortex and sclerotic vessels. In diabetic nephropathy, 
HA is increased at all stages of disease but not correlated with progression (Lewis et al., 2008). 
HA can act as a sink for cells and proteins within a tissue and be both pro- and anti-inflammatory. 
Therefore, it is difficult to know if the increase in HA is detrimental or beneficial in these patients. 
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1.5.2 Chondroitin sulfate  
Chondroitin Sulfate (CS) is a GAG mainly present within cartilage, bone, ligaments, tendons, blood 
vessels, brain and skin. CS provides strength and elasticity, hence providing resistance to 
mechanical stress (Henrotin et al., 2010). CS is made of repeating disaccharides of a glucuronic 
acid and N-acetyl galactosamine GlcA-β-(1→3)-GalNAc-β-(1→4) and is synthesised in the 
endoplasmic reticulum/Golgi apparatus. The polymer bound to a core protein during synthesis and 
can be found in extracellular matrix, basement membrane where it can act as a cellular receptor.  
Like other GAGs attached to a core protein, CS synthesis starts with the initiation step (Figure 1-6), 
a serine residue covalently linked to a linkage tetrasaccharide structure GlcA-β-(1→3)-Gal-β-
(1→3)-Gal-β-(1→4)-Xyl-β-1→O-Ser. Xylose is added to serine residues located in the sequence 
“Glutamic acid/Aspartic Acid-X-Serine-Glycine” by xylosyltransferase (xylosyltransferases 1 and 
2, XylT-1 and XylT2, XYLT1 and XYLT2). Gal residues are added by two different 
galactosyltransferases, β-1,4-galactosyltransferase 7 (β4GalT7, B4GALT7), β-1,3-
galactosyltransferase 6 (β3GalT6, B3GALT6) and finally GlcA is added by a glucuronyltransferase 
β-1,3-glucuronyltransferase 1 (GlcAT-1, B3GAT3). The enzymes responsible for CS elongation 
are complex and have been studied in vitro. Three chondroitin synthase with two 
glycosyltransferase activities (GlcA and GalNAc) were identified (ChSy-1-3) with a chondroitin 
polymerising factor (ChPF) and two chondroitin GalNAc transferases (ChGn-2-2) (Silbert and 
Sugumaran, 2002; Mikami and Kitagawa, 2013).  
For most GAGs, the synthesis is followed by the addition of sulfate groups by sulfotransferases. 
Their activity is essential for the overall final negative charge. They catalyse the addition of a 
sulfate group from the donor 3’-phosphoadenosine 5’-phosphosulfate (PAPS) to a GalNAc, GlcA 
and IdoA. CS is classified by its sulfation patterns; chondroitin sulfate unit A is sulfated at position 
C4, chondroitin sulfate unit C is sulfated at position C6. Additionally, the generation of disulfated 
units by the action of a 6-sulfotransferase and a uronyl 2-O-sulfotransferase generates the 
chondroitin sulfate D unit. Finally, a GalNAc4S-6S sulfotransferase generates the chondroitin 
sulfate E unit (Lindahl et al., 2015). 
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Figure 1-6: Initiation step: linkage tetrasaccharide synthesis to the core protein 
For Chondroitin Sulfate, Dermatan Sulfate and Heparan Sulfate, synthesis begins with the 
assembly of a linkage tetrasaccharide to the core protein. Each sugar is added to the non-reducing 
end by specific enzymes (xylosyltransferases 1 and 2, XylT-1 and XylT2, XYLT1 and XYLT2), 
β-1,4-galactosyltransferase 7 (β4GalT7, B4GALT7), β-1,3-galactosyltransferase 6 (β3GalT6, 
B3GALT6), and β-1,3-glucuronyltransferase 1 (GlcAT-1, B3GAT3). Xyl: xylose, Gal: galactose, 
GlcA: glucuronic acid. 
CS has anti-apoptotic, anti-inflammatory activities (Monfort et al., 2008) and has been extensively 
used in clinical trials to treat osteoarthritis (Clegg et al., 2006; Gabay et al., 2011). It is actually 
recommended for osteoarthritis patients by the Osteoarthritis Research Society International 
(Zhang et al., 2008). In the embryonic kidney, CS is the predominant GAG (representing 77%) but 
in adults the predominant GAG is HS and there are limited studies of CS function in kidney diseases 
(Steer et al., 2004). Diabetic rats showed an abnormal distribution of CS proteoglycans (CSPG) in 
glomerular capillaries (McCarthy et al., 1994). These results are consistent with the increase of 
CSPG NG2 in strepozotocin-induced diabetic rats with a potential role in mesanglial proliferation 
(Xiong et al., 2007). However, Joladarashi et al. showed conflicting results in strepozotocin-
induced diabetic rats (Joladarashi et al., 2011). In this study, the CS content was decreased. The 
difference in findings can be explained by the difference in the model studied (Sprague Dawley 
rats vs Wistar) and the duration of strepozotocin treatment (2, 4 and 8 weeks vs 60 days 
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respectively). Furthermore,  Joladarashi et al. studied CS by purification while Xiong et al. only 
studied one CSPG by mRNA and protein level assessment (Xiong et al., 2007; Joladarashi et al., 
2011) It is possible that some CSPG are decreased while others are upregulated during 
inflammation and Joladarashi et al. looked at total CS modulation and no specific PGs (Joladarashi 
et al., 2011). Nonetheless, these studies highlight a potential role of CSPGs in the development of 
glomerulosclerosis. 
 
1.5.3 Dermatan sulfate 
Dermatan Sulfate (DS) is a stereoisomer of chondroitin sulfate. Hence, the presence of CS/DS 
hybrids GAGs in some tissues. DS is ubiquitous and is predominant in the skin. It is involved not 
only in wound healing but also in development, infection and cancer. DS synthesis starts with CS 
synthesis in the endoplasmic reticulum/Golgi apparatus as detailed in section 1.5.2. It is the 
epimerisation of GlcA to IdoA in CS that generates DS. Therefore, DS is composed of repeated 
units of IdoA-β-(1→3)-GalNAc-β-(1→4) (Trowbridge and Gallo, 2002). DS can be monosulfated 
at position 4 by a specific sulfotransferase (Dermatan 4-sulfotransferase) and disulfated on position 
4 and 6 by the same sulfotransferase as CS (GalNAc4S-6S sulfotransferase) and finally, 2-O 
sulfation is performed by the uronyl 2-O-sulfotransferase. 
The most studied DS proteoglycan (DSPG) are small leucine-rich proteoglycans (SLRP) including 
decorin, and biglycan. SLRPs have been extensively studied in renal diseases (Schaefer, 2011). 
Decorin is the best studied SLRP and is expressed by renal fibroblast. During renal fibrosis, decorin 
accumulates in the interstitium where it interacts with collagen. An important function of decorin 
within the matrix is its ability to retain TGFβ and hence have anti-fibrotic activities (Border et al., 
1992). This was shown in a murine model of renal fibrosis where decorin -/- mice had more 
damaged tubules and leukocytes infiltration compared to WT after unilateral ureteral obstruction 
(Schaefer et al., 2002). Interestingly, the kidney releases soluble biglycans after ischemia 
reperfusion injury (Moreth et al., 2014). Biglycan is a ligand of toll like receptors 2/4 and can 
activate macrophages (Schaefer et al., 2005; Babelova et al., 2009). Therefore, biglycan plays an 
important role in pro-inflammatory responses. In line with these results, biglycan was increased in 
kidneys and plasma of patients with systemic lupus erythematosus (Moreth et al., 2010). DSPGs 
play a central role in renal inflammation and fibrosis and further research may lead to the use of 
DSPG to regulate disease progression. 
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1.5.4 Keratan Sulfate 
Keratan Sulfate (KS) is mainly found in the ECM of bones, cartilages, cornea and brain. This 
polymer differs from other GAGs as it does not have an acidic residue. KS structure is composed 
of the repeating disaccharides Gal-β-(1→4)-GlcNAc-β-(1→3) (Pomin, 2015). The attachment of 
KS chains to a core protein can be on asparagine residues by N-linkage (KSI) or on threonine and 
serine residues by O-linkage (KSII). KSI is mainly corneal while KSII is skeletal, shorter and more 
sulfated (Funderburgh, 2000). A third type of KS was found within the brain with a serine O-linked 
to a mannose (Krusius et al., 1986). Not all enzymes involved in KS synthesis have been 
characterised. For what is known KS is synthesised by the activity of N-
acetylglucosaminyltransferase, N-acetylglucosaminyl-6-sulfotransferase (GlcNAc6ST), 
Galactosyltransferase and KS galactosyl sulfotransferase (Caterson and Melrose, 2018). 
KSs have been mainly studied in the cornea and the central nervous system where it has been found 
implicated in the development of macular dystrophy (Edward et al., 1990) and Alzheimer’s 
diseases (Lindahl et al., 1996). In connective tissues, KS proteoglycans (KSPG) also contain CS 
and are important for tissue hydration (Caterson and Melrose, 2018). KS levels in the kidney are 
negligible.  
 
1.5.5 Heparan sulfate and heparin 
Heparan sulfate (HS) is a ubiquitous GAG synthesised by all mammalian cells. HS is present on 
the ECM, basement membranes and on cell surfaces. In contrast, heparin is mainly synthesised by 
mast cells and bipotential glial progenitor cells. Since its discovery in 1916, heparin has been 
intensively investigated for its anticoagulation activity (Esko and Selleck, 2002). HS also has 
anticoagulant activity but is less effective than heparin. Their anticoagulant activity is due to their 
ability to bind the serine protease inhibitor antithrombin III (AT). Heparin enhances antithrombin 
neutralisation of coagulation factors  (Jordan et al., 1980). 
HS and heparin are made up of the repeat disaccharide unit containing an uronic acid (GlcA or 
IdoA) and a glucosamine. HS and heparin biosynthesis start with the initial disaccharide GlcNAc-
α-(1→4)-GlcA-β-(1→4). This disaccharide can be modified by the activity of sulfotransferase and 
epimerase (discussed in section 1.6). Heparin, which is a highly sulfated form of HS, is extensively 
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modified with more than 80% of GlcNAc are modified to GlcNSO3 and more than 70% of GlcA 
are IdoA residues (Lindahl et al., 2015). Heparan sulfate biosynthesis and its biological 
significance is discussed in section 1.6. 
 
1.6 Heparan Sulfate  
1.6.1 HS synthesis 
HS synthesis occurs in the endoplasmic reticulum (ER) and Golgi apparatus as described in Figure 
1-6, where a uridine-diphospho-D-Xylose is attached to a serine residue of a core protein and two 
Gal molecules are added by the β-1,4-galactosyltransferase 7 (β4GalT7, B4GALT7) and β-1,3-
galactosyltransferase 6 (β3GalT6, B3GALT6) respectively.  Finally, GlcA is attached by a 
glucuronyltransferase β-1,3-glucuronyltransferase 1 (GlcAT-1, B3GAT3) creating what is named 
the GAG-protein linkage region (Breton et al., 2012; Hull et al., 2017).  
Following synthesis of this tetrasaccharide linkage, the HS chain is ready to be extended by the 
addition of repeated glucuronic acid and glucosamine units. The polymerisation step, described in 
Figure 1-7, starts with addition of a GlcNAc by the GlcNAc transferase I enzyme (GlcNAcTI) and 
GlcA by GlcA transferase II. The next GlcNAc residue will be added by GlcNAc transferase II as 
GlcNAcTI is an initiating GlcNAc transferase and GlcNAcTII transfers to the elongating chain. 
The polymerisation continues with the alternate addition of GlcNAc and GlcA.  
It is thought that the exostosin (EXT) gene family members are also involved in both initiation and 
elongation of the HS chain. The two enzymes EXT1 and EXT2 are known for their 
glycosyltransferase activity (Lind et al., 1998). However, their mode of action is controversial as 
the two proteins form a hetero-oligomer directed to the Golgi. Overexpression of only one protein 
targets it to the ER. It is therefore speculated that the EXT1-EXT2 complex could be the functional 
form of the enzyme (Kobayashi et al., 2000; McCormick et al., 2000). The activity of EXT-like 
(EXTL) enzyme is less clear. Even though EXTL2 and EXTL3 have demonstrated to have GlcNAc 
transferase activity (Kitagawa et al., 1999; Kim et al., 2001), they do not seem to have the same 
mode of action. While EXTL3 can initiate the polymerisation by adding a GlcNAc to the linkage 
tetrasaccharide, EXTL2 is suggested to end the polymerisation process (Katta et al., 2015). The 
precise role of the EXT family in HS elongation remains unclear. 
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Figure 1-7: HS polymerisation step 
Following the initiation step, GlcNAc transferase I initiates the HS polymerisation by adding a 
GlcNAc to the growing chain. The polymerisation process is catalysed by the alternating activities 
of GlcA transferase and GlcNAc transferase. Some of the enzymes involved in the polymerisation 
process are hypothesized to be members of the exostosin family and are highlighted in green. Xyl: 
xylose, Gal: galactose, GlcA: glucuronic acid, GlcNAc: N-acetylglucosamine. 
 
 
1.6.2 HS modification 
HS is implicated in chemokine and growth factor binding. However, it is not the HS backbone that 
is important for the binding, but the additional sulfation patterns. HS can be N, 2-O, 6-O and 3-O 
sulfated as described below.  
First, GlcNAc can be deacetylated and N-sulfated (GlcNS) by a N-deacetylase/N-sulfotransferase. 
Second, GlcA can be transformed to IdoA by the C5-epimerase enzyme. Additionally, GlcNAc 
and GlcNS can be 6-O-sulfated (GlcNS(6S); GlcNAc(6S)) (Rabenstein, 2002; Li and Kusche-
Gullberg, 2016; El Masri et al., 2017).  Glucuronic and iduronic acids can be 2-O-sulfated 
(GlcA(2S) and IdoA(2S) respectively), Ido(2S) is more abundant. One last modification that GlcA 
can undergo is a 3-O-sulfation on both GlcNS and GlcNS(6S) which finally gives GlcNS(3S) and 
GlcNAc transferase I/ EXTL3
GlcA transferase II/ EXT1/EXT2
GlcNAc transferase II
GlcNAcCore protein Xyl Gal GlcA
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GlcNS(3,6S) (Rabenstein D.L., 2002). The enzymes responsible of Heparan Sulfate modification 
include: 
-Four isoforms of N-deacetylase/N-sulfotransferase (NDST 1-4) 
-One C5 epimerase 
-One 2-O-sulfotransferase (HS2ST) 
-Three isoforms of 6-O-sulfotransferase (HS6ST-1, 2, 3) 
-Seven isoforms of 3-O-sulfotransferase (HS3ST 1-3A, 3B-6) 
The activity of these enzymes is responsible for HS binding to many proteins involved in cell 
migration, cell adhesion and inflammation such as fibroblast growth factors, hepatocyte growth 
factor, chemokines, L and P selectins, fibronectin, TGFβ binding proteins, vascular endothelial 
growth factors (Esko and Linhardt, 2009). Modulating HS sulfation is important for protein binding 
and is a tool the body can use to increase cell signalling during inflammation. Recently, a study 
looking at tissue from idiopathic pulmonary fibrosis showed an increase in HS 2-O-sulfation 
(Westergren-Thorsson et al., 2017). Therefore, research on HS modifying enzymes has focus on 
elucidating their mode of action and specificity to better understand what controls HS function. 
 
1.6.3 HS modifying enzymes 
All enzymes and all isoforms have their specificity and the knock-out of different isoforms does 
not lead to the same phenotype. Despite having the same function, some enzyme isoforms are lethal 
when others are not (Table 1-4).   
It appears that controlling the enzyme responsible for these patterns is as important as the 
expression of a receptor on the cell surface. It is therefore essential to understand the mechanisms 
leading to these modifications and the potential physiological effects they have both in health and 
disease. 
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Table 1-4: HS modifying enzymes modulation and implication in development, inflammation and disease progression 
WT: Wild Type; KO: Knock Out; IP: Intraperitoneal; LPS: Lipopolysaccharides. Adapted from (Ferreras et al., 2015)  
Enzyme studied Model Methods / Analysis Observations Ref 
NDST (1-4) 
N-deacetylase-
Sulfotransferase  
 
 
 
Mice NDST1 -/- endothelial cell specific 
Mice NDST1-/- endothelial cell and 
leukocytes specific 
 
 
 
 
 
 
NDST1 -/- mice 
 
 
NDST2 -/- mice 
Acute peritonitis, contact dermatitis     
Antiglomerular basement membrane 
nephritis 
 
 
Acute inflammatory reaction (induced by 
IP thioglycollate); air pouch model 
 
Repetitive allergen exposure Analyses of 
airway remodeling 
 
Generation of NDST1 null mice 
 
 
Intraperitoneal injection of IgE followed by 
anti IgE antibodies injection 
Impaired inflammatory responses. Decreased neutrophil infiltration 
Decrease in granulocyte and macrophage influx. Improved renal function and 
reduced glomerular injuries (creatinine blood urea nitrogen; glomerular 
hyalinosis) 
Decrease in chemokine presentation, migration and neutrophil influx 
Less macrophage infiltration and peribronchial fibrosis compared to WT 
Non-viable, neonatal death due to lung defects 
No significant difference in neutrophil influx in the peritoneum compared to 
NDST2 +/+ mice but have decreased number of connective tissue mast cells  
(Wang et al., 2005) 
 
 
(Rops et al., 2014) 
 
 
 
(Wang et al., 2005) 
 
(Ge et al., 2014) 
 
 
(Fan et al., 2000)  
 
 
(Forsberg et al., 1999) 
HS2ST 
2-O-
sulfotransferase 
Mice HS2ST -/- endothelial cell specific Acute peritonitis Increase in neutrophils and monocyte infiltration, enhanced chemokine binding 
and number of neutrophils attached to the endothelial cell surface 
 
(Axelsson et al., 2012) 
 
 
HS3ST 1-3A, 3B-
6 
3-O-
sulfotransferase  
HS3ST3B overexpression in pancreatic 
cell line 
Analysis of epithelial-mesenchymal 
markers 
 
 
EMT processes promoted 
 
 
 
(Song et al., 2011) 
 
 
 
HS6ST-1,2,36-6-
O-sulfotransferase  
HS6ST1 overexpressing renal epithelial 
cells 
 
Flow cytometry 
 
 
Increased binding of FGF2  
 
 
(Alhasan et al., 2014) 
 
 
 
 
Endosulfatases 
(SULF1,2) 
 
Sulf2 KO type II alveolar epithelial cells 
 
Sulf1/2 double KO MEFs 
 
TGF beta stimulation 
 
FGF2 stimulation 
 
Increase in TGF-β1 target gene expression  
 
Increase in FGF2 response compared to WT.  
 
(Yue et al., 2013) 
 
(Lamanna et al., 2008) 
 
Heparanase 
(hps) 
 
 
 
 
 
Mice overexpressing hps 
 
 
Colon samples from ulcerative colitis; 
Hps tg mice 
 
 
Hps -/- mice 
 
Hps-silenced tubular cells 
 
Hps -/- effector T cells 
 
 
Hps -/- mice 
Neutrophil chemoattraction into cremaster 
muscle  
 
Histology, mouse model of colitis 
 
 
 
LPS injection 
 
Pro-fibrotic stimulati 
 
Injection of Hps -/- effector T cells in WT 
mice with lymph node or skin inflammation 
 
Zymosan induced peritonitis 
Drop in leukocyte recruitment 
 
 
Hps overexpression. Compared to WT, elevated hps in colonic epithelium have 
similar leukocyte infiltration during acute phase and increased mucosal 
infiltration during chronic phase 
 
Inhibition of neutrophil adhesion to pulmonary microvasculature  
 
Reduced TGF synthesis, no change in EMT  
 
Hps not essential for lymphocyte extravasation through inflamed lymph nodes 
and inflamed skin vessels. 
  
Hps contributes to monocyte but not neutrophil entry to inflammation site  
(Massena et al., 2010) 
 
 
(Lerner et al., 2011) 
 
 
 
(Schmidt et al., 2012) 
 
(Masola et al., 2014) 
 
(Stoler-Barak et al., 2015) 
 
 
(Stoler-Barak et al., 2015) 
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1.6.4 N-deacetylase/N-sulfotransferase 
NDSTs are Golgi transmembrane proteins with two catalytic activities. They are capable of N-
deacetylation and N-sulfation. The first deacetylation process removes the acetyl groups from 
GlcNAc and the NDST sulfotransferase activity then adds a sulfate group to GlcN. This 
modification is essential for HS synthesis as other modulating enzymes require GlcNS residues 
(Grobe et al., 2002; Carlsson et al., 2008). Vertebrates have 4 NDSTs but the reason for having 4 
is still not clear. Their discovery is quite recent (Pettersson et al., 1991; Hashimoto et al., 1992; 
Aikawa and Esko, 1999), NDST1 and NDST2 are ubiquitous while NDST3 and 4 are mainly 
expressed during embryonic development. Modeling NDST sulfotransferase domains showed 
different substrate binding sequences. Furthermore, cells had higher N-sulfation patterns when 
transfected with NDST2 than NDST1 (Pikas et al., 2000). Additionally, an increase in N-sulfation 
was accompanied by an increase in HS length. Hence NDSTs are important for N-sulfation and 
impact HS total length. NDST1-/- mice are non-viable and die from lung defects. However, 
NDST1-/- podocytes specific led to foot effacement with an abnormal cell-matrix interaction 
(Sugar 2014). Not only is NDST1 important for morphogenesis but it is also essential for 
inflammation processes. As seen Table 1-4, cell-specific NDST1-/- in murine models of dermatitis, 
nephritis and acute inflammation all showed a decrease in leukocyte infiltration (Wang et al., 2005; 
Ge et al., 2014; Rops et al., 2014). HS is important for chemokines binding and leukocyte adhesion 
to the endothelium (see section 1.8). NDST2-/- mice are viable and do not show impaired leukocyte 
infiltration suggesting that NDST1 might me more important for HS biosynthesis.  
 
1.6.5 C5-epimerase 
After N-deacetylation-sulfation of the GlcNAc residue, the other component of the HS disaccharide 
is also modified. The action of C5-epimerase, a Golgi transmembrane protein, transforms GlcA 
into IdoA. This modification is important for flexible conformation and the activity of 2-O-
sulfotransferase (Qin et al., 2015). To date, only one C5-epimerase protein has been identified. C5-
epimerase -/- mice are non-viable, they lack kidneys and show mild skeletal and lung 
malformations (Li et al., 2003), with other organs not affected. The renal agenesis observed in 
these animals highlights a potential importance of 2-O-sulfation in renal development. Mice 
lacking HS2ST1 also lack kidneys (Bullock et al., 1998). Some studies have shown that C5-
epimerase and HS2ST1 interact in vitro and in vivo (Pinhal et al., 2001; Préchoux et al., 2015). 
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This interaction seems essential for their translocation within the Golgi apparatus. One concept 
about HS biosynthesis speculates that the modifying enzymes interact within the Golgi to form a 
physical complex named the “gagosome” (Esko and Selleck, 2002). However, further investigation 
will be required to validate this model. 
 
1.6.6 Heparan Sulfate 2-O-sulfotransferase 1 
In addition to N-sulfation and the generation of IdoA, HS can be O-sulfated. HS 2-O-sulfation is 
catalysed by only one enzyme, HS2ST1, a transmembrane Golgi protein. Surprisingly HS2ST1 has 
two substrates and is able to add a sulfate group to GlcA and preferentially to IdoA residues (Rong 
et al., 2001). IdoAS is important for protein binding, including FGF2 (Maccarana et al., 1993), 
lipoprotein lipase (Parthasarathy et al., 1994), platelet derived growth factor (Feyzi et al., 1997) 
and IL8 (Spillmann et al., 1998). 
Interestingly, endothelial cell specific HS2ST1 -/- resulted in an increase in leukocyte infiltration 
and an increase in chemokine and L-selectin binding (Axelsson et al., 2012). This pro-inflamatory 
effect of HS2ST1 inactivation is unexpected as generally a decrease in sulfation inhibits protein 
binding.  One explanation could be the increase in N- and 6-O-sulfation observed in the HS2ST1 -
/- endothelial cells might be responsible for the enhanced inflammation. The same authors showed 
that the inactivation of HS2ST1 in a myeloid lineage did not have the same effect. Therefore, the 
decrease in 2-O-sulfation and its effect on inflammation is most important in the endothelium.  
Additionally, HS 2-O-sulfation is crucial for renal development. Gene trap mutation of HS2ST in 
mice stopped kidney development and led to lethality (Bullock et al., 1998). It is suggested that 
HS2ST impaired kidney development is due to a defect in metanephric mesenchyme induction 
(Shah et al., 2010). A change in HS 2-O-sulfation can also be observed in pathological conditions. 
Immunostaining of HS 2-O-sulfation is increased during renal allograft rejection (Alhasan et al., 
2014).  
 
1.6.7 Heparan Sulfate 6-O-sulfotransferases 
HS 6-O-sulfation is generated by three different enzyme isoforms. HS6ST1, 2 and 3 are 
transmembrane Golgi proteins catalysing the addition of a sulfate group at the C6 of a GlcN. 
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HS6STs can be secreted to the extracellular space (Habuchi et al., 1995) mediated by the activity 
of a -secretase (Nagai et al., 2007). This secretion can potentially be a regulatory mechanism of 
the cell to decrease the activity of HS6ST, hence, limit HS 6-O-sulfation. Each isoform has its 
preferential substrate. Habuchi et al. cloned all HS6STs in mice and observed that HS6ST1 
catalysed the sulfation of IdoA-GlcNS residues (Habuchi et al., 2000). However, IdoA seems to 
prevent HS6ST2 activity which preferentially modifies Glc-GlcNS. HS6ST3 can add a sulfate 
group to both IdoA-GlcNS and Glc-GlcNS with a preference to 2-O-sulfated residues (Jemth et al., 
2003). Murine and Human studies showed that three isoforms do not have the same pattern of 
expression in the body. HS6ST1 is mainly expressed in liver, kidney and intestine whereas HS6ST2 
is predominantly found in brain, ovary, placenta and spleen. HS6ST3 is expressed ubiquitously but 
at low levels (Habuchi et al., 2000, 2003). 
HS6STs are important in development. HS6ST1-/- mice can be non-viable depending on the 
genetic background. The decrease of vascular endothelial growth factor in the placenta of null mice 
may explain this mortality. However, when viable, mice are smaller with abnormal skeletal 
development and abnormal eye and lung morphogenesis compared to WT mice (Habuchi et al., 
2007). In contrast,  HS6ST2 -/- mice are viable and develop normally (Habuchi and Kimata, 2010). 
These observations suggest that HS6ST1 is more important than HS6ST2 in development.  
HS 6-O-sulfation has been extensively studied for binding growth factor including FGF family.  
HS 6-O-sulfation is increased in idiopathic pulmonary fibrosis (Lu et al., 2014; Westergren-
Thorsson et al., 2017) and in chronic renal rejection (Alhasan et al., 2014). FGF2 binding to its 
receptor requires HS 6-O-sulfation. Hence the increase in 6-O-sulfation in fibrosis potentially 
increases FGF2 signalling and disease progression.  
 
1.6.8 Heparan Sulfate 3-O-sulfotransferases 
1.6.8.1 Catalytic activity, specificity and localisation 
The addition of a sulfate group to the C3 position is catalysed by HS 3-O-sulfotransferases 
(HS3STs). HS3STs like other HS sulfotransferases are Golgi transmembrane proteins, with the 
exception of HS3ST1 which does not possess a transmembrane domain. The HS3ST family, with 
7 members (HS3ST1, 2, 3A, 3B, 4, 5, 6), is the largest of all HS sulfotransferases. HS 3-O-sulfation 
is a rare modification and despite the number of enzymes involved in generating this pattern. HS 
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3-O-sulfated glucosamine residues represents around 1% in porcine endothelial cells (Marcum et 
al., 1986) and 6% in follicles (De Agostini et al., 2008). HS3STs are very well conserved within 
all vertebrates. However, invertebrates have less isoforms. Thacker et al. proposed that HS3ST 
originally emerged in a common ancestor of bilaterians (animals with bilateral symmetry) and 
cnidarians (see arrow, Figure 1-8) (Thacker et al., 2014). 
 
Figure 1-8: HS3ST evolution 
HS3STs are well conserved amongst animals. It is hypothesised that the first HS3ST originates 
from a common ancestor of bilaterians and cnidarians (arrow). From (Thacker et al., 2014). 
HS3STs are heterogeneously expressed throughout the human body and vary from organ to organ, 
see Table 1-5. The most common forms are HS3ST1, HS3ST3A and HS3ST3B which are widely 
expressed. HS3ST5 is found in brain, spinal cord and skeletal muscle and HS3ST6 is mainly found 
in liver and kidney. Finally, HS3ST2 and HS3ST4 are predominantly expressed in the brain (Table 
1-5).  
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Table 1-5: An overview of HS3STs localisation and types 
Organs where the sulfotransferase is predominantly expressed are highlighted in bold. Research on 
HS3ST3A/B tissue expression used a probe detecting both isoforms, not discriminating them and 
giving limited information, hence the italic style (Shworak et al., 1999; Xia et al., 2002; Mochizuki 
et al., 2003, 2008; Xu et al., 2005). 
Considering the rare occurrence of HS 3-O-sulfation, it could be suggested that all enzymes 
generate the same pattern. However, experiments show that this is not the case. Although they need 
the high energy sulfate donor PAPS (3’-phosphoadenosine 5’-phosphosulfate) for their activity, 
they do not have the same substrate specificity. Initial experiments showed that Chinese Hamster 
Ovarian (CHO) cells that do not have HS 3-O-sulfation, became sensitive to Herpes Simplex Virus-
1 (HSV-1) after HS3ST3 transfection. However, when transformed with HS3ST1, the virus was 
not able to enter the CHO cells implying that these enzymes generate different 3-O-sulfation 
patterns (Shukla et al., 1999). Additionally, HS3ST1 is known to generate an anticoagulant HS 
(Liu et al., 1996). Consequently, HS3STs are classified in two different groups depending on their 
activity, the ones generating the antithrombin III binding site also named anticoagulant HS (AT-
type) and the ones generating the herpes simplex virus type 1 glycoprotein D (gD-type) (Thacker 
et al., 2014).  
Isoforms 2,3A,3B 4 and 6 form herpes simplex virus binding sites (gD binding site) and have 80% 
sequence identity (Lawrence et al., 2007). In contrast, HS3ST1 and 5, which have 71% sequence 
identity, generate anti-thrombin binding sites. HS3ST1 has a preferred target for GlcA-GlcN±6S 
and IdoA 2-O-sulfation prevents its action (Zhang et al., 2001). HS3ST5 generates both AT-type 
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and gD-type and is not influenced by 2-O-sulfation patterns (Xia et al., 2002). HS3ST1, 3 and 5 
have been crystallised and their substrates, displayed Figure 1-9  have been extensively studied.  
 
 
 
Figure 1-9: HS3ST1, 3 and 5 substrates specificity 
HS3ST1 catalyses the addition of a sulfate group to GlcNS±6S and generates AT-type HS, GlcA-
GlcNS3S±6S. HS3ST3 transfers a sulfate group to the residue GlcNH2±6S and generates gD-type 
HS, IdoA2S-GlcNH23S±6S, which is an entry receptor for HSV-1. HS3ST5 catalyse both 
reactions. R: H or SO3-. From (Xu et al., 2005). 
 
Recent research has addressed the difference in the isoforms’ substrate. Previous work with 
computer modelling (Raman et al., 2002) and recombinant protein experiments (Edavettal et al., 
2004) have provided information about the structure-function relationship. Moon and co-workers 
compared HS3ST1 and HS3ST3 conformations when binding oligosaccharides and discovered that 
their interactions were not similar. Interestingly, the IdoA2S was in a chair conformation when 
interacting with HS3ST1 while in a skew boat conformation in contact with HS3ST3 (Moon et al., 
2012). This change in conformation could explain why 2-O-sulfation prevents HS3ST1 action.  
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1.6.8.2 HS3STs in embryonic development 
Recent research in mice showed that HS 3-O-sulfation plays a role in development by supporting 
stem cell differentiation (Hirano et al., 2012). HS3STs were found to regulate axonal growth cone 
collapse (Thacker et al., 2016a) and were expressed differentially during neuronal differentiation 
(Hasegawa and Wang, 2008). In addition, the study of null animals emphasised the role of HS3STs 
in organogenesis. Depending on the strain, HS3ST1-/- mice generation can be lethal or can induce 
growth retardation. These mice showed normal coagulation (HajMohammadi et al., 2003), 
potentially due to the redundancy of the HS3STs function. The HS3ST1-/- mice developed a 
spontaneous eye degeneration which was not expected (Shworak et al., 2003). Clark et al.  showed 
that HS 3-O-sulfation was found on blood vessels and the membrane between retina and vitreous 
body within the human eye (Clark et al., 2011). Furthermore, the dysregulation of factor H binding 
to HS is thought to play a role in the development of macular degeneration (Langford-Smith et al., 
2014). Therefore, one explanation could be the dysregulation of factor H binding in HS3ST1-/- 
mice causes eye degeneration due to an increase in complement activation. However, this is a 
hypothesis which stills requires testing. HS3STs are also important in non-mammalian animals 
where they are implicated in cilia function (Neugebauer et al., 2013) and cardiac contractility 
(Samson et al., 2013) of the zebrafish and neuronal development, neuronal branching of 
Caenorhabditis elegans (Tecle et al., 2013). The role of HS3STs in human development is 
understudied but is better documented in physiological and pathological conditions. 
 
1.6.8.3 HS3STs in cancer 
Recently, there has been increasing interest in the function of HS3STs in cancer. In cancer 
evolution, three states can be observed: the primary tumor state, micro metastatic dissemination, 
when cancer cells migrate from the primary tumor to the circulation, and finally cell proliferation 
in distant organs (metastatic state). HSPGs are involved in cell contact, in cell motility and are 
crucial for growth factor-binding. It is therefore not surprising that they are implicated in cancer 
progression (Sasisekharan et al., 2002). In the early stages of cancer progression, HS3ST3B 
promotes epithelial to mesenchymal transition in pancreatic cells with a potential role in cancer 
development (Song et al., 2011). Additionally, Zhang et al. found that HS3ST3B increased tumor 
growth and angiogenesis (Zhang et al., 2015). They suggested that this pro-oncogenic mechanism 
was induced by the activation of Vascular Endothelial Growth Factor (VEGF). HS3ST4 was shown 
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to inhibit the elimination of cancer cells by the innate immune system cells (Biroccio et al., 2013). 
In vitro, HS3ST2, 3B and 4 increased breast cancer cell proliferation (Hellec et al., 2018). In 
contrast, HS3ST2 is downregulated in primary breast cancer (Miyamoto et al., 2003). This 
downregulation by gene methylation is thought to modulate cell invasiveness (Bui et al., 2010; 
Kumar et al., 2014). Furthermore, HS3ST3A displayed both anti- and pro-oncogenic activity 
depending on the breat cancer cell line studied in vitro and breast cancer subtype in patients (Mao 
et al., 2016). 
 
1.6.8.4 HS3STs in Alzheimer’s disease 
Alzheimer’s disease is characterised by the accumulation of amyloid plaques and hyper 
phosphorylated tau proteins. Sulfated GAGs were found to promote tau protein and β-amyloid 
assembly into filaments (Goedert et al., 1996; Castillo et al., 1999). Additionally,  HS3ST2 and 
HS3ST4 are overexpressed in patients with Alzheimer’s disease (Sepulveda-Diaz et al., 2015). 3-
O-sulfated HS can bind to tau and Sepulveda-Diaz et al. suggested that HS3ST2 might regulate the 
abnormal phosphorylation of tau (Sepulveda-Diaz et al., 2015). 
 
1.6.8.5 HS3STs and viral infection 
There is interest in the role of HS in viral infection. Because HS is present on all mammalian cells, 
viral particles with a HS binding site have an advantage for invading cells. For instance, Human 
immunodeficiency virus (HIV), Hepatitis C virus (HCV), dengue virus and herpes simplex virus 
(HSV) all use HS to bind their target cells (Liu and Thorp, 2002). The gD-type HS3STs generate 
the binding site of the viral glycoprotein gD required for the HSV viral envelope to fuse with the 
host cell membrane (Shukla et al., 1999). A synthetic peptide binding 3-O-sulfated HS showed 
inhibition of HSV-2 infection in mice (Ali et al., 2012). In line with these results, 3-O-sulfated 
octasaccharides can inhibit HSV-1 cell invasion in vitro (Copeland et al., 2008). These 
observations highlight the need to understand and target HS3ST activity to generate new 
therapeuties in viral diseases. 
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1.6.8.6 HS3STs in ovulation 
Human follicular fluid is rich in HS 3-O-sulfation (De Agostini et al., 2008). The potential role for 
HS3ST in reproduction was initially proposed following the observation that HS3ST1-/- mice had 
impaired fertility. It was speculated that anticoagulant HS (aHS) may be essential for reproduction. 
The inner follicle contains the oocyte and granulosa cells (GC). GCs surround the oocyte and 
secrete hormones that influence oocyte maturation. Recent research showed that GCs synthesise 
aHS before and after ovulation to potentially protect the oocyte from proteolysis (Princivalle et al., 
2001; Hasan et al., 2002; De Agostini, 2006). Hence, aHS seems important in maintaining a 
favourable environment to oocyte development during the ovulation cycle. 
 
1.6.8.7 HS3STs in the kidney 
In the kidney, HS 3-O-sulfation has been described in the glomerulus, tubular basement membrane 
and blood vessels (Girardin et al., 2005). The Glomerular Basement Membrane (GBM) displayed 
an unusual disaccharide unit with a 3-O-sulfated GlcA without 6-O-sulfation (Edge and Spiro, 
1990). The relevance of this finding is yet to be determined. Interestingly, HS3ST1  expression 
correlates with glomerular filtration rate (Bunnag et al., 2009) and its expression was significantly 
modulated in kidney transplantation (Einecke et al., 2010; Sagoo et al., 2010). However, the 
mechanisms and consequences behind this change have not been described and require further 
investigation.  
 
1.6.9 HS sulfatases and endosulfatases 
Sulfatases are important as a mechanism to regulate HS on the cell surface and in the ECM.  
6-O-sulfated HS is desulfated by the activity of two endosulfatases, SULF1 and SULF2. SULF1/2 
are extracellular enzymes that preferentially remove a sulfate group from the trisulfated 
disaccharide IdoA2S-GlcNS6S (Frese et al., 2009). SULF1-/- and SULF2-/- mice are viable 
(Lamanna et al., 2006) but show structural abnormalities within the nervous system (Kalus et al., 
2009). These observations suggest that the SULFs and probably HS 6-O desulfation are essential 
to neuronal development. Additionally, the inactivation of SULF1 generated more HS structure 
modification compared to SULF2-/- with higher increase of trisulfated disaccharide IdoA2S-
GlcNS6S and decrease in IdoA2S-GlcNS (Nagamine et al., 2012). Because 6-O-sulfation is 
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important for growth factor binding and signalling, SULFs are essential regulators of cell 
proliferation, migration and differentiation. Their action can increase activity of some cytokines 
for example bone morphogenetic protein, or diminish activity of other such as FGF, VEGF and 
heparin-binding EGF-like growth factor (HB-EGF) (Nagamine et al., 2012). Furthermore, SULF 
expression can be controlled by pro-fibrotic factors such as TGF1 (Yue et al., 2008). All together 
these observations show that SULFs are important in inflammatory processes. In addition SULF2 
is overexpressed in cancer and in idiopathic pulmonary fibrosis (Yue et al., 2013; Vivès et al., 
2014) while SULF1 is downregulated in many cancers (Dai et al., 2005). 
Additionally, heparanase and three heparin lyases have endoglycosidase activity (Desai et al., 
1993). The three heparin lyase enzymes can cleave highly sulfated HS between 2-O-sulfated IdoA 
and GlcNS (Heparin Lyase I (heparinase) and II) and poorly sulfated HS between GlcA and either 
GlcNAc or GlcNS (Heparin Lyase II and III (heparitinase)).  Nitrous acid can also cleave HS 
(Shively and Conrad, 1976).  
Heparanase specificity has been widely studied and recently the cleavage sites of heparanase have 
been identified between GlcA and GlcNS3S or GlcNS6S but also between GlcA and GlcNS when 
there is a 2-O-sulfated GlcA2S next to the cleavage site. The repeating pattern of IdoA2S-GlcNS 
has an inhibiting action on the enzyme (Peterson and Liu, 2010). Heparanase has been widely 
studied in renal diseases (Van Den Hoven et al., 2007; Masola et al., 2015) and was overexpressed 
in the glomeruli of patients with overt diabetic nephropathy (Van Den Hoven et al., 2006) and in 
rats with Adriamycin nephropathy (Kramer, 2006). In a murine model of diabetic nephropathy, 
heparanase -/- mice did not develop proteinuria and had unchanged urinary levels of albumin after 
streptozotocin injections (Gil et al., 2012).  
Additionally, heparanase plays a role in TGF1 expression in tubular cells (Masola et al., 2014). 
Glycosidases are also important tools for us scientists to study the impact of HS cleavage in 
inflammation and fibrosis.  
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1.7 HS in renal development and renal diseases  
The involvement of HS and HS modifying enzymes in renal development and disease progression 
have been discussed in section 1.6 and is summarised Table 1-6. 
Interestingly, HS 2-O-sulfation seems crucial in renal development with C5-epimerase and 
HS2ST1 -/- mice developing renal agenesis (Bullock et al., 1998; Li et al., 2003). This agenesis 
could be due to an impaired ureteric bud branching, important in early stages of development as 
observed in rat embryos treated with heparitinase (Steer et al., 2004). The changes in HS sulfation 
in kidney disease vary between diseases (Table 1-6). 
However, the study of GAGs is very complex and the use of antibodies can be misleading as HS 
can be masked by attached cationic proteins. 
. 
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Table 1-6: HS involvement in renal development and diseases  
STZ: streptozotocin SLE:  Systemic Lupus Erythematosus
 Model Methods/analysis Observations References 
In
 v
iv
o
 m
o
d
el
s 
rat embryos treatment with heparitinase impaired ureteric bud branching (Steer et al., 2004) 
HS2ST1-/- mice morphological studies renal agenesis  (Bullock et al., 1998) 
NDST1-/- specific podocytes functional studies glomerular hypertrophy, increased albumin to creatinine ratio (Sugar et al., 2014) 
EXT1 -/- mice morphological studies hypertrophic glomeruli (Chen et al., 2008) 
C5-epimerase-/- mice Morphological studies Renal agenesis, lung and skeletal malformations (Li et al., 2003) 
Adriamycin nephropathy staining increase in heparanase  (Kramer et al., 2006a) 
Heparanase -/-, STZ induced diabetic 
mice 
functional and histological studies decrease in albuminuria and renal damages (Gil et al., 2012) 
STZ induced diabetic mice and rats staining, WB, mRNA level  increase in heparanase expression (Van Den Hoven et al., 2006) 
H
u
m
an
 s
tu
d
ie
s 
lupus nephritis staining (JM403) decrease in HS (Van Den Born et al., 1993) 
SLE nephritis staining (EW3D10, GlcNS6S) increase in HS N and 2-O-sulfation (Rops et al., 2007) 
glomerulonephritis staining (JM403) decrease in HS (Van Den Born et al., 1993) 
diabetic kidneys disaccharide analysis decrease in HS 3-O-sulfation (Edge and Spiro, 2000) 
diabetic kidneys staining (LKIV69, HS4C3) increase in HS sulfation (Wijnhoven et al., 2006) 
diabetic nephropathy staining heparanase overexpression and HS loss (Van Den Hoven et al., 2006) 
diabetic nephropathy staining (JM403) decrease in HS (Van Den Born et al., 1993) 
minimal change nephrotic syndrome staining (HS3A8, EW3D10, EW4G20) no change (Wijnhoven et al., 2007) 
minimal change disease staining (JM403) decrease in HS (Van Den Born et al., 1993) 
Blood of tolerant transplanted patients gene expression analysis increase in HS3ST1 expression (Sagoo et al., 2010) 
kidney failing grafts gene expression analysis increase in HS3ST1 expression (Einecke et al., 2010) 
kidney transplant biopsies gene expression analysis HS3ST1 correlates with glomerular filtration rate (Bunnag et al., 2009) 
chronic rejection staining (HS3A8) increase in HS 2 and 6-O-sulfation (Alhasan et al., 2014) 
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Finally, HS is important in the GBM for the control of complement activation, an essential 
component of the innate immune system. The regulation of the complement system on the GBM 
is critical as it can trigger several kidney diseases. Briefly, the complement system has three 
pathways. The classic pathway mediated by immune complexes, the lectin pathway activated by 
glycans and the alternative pathway activated on the surface of pathogens. Activation of 
complement can mediate inflammation, clear cell debris and immune complexes (Borza, 2017) and 
is therefore tightly regulated. Factor H is a glycoprotein regulating the alternative pathway. Factor 
H can bind to HS of glomerular endothelial cells (Jokiranta et al., 2005; Loeven et al., 2016) and 
it is speculated that loss of HS on the GBM may compromise complement regulation by factor H 
(Borza, 2016). The alternative pathway of complement activation is implicated in lupus nephritis 
(Sato et al., 2011) and anti-GBM disease (Ma et al., 2014). Research on HS and the factor H 
interaction in renal diseases could identify new therapeutic avenues. 
 
1.8 HS in inflammation 
1.8.1 Chemotaxis 
Inflammation is a rapid response to protect and heal the body. However, when uncontrolled, this 
process can lead to fibrosis in CKD and renal rejection following transplantation. To initiate 
inflammation, the access of leukocytes to the injured tissue requires migration through the blood 
vessel wall.  
Leucocyte migration to injured tissue involves binding to the endothelium, degradation of the 
basement membrane and, finally, transmigration (Ferro, 2013) (Figure 1-10). HS on both the ECM 
and cell surface contributes to cell migration because of its binding to essential inflammatory 
proteins: chemokines. Chemokines are chemotactic cytokines. 
It is widely accepted that leukocyte adhesion to endothelial cells is triggered by chemokines.  
Historically, it was believed that soluble chemokines triggered this attraction. However, they would 
be too easily removed by blood flow and circulating leukocytes would be activated which could be 
harmful. Therefore another hypothesis has emerged based on the observation that immobilised IL-
8 attracts leukocytes in vitro (Rot, 1993) and that the immobilisation domain is required for 
transcytosis (Middleton et al., 1997). HS can control the function of chemokines by preventing 
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their proteolysis, regulating receptor activation and immobilising them to create a gradient that 
attract leukocytes to injured tissue (see Figure 1-10). Originally this was a hypothetical function of 
chemokines and had never been demonstrated in vivo. The first time a chemokine gradient was 
demonstrated was in 2013 when Weber M et al. showed chemokine driven attraction of dendritic 
cells along lymphatic vessels in murine tissue (Weber et al., 2013). Different models of 
inflammation in mice have been studied and correlated to HS enzymes (Table 1-4).  
For neutrophil migration, L selectin and the expression of P and E selection on endothelial cells is 
also crucial (Figure 1-10). Recent studies investigating chemotaxis demonstrated that HS 
participates in L-selectin binding to leukocytes. Weak L selectin binding and increased rolling 
velocity are observed when HS biosynthesis is altered in mice lacking NDST1 enzyme (Wang et 
al., 2005). This highlights the fact that leukocyte rolling is influenced by HS sulfation. It can be 
hypothesised that having under sulfated HS decreases chemokine presentation, chemokine gradient 
and L selectin binding impairing leukocyte entry to the injured tissue. Hence HS sulfation patterns 
could either become biomarkers or targets for inhibiting chemotaxis.  
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Figure 1-10: Heparan Sulfate in chemotaxis and fibrosis development 
From (Ferreras et al., 2015)
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1.8.2 HS in fibrosis and pro-fibrotic factor binding 
Heparan sulfate proteoglycans are increased in the development of fibrosis with an excess of 
Collagen XVIII and perlecan. This phenomenon has been observed in kidney isografts and 
allografts in rats (Rienstra et al., 2010).  
 
The mechanisms leading to fibrosis are complex and many factors are involved. The excess matrix 
deposition is mainly driven by myofibroblasts but other cells, including glomerular and tubular 
epithelial cells, can produce matrix components such as collagen (Kreisberg and Karnovsky, 1983; 
Creely et al., 1988).  
Fibroblasts are the key mediators of fibrosis. These cells have a characteristic phenotype with an 
elongated cell body (spindle shape), large Golgi apparatus and rough endoplasmic reticulum due 
to their intense synthetic activity. In tissue healing, myofibroblasts (activated fibroblasts) invade 
the injured tissue. They have both fibroblast and smooth muscle characteristics (Sappino et al., 
1990). Fibroblast activation is stimulated by mechanical stress and pro-fibrotic cytokines that are 
secreted by cells and sequestered by the matrix. During inflammation, fibroblasts are receptive to 
Platelet Derived Growth Factors (PDGF), Interleukin-13 (IL-13), Transforming Growth Factor β1 
(TGFβ1) and Fibroblast Growth Factor 2 (FGF2) (Horvath et al., 1996; Leask and Abraham, 2004).  
Endothelial cells, and macrophages secrete PDGF which triggers fibroblast proliferation, 
differentiation, and ECM production (Scotton and Chambers, 2007). T cells secrete IL-13 which 
stimulates myofibroblast differentiation, collagen production and matrix metalloproteinase 
expression (Fuschiotti, 2011; Fuschiotti et al., 2013). Neutrophils and macrophages secrete TGF-
β1 a factor that plays key roles in fibrosis progression by stimulating inflammatory cytokine 
production and inducing ECM synthesis by fibroblasts (Leask and Abraham, 2004). Transforming 
Growth Factor TGFβ1 is modulated by HS (Lyon et al., 1997). 
Macrophages and endothelial cells secrete FGF2 that stimulates fibroblasts proliferation. 
Additionally, FGF2 effect on renal fibroblast proliferation requires HSPG expression on the cell 
surface (Clayton et al., 2001; Kalluri and Zeisberg, 2006). Because FGF2 binding requires HS, this 
interaction is an attractive target when studying HS in fibrosis.   
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1.8.2.1 HS and FGF2 
There are more than 20 members in the FGF family involved in cell growth and development 
(Basilico and Moscatelli, 1992). FGF signalling requires the interaction between FGF, HS and a 
cell-surface tyrosine kinase receptor (Guimond and Turnbull, 1999). To date, four FGF receptors 
families have been identified (FGFR1, FGFR2, FGFR3 and FGFR4).  
FGF2 was first isolated from pituitary extracts and named basic fibroblast growth factor for its 
basic and mitotic properties (Armelin, 1973; Gospodarowicz and Moran, 1975). FGF2 is 
implicated in proliferation, migration, differentiation and angiogenesis (Murphy et al., 1990; 
Holland and Varmus, 1998; Javerzat et al., 2002). In vivo and crystallography studies showed that 
HS sulfation is essential for FGF2 signalling. HS 2-O sulfation is important for binding to FGF2 
(Maccarana et al., 1993), while 6-O-sulfation plays a role in FGFR1 binding (Pye et al., 1998; 
Schlessinger et al., 2000; Sugaya et al., 2008). This was further confirmed by using mouse 
embryonic fibroblasts HS6ST1 and HS6ST2 -/- which demonstrated decreased FGF2 signalling 
(Sugaya et al., 2008). 
FGF signalling cascades have been well documented. The tyrosines present in the intracellular 
domain of FGF receptors are phosphorylated and can activate four different pathways, PI3/Akt 
pathway, PLCγ the Janus kinase/signal transducer and activator of transcription (Jak/Stat) and ERK 
pathways (Lanner and Rossant, 2010).  
The increase in HS 2-O and 6-O-sulfation seen in chronic rejection could be associated with the 
increase in FGF2 activity associated with fibrosis (Alhasan et al., 2014). Hence, targeting FGF2 
binding to HS is an interesting avenue for preventing fibroblast activation and therefore limiting 
fibrosis. 
 
1.8.2.2 HS and HB-EGF  
Heparin Binding Epidermal growth factor like (HB-EGF) is a member of the EGF family with 
mitogenic activity (Higashiyama et al., 1991). It was first isolated in 1990 from culture media of 
macrophages by heparin Sepharose affinity chromatography (Besner et al., 1990). HB-EGF has 
two forms, it is first synthesised as a transmembrane protein (proHB-EGF) which can be cleaved 
into a soluble growth factor. HB-EGF expression is triggered by hypoxia in neuronal cells (Jin et 
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al., 2002) and in burn injury (Cribbs et al., 2002).  HB-EGF can signal through EGF receptors to 
activate Jak/Stat, ERK, PI3K-Akt and PLCγ pathways (Knudsen et al., 2014). To date, the specific 
sequence binding of HB-EGF to HS is yet to be determined. 
Following intestinal ischemia reperfusion, HB-EGF -/- mice showed increased injury (El-Assal et 
al., 2008) suggesting a protective role for HB-EGF. Additional studies from the same group 
showed that HB-EGF administration following ischemia reperfusion accelerated intestinal 
recovery (El-Assal and Besner, 2005). In the kidney, HB-EGF has been identified to be important 
for tubular cells repair (Sakai et al., 1997). In fibrosis, HB-EGF was found to be protective in liver 
fibrosis (Huang et al., 2012; Takemura et al., 2013). Furthermore, renal transplants show a strong 
staining for HB-EGF (Celie et al., 2012; Talsma et al., 2017) making it an attractive  growth factor 
to study for preventing fibrosis. 
 
1.8.3 HS and therapeutics  
The current knowledge on HS and proteins interaction enables the development of therapeutic 
opportunities to treat inflammation and fibrosis. Research have shown that heparin was beneficial 
in different in vivo models of kidney diseases. For instance, daily injection of low molecular weight 
heparin (LMWH) decreased collagen, fibronectin, TGFβ and macrophage infiltration in a rat model 
of renal fibrosis (Pecly et al., 2006). In line with these results, Braun et al. showed that LMWH 
was beneficial in chronic renal rejection with a decrease in proteinuria and reduced leukocytes 
infiltration in treated rats (Braun et al., 2001). 
Furthermore, considering the side effects of the use of heparin, derivatives of anticoagulant heparin 
were developed and showed promising results. One of the first study to demonstrate the beneficial 
effect of non-anticoagulant heparin was Diamond et al. in a rat model of glomerulosclerosis 
(Diamond and Karnovsky, 1986). The authors showed a decrease in proteinuria, and normal 
glomerular filtration rate in rats treated with nonanticoagulant heparin.  Later, Purkerson et al 
demonstrated that N-desulfated-acetylated heparin and heparin provided similar protection in rat 
subtotal nephrectomy (Purkerson et al., 1988). In puromycin-induced glomerulosclerosis, non-
anticoagulant heparin injection induced a better renal function and limited macrophages infiltration 
(Ceol et al., 2003). Furthermore, after transplantation, glomerular infiltration and TGFβ expression 
decreased in rat kidneys treated with a hypersulfated derivative of heparin (Gottmann et al., 2007).  
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Interestingly, small HS mimetics which are heparin derivatives can be generated not only to study 
specific protein bindings (Freeman et al., 2005) but also to modulate protein activities (Sheng et 
al., 2013). HS mimetics have a wide range of action including reducing CCL5 chemotactic 
activities (Sheng et al., 2013), decreasing FGF2 activation of ERK signalling in muscle satellite 
cells (Ghadiali et al., 2017) and reducing heparanase expression in vivo (Hammond et al., 2013). 
HS mimetics have been assessed in clinical trial for cancer treatment (Liu et al., 2009). 
Another approach to target HS binding to proteins is to synthesise HS based antagonist chemokine 
or peptides that can interfere with binding. Hence, the modified proteins or peptides can compete 
with the WT protein and decrease its activity. These methods are described section 5.1. 
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1.9 Questions raised by this study 
HSPGs main functions are regulated by the negative charge carried by their GAGs. Some of them 
can carry HS 3-O-sulfation, a rare but functionally important modification. To date, no study has 
documented the changes in HS 3-O-sulfation in renal fibrosis. Is this modification important in 
fibrosis? Does it increase or rather decrease following injury? 
Additionally, whether HS 3-O-sulfation increases or decreases, little is known about the growth 
factors affected by these changes. Do growth factors modulate HS3ST expression during renal 
fibrosis? Are growth factor binding and signalling events changed by HS 3-O-sulfation? 
Finally, with our knowledge of HS in fibrosis, is it possible to alter FGF2 binding by generating 
HS binding peptides? Can FGF2 binding to renal epithelial cells be altered by positively charged 
peptides?  
 
1.10 Aims  
This project had the ambition to: 
1. Determine if HS sulfation and HS modifying enzymes change during the development of 
renal fibrosis 
2. Understand how HS3STs expression is regulated and identify growth factors modulated by 
HS 3-O-sulfation 
3. Generate heparin binding peptides that could compete with FGF2 binding to HSPGs
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 General material and methods 
2.1 Cell Culture 
All experiments handling tissue culture were performed in a containment class II cabinet. Cells 
were maintained at 37°C under 5% CO2 in a humidified incubator. Control Of Substances 
Hazardous to Health (COSHH) and BIOCOSHH risk assessments were in placed before doing any 
experiment.  
 
2.1.1 Cell lines and media 
In this project, two models of human immortalised renal epithelial cells and one immortalised rat 
renal fibroblasts cells were studied. From the American Tissue Culture Collection, HK2 cells are 
cortex/proximal tubular epithelial cells isolated from a normal adult kidney and immortalised with 
the human papillomavirus 16. HK2 doubling time is not clearly known with studies showing time 
between 34.1 to 96h (Iwata and Zager, 1996; Keshari et al., 2013; Belmonte et al., 2016). 
HKC8 are cortex/proximal tubular cells isolated and immortalised by a hybrid virus, adenovirus 
12-SV40. They were isolated from the healthy pole of a renal cell carcinoma nephrectomy. HKC8 
doubling time is 20h.  
HK2 and HKC8 (Figure 2-1) have the feature of differentiated proximal tubule cells (Ryan et al., 
1994; Racusen et al., 1997). However, they display different features at the brush border. HK2 
cells have higher alpha-methyl-glucopyranoside uptake, gamma-glutamyl transpeptidase activity 
and NaK ATPase activity than HKC8. They have similar alkaline phosphatase and Glutathione-S-
transferase activity. HKC8 have no Glucose-6-phosphatase activity but have higher lysosomal and 
mitochondrial activity than HK2 (cathepsin B, succinate dehydrogenase, N-acetyl-beta-D-
Glucosaminidase (Racusen et al., 1997)). 
NRK-49F are rat renal fibroblasts from the American Tissue Culture Collection and have fusiform 
shape. 
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Figure 2-1: HK2 and HKC8 in culture  
HK2 (A) and HKC8 cells (B) are human renal epithelial cells. Both cell lines display a typical 
epithelial cuboidal shape. Magnification 200x. 
All media were supplemented with 2mM L-Glutamine, 100U/mL Penicillin, 100μg/mL (Sigma). 
HK2 were grown in Dulbecco’s Modified Eagle Medium (DMEM, Sigma, D5671) supplemented 
with 10% heat inactivated Fetal Bovine Serum (FBS). HKC8 were cultured in DMEM-F12 (Sigma, 
D6421) supplemented with 5% FBS. NRK-49F were cultured in DMEM supplemented with 5% 
FBS. 
 
2.1.2 General handling  
Cells were grown in T75 flasks and trypsinised with Trypsin-EDTA solution (Sigma) when 
confluent. Trypsin detaches the cells by cleaving peptide chains mainly at positively charged 
Lysine and Arginine on carboxyl side. EDTA prevents the inhibition of trypsin by chelating Ca2+ 
and Mg2- ions that are required for cell adhesion (e. g. integrin adhesion). Cells were washed with 
phosphate buffer solution (PBS, sigma) prior to trysinisation to remove any left-over medium that 
could inhibit the protease. Flasks were incubated at 37˚C to allow trypsin activity at the optimum 
temperature. Cells were collected by using medium with FBS that neutralises trypsin and then 
centrifuged 5 minutes at 300g. For cell counting, pellets were collected and suspended in 1mL 
PBS. A volume of 50μL was collected, diluted 20 times in trypan blue solution (0.4%), a dye that 
enters all cells but is actively excreted by living cells and counted with a Neubauer 
haemocytometer.  
For cells cryopreservation, cell pellets from T75 flasks with a confluency of more than 90% were 
A                                                                          B 
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suspended in a solution of 90% FBS, 10% Dimethyl sulfoxide (DMSO), a compound that prevents 
crystal formation during freezing and split in three 1mL cryovials. Vials were frozen at -80˚C in a 
freezing container (Thermo Scientific) filled with isopropanol that slows down the freezing 
process. Stocks were stored in a -80°C freezer for short-term storage or in liquid nitrogen for long 
term storage.  
For thawing cells, cryovials were defrosted at 37°C in a water bath, suspended in 3mL of complete 
medium and seeded into a T75 flasks containing 20mL of complete medium. Media were changed 
after 16h to remove DMSO. 
Cells were screened for mycoplasma once a month with the MycoAlert kit from Lonza. 
Mycoplasma are small self-replicating bacteria with no cell wall. They can interfere with protein, 
RNA, DNA production, cell cycle, cell signalling, cell membrane integrity (Drexler and Uphoff, 
2002). A volume of 200μL of supernatant from cells cultured more than 24h were collected and 
centrifuged for 5 minutes at 300g and mycoplasma detection was carried out according to the 
manufacturer’s protocol. The MycoAlert kit allows the detection of mycoplasma by lysing them 
and sensing the ability of a mycoplasma specific enzyme to transform ADP to ATP. The ATP 
produced was detected by bioluminescence. Mycoplasma positive cells were treated with 
MycoZapTM, elimination reagent, Lonza. 
 
2.2 Molecular Biology  
The University safety policy was followed for all experiments in accordance with COSHH 
regulations and approved GM project (03/31 a2). 
 
2.2.1 RNA extraction 
Reverse-Transcriptase and quantitative Polymerase Chain Reaction have been developed to study 
genes expression. Because of the instability and sensitivity of RNAs to RNAse, caution was taken 
during the procedure. RNAses can be found in the environment, as it is a way of protecting 
ourselves against pathogens. Furthermore, equipment and the experimenter are a source of DNA 
contamination. Therefore, filter tips, clean benches, pipettes and gloves were used at all time.  
Initially this method starts with the extraction of RNAs from a sample. In this study, two methods 
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of RNAs extractions were used. A column based one with the Qiagen RNeasy Plus Mini Kit for 
cell culture RNAs extraction and a Trizol/Chloroform method for mice tissue RNA extraction. The 
Trizol/chloroform technique is an effective method that includes three main steps: cell lysis; a 
phase separation to isolate RNAs from proteins, fatty acids, carbohydrates and DNA and finally 
RNAs precipitation and wash. The Qiagen RNeasy Plus Mini Kits is based on the same principles 
without the need to have a phase separation. Instead it uses a silica membrane, buffers containing 
guanidine thiocyanate (denaturing proteins), alcoholic buffers (to wash RNAs) to isolate RNA.  
Prior to use the Qiagen RNeasy Plus Mini Kits, cells coated on 6-well plates were washed with 
PBS, trypsinised, centrifuged 5 minutes at 300g and suspended in 1mL of PBS before a last 
centrifugation at 300g 5 minutes. Depending on their size, final pellets were vortexed in 350 to 
600µL of RLT plus buffer, a buffer that helps genomic DNA to bind to the gDNA eliminator spin 
column. This is to avoid any genomic DNA contamination. RLT buffer was supplemented with β-
mercaptoethanol to denature RNase. Samples were deposed onto a gDNA eliminator spin column 
and centrifuged 1 min soft mode at 10 000g. Columns were discarded and 1 volume of 70% ethanol 
was mixed by pipetting to the flow-through which was then deposed onto a RNeasy spin column 
and centrifuged 15 seconds at 10 000g. Flow-through was discarded and 700μL of RW1 buffer 
(containing guanidine salt and ethanol) was added to the column to wash it from carbohydrates, 
proteins, fatty acids that do not bind to the silica membrane of the column and centrifuged 15 
seconds at 10 000g. Once again, flow-through was discarded and 500μL of RPE buffer (a mild 
washing buffer with confidential composition) was added and tubes were centrifuged 15 seconds 
at 10 000g. This operation was repeated with a longer centrifugation (2 minutes). Finally, the 
columns were placed in a 1.5mL tubes, 30 to 40μL of Rnase free water was added onto it and tubes 
were centrifuged 2 minutes soft mode 10 000g.  
For tissue extraction, RNAs extraction was performed with a Trizol/ chloroform technique. Small 
pieces of tissue were lysed and homogenised in 200 µL of TRI reagent (Ambion) using the Tissue 
Lyser II by Qiagen. An additional volume of 500µL of TRI reagent was added and mixed by 
inversion. The RNA was isolated from the protein by adding 200µL of chloroform (AnalaR) and 
mixed by inversion. The samples were centrifuged at 14 000g for 15 minutes at 4ºC. Each aqueous 
phase containing soluble RNAs was collected and mixed by inversion with 500µL of isopropanol. 
The tubes were left at room temperature for 10 minutes and spinned down at 14 000g for 10 minutes 
at 4ºC. The precipitated RNAs formed a pellet that was suspended in 1mL of 70% ethanol and 
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centrifuged at 14000g for 10 minutes at 4ºC. Lastly pellets were air dried and suspended in 30μL 
of RNAse free water (Ambion). To avoid gDNA contamination 1 μg of sample was treated with 
RQ1 DNAse (Promega) for 30 minutes at 37°C. Next, samples were treated with DNase stop 
solution (Promega) 10 minutes 65°C to inactivate any DNAse before starting the reverse 
transcription. 
RNAs are composed of aromatic nucleobases that absorb 260nm wavelength light. Therefore, after 
extraction, all RNA concentrations were determined using a Nanodrop analysing density optic at 
260nm. Proteins contaminations were determined by measuring the samples absorbance at 280nm. 
Phenol and guanidine thiocyanate contaminations were determined by measuring the samples 
absorbance at 230nm. Samples with both ratios above 1.8 were considered as of good quality.   
 
2.2.2 Reverse Transcription and real time Polymerase Chain Reaction  
Complementary DNA (cDNA) was generated using Tetro cDNA synthesis kit (Bioline) containing 
the Moloney Murine Leukemia Virus Reverse Transcriptase. Briefly up to 5µg of RNA from cells 
extraction or up to 1μg from tissue extraction were incubating with Oligo dT primers, a 
deoxyNucleotides TriPhosphates mix, RT buffer, a ribosafe inhibitor and the transcriptase and 
RNAse treated water for a final volume of 20µL. Samples were incubated 30 minutes at 45°C, a 
temperature where the reverse transcriptase is active. Finally, samples were incubated 5 minutes at 
85°C to inactivate the reverse transcriptase. RNA were stored at -20°C for short-term storage and 
-80°C for long term. 
 
Real Time Quantitative Polymerase Chain reaction is a powerful technique for assessing the 
difference in genes expression between two samples. In this study, TaqMan probes (Thermofisher) 
were used to amplify cDNA (Table 2-1).  
The Probes carry a FAM fluorophore at their 5’ end and a quencher at their 3’end. When the 
fluorophore and the quencher are next to each other, no fluorescence can be detected. When the 
target gene is present, the probe binds to it and during elongation, the activity of Taq polymerase 
cleaves the probe, releasing the fluorophore and enabling fluorescent activity. This method allows 
DNA amplification and quantification to happen at the same time. The probe system was chosen, 
as it is specific to the gene of interest, Taqman probes being mostly designed between 2 exons. 
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Technically, RT samples were added to a blend of 10µL of 2x Sensifast Probe Hi-ROX mix 
(Bioline), 1µL of 10mM Probes (life technologies) and adequate volume of RNAse free H2O for a 
final volume of 20µL. Triplicates were added in a 96-well plates and amplified using StepOnePlus 
real time PCR thermal cycler (Applied Biosystems). The PCR cycling conditions included an initial 
polymerase activation at 95°C for 5 minutes followed by 40 cycles of denaturation at 95°C for 10 
seconds and annealing/extension at 60°C for 20 seconds.  
HPRT was defined as housekeeping gene to normalise CT values. DNA and water contaminations 
were assessed. Samples were analysed using the comparative ΔΔCT method.
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Table 2-1: Taqman Probes 
Gene expression was determined by using TaqMan probes from ThermoFisher. Genes’ names, symbols and manufacturer references are 
displayed in the table below. Hs: Homo sapiens, Mm: Mus musculus. Suffix m indicates probes that are designed between two exons 
whereas s defines probes that bind within a single exon. 
 
Species Gene name Gene Symbol Reference 
Human Heparan sulfate-glucosamine 3-O-sulfotransferase 3B1 HS3ST3B1 Hs01391447_m1 
Human Heparan sulfate-glucosamine 3-O-sulfotransferase 1 HS3ST1 Hs00245421_s1 
Human N-deacetylase and N-sulfotransferase 1 NDST1 Hs00925444_mH 
Human heparan sulfate-glucosamine 3-sulfotransferase 5 HS3ST5 Hs00999394_m1 
Human Heparan sulfate-glucosamine 3-O-sulfotransferase 3A1 HS3ST3A Hs00925624_s1 
Human Hypoxanthine guanine phosphoribosyl transferase HPRT1 Hs02800695_m1 
Human Heparan sulfate-glucosamine 3-O-sulfotransferase 1 HS3ST1 (for plasmid) Hs01099196_m1  
Mouse Heparan sulfate 6-O-sulfotransferase 1 HS6ST1 Mm01229698_s1 
Mouse Heparan sulfate (glucosamine) 3-O-sulfotransferase 6 HS3ST6 Mm01299930_m1 
Mouse Heparan sulfate (glucosamine) 3-O-sulfotransferase 1 HS3ST1 Mm01964038_s1 
Mouse Heparan sulfate (glucosamine) 3-O-sulfotransferase 3B1 HS3ST3B1 Mm03052977_s1 
Mouse Hypoxanthine guanine phosphoribosyl transferase HPRT Mm03024075_m1 
Mouse Sulfatase 1 SULF1 Mm00552283_m1 
Mouse Sulfatase 2 SULF2 Mm01248029_m1 
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2.2.3 Bacterial transformation 
Plasmid EX-TO223-M13 containing HS3ST1 enzyme sequence was purchased from GeneCopoeia 
(Figure 2-2). The plasmid was amplified by bacterial transformation as pictured Figure 2-3. 
Transformation of E.coli DH5α (Invitrogen) competent cells was performed by heat shock (45 
minutes on ice, 40 seconds at 42°C followed by 2 minutes on ice). The change in temperature 
changes the fluidity of the bacterial membrane, allowing the plasmid to penetrate the host. Varying 
concentrations of plasmid (4, 8, or 10ng) were added to 50µL of competent cells. After 
transformation, bacteria were incubated for 1 hour at 37°C in 1mL LB medium (Lysogeny Broth 
Invitrogen Ref 12780.052) under agitation. Bacterial suspensions were then streaked at 37°C for 
growth overnight onto LB Agar plates supplemented with 100µg/mL Ampicillin (AMP), the 
antibiotic plasmid selection. After 15 hours of incubation, a single colony from each plate was 
selected and incubated overnight in 10mL of LB medium complemented with AMP. 
 
Figure 2-2: EX-TO223-M13 HS3ST1 
To initiate gene expression T7 (bacterial promoter) and Cytomegalovirus (CMV, eukaryote 
promoter) were upstream of HS3ST1. A Flag Tag sequence was added at the C-term of HS3ST1 
to label the generated protein. BsrGI restriction endonuclease cleavage sites are used for plasmid 
digestion and removal of the HS3ST1 sequence. The coding sequence for the resistance to 
Ampicillin (AMP) was used for bacterial selection and Neomycin for eukaryote cells selection.  
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Figure 2-3 Plasmid amplification protocol 
Competent bacteria were transformed by heat shock and seeded on agar plate overnight at 37°C. A 
single colony was amplified in LB medium overnight under agitation at 37°C and the plasmid was 
isolated and analysed the following day. 
 
2.2.4 Plasmid purification and analysis 
Bacterial cells lysis and plasmid purification were performed using Plasmid Mini Kits (Qiagen). 
Bacterial pellets from 3mL culture were collected by centrifugation (15 minutes 6000g at 4°C) and 
suspended in 0.3mL of suspension buffer (50 mM Tris·Cl pH 8.0, 10 mM EDTA, 100 μg/ml RNase 
A) and lysed with 0.3mL of an alkaline solution (200mM NaOH, 1% Sodium Dodecyl Sulfate 
(SDS) (w/v)) at room temperature. SDS is a detergent that releases bacterial contents by 
solubilising phospholipids and denaturing proteins present in the membrane, NaOH gives alkaline 
condition that denatures DNA. Lysates were neutralised with 0.3ml of a cold solution of 3M 
potassium acetate pH 5.5 and centrifuged 10 minutes at 15 000g. Under these conditions only 
plasmid DNA will acquire its correct conformation and therefore be in solution. Supernatants were 
added onto an equilibrated anion exchange column where under low salt conditions DNAs bind. 
Two salt washing steps with a solution of 1.0M NaCl, 50 mM MOPS, pH 7.0, 15% isopropanol 
(v/v) removed remaining metabolites, protein and RNAs from the column. DNA was eluted by 
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adding 1.25M NaCl, 50mM Tris·Cl pH 8.5 15% isopropanol (v/v) onto the column. Plasmid DNA 
was precipitated with isopropanol and centrifuged 30 minutes at 15 000g. The remaining pellet was 
washed with 1mL of 70% ethanol and centrifuged 10 minutes 15 000g. Dried pellets were 
suspended in 40µL of Tris EDTA Buffer.  
Nucleic acid concentrations of the samples were calculated from their UV absorbance at 260nm 
with a nanodrop. To verify the plasmid integrity, samples isolated from the plasmid purification 
underwent restriction enzymes digests with the enzyme SalI that cleaves 2 sites of the plasmid. 
Following enzymatic digestion, all samples were loaded with 6X blue dye (promega) on a 0.8% 
agarose gel with 0.5-1μg/mL ethidium bromide and subjected to electrophoresis in Tris Acetate 
EDTA 1X buffer at 90V for 1-1h15. Fragments were visualised using AlphaImager. Plasmid 
sequencing was carried out by Source Bioscience. 
To generate an empty plasmid (plasmid without HS3ST1 sequence), 3μg of plasmid were digested 
with 30U of BsrGI (Bsp 1407I, ThermoFisher) in 1X Tango buffer for 3h at 37°C in a final volume 
of 40μL. The whole digestion was run into a 0.8% agore gel for 1h15 at 90V. The digested plasmid 
was quickly cut out of the gel under a U.V light and extracted using QIAquick Gel Extraction Kit 
Plasmid extraction. The final plasmid was ligated 3h at room temperature using T4 DNA ligase.  
 
2.2.5 Proteins extraction 
Cells proteins were extracted using CelLytic M (Sigma) complemented with anti-protease 
(Complete Mini Protease Inhibitor Cocktail, Roche) and for Phospho STAT3 analysis with anti-
phosphatase (Roche). At the time of extraction, 6-well plates were quickly placed on ice, washed 
twice with cold PBS and up to 200μL of lysis buffer was added into each well. The plates were 
placed on ice on a rotor for 15 minutes then scrapped. Lysates were collected in 2mL tubes and 
centrifuged 15 000g for 15 minutes at 4°C.  
Supernatants protein concentration was estimated with a PierceTM BCA Protein Assay Kit from 
ThermoFisher. This kit is based on the ability of bicinchoninic acid (BCA) to form a violet 
compound when 2 BCA bound to Cu1+. In alkaline condition, proteins will transform Cu2+ into 
Cu1+. The more concentrated the samples the more Cu1+which lead to the formation of a purple 
compound that absorbs light at 562nm. A standard curve with purified amounts of bovine serum 
albumin was used to determine the unknown samples concentration (Figure 2-4).  
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Figure 2-4: Protein concentration standard curve  
For protein quantification, a standard curve was generated using a serial dilution of known Bovine 
Serum Albumin concentration. The concentration was correlated to the absorbance at 562 with a 
linear function y (absorbance) = A x (protein concentration) + B. The coefficient of determination 
(R2) indicates how the equation fits the data with 1 being a perfect fit. 
 
2.2.6 Western Blot 
A list of antibodies used for Western Blot can be found Table 2-4. Between 10 to 50μg of protein 
extracts samples were denatured 10 minutes at 95°C in Laemmli buffer (BioRad) with β-
mercaptoethanol (5mM). Samples were electrophoretically separated by SDS Polyacrylamide gel 
with a 5% acrylamide stacking gel and a 10% acrylamide resolving gel (see composition Table 
2-2).  
The acryl-bisacrylamide creates a network for the proteins to go through. SDS is an anionic 
detergent that will denature proteins and charge them. TEMED and ammonium persulfate were 
added lastly to the mix as they catalyse the polymerisation. To determine protein sizes, samples 
were loaded together with a protein ladder (Page Ruler, Thermo Scientific) and transferred by semi 
dry transfer (BioRad) to a nitrocellulose membrane (BioRad). The main buffers used for Western 
Blot can be found in Table 2-3. 
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Table 2-2: SDS-Page gel composition 
Membranes were blocked for 1hour at room temperature in 0.1% Tween Tris-buffered saline (TBS) 
with 5% fat free milk or 5% Bovine Serum Albumin (BSA) when looking at phosphorylated 
proteins and probed overnight at 4°C using the following primary antibodies diluted in blocking 
buffer (Table 2-4). 
Electrophoresis Buffer 5X TBS 10X 
250mM Tris base (30.3g) 152mM Tris-HCL (24g) 
250mM MOPS (52.3g) 46mM Tris base (5.6g) 
17mM SDS (5g) 1.5M NaCl (88g) 
5mM EDTA (1.5g) H2O for final volume of 1L 
H2O for final volume of 1L pH 7.6 
Table 2-3: Western Blot buffer composition 
Following overnight incubation, membranes were washed in TBS 0.1% Tween 3 times for 5 
minutes. Membranes were incubated with the corresponding secondary antibodies conjugated with 
Horse Radish Peroxidase (R&D) (Table 2-4) for 1h at room temperature under agitation. 
Membranes were washed 3 times for 5 minutes with TBS 0.1% Tween and finally immunopositive 
bands were visualised by enhanced chemiluminescence using Supersignal West Pico, 
Chemiluminescent, Thermo Scientific Reagents. The membrane was then exposed to X-ray films.    
Stacking gel (5%) Resolving gel (10%) 
4.1mL H2O 4mL H2O 
1mL 30% acryl-bisacrylamide mix 3.3mL 30% acryl-bisacrylamide 
0.75mL 0.5M Tris pH 6.8 2.5mL 1.5M Tris pH 8.8 
60μL SDS 10% 0.1mL SDS 10% 
60μL ammonium persulfate 10% 0.1mL ammonium persulfate 10% 
6μL TEMED 4μL TEMED 
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 Type Target Reference Manufacturer Dilution 
I Rabbit monoclonal Stat3 Y705 ab76315 Abcam 1:20 000 
I Rabbit polyclonal Flag tag DYKDDDDK 2368 Cell signalling 1:3000 
I Mouse monoclonal alpha Tubulin T6074 Sigma 1:4000 
I Rabbit monoclonal Phospho-Erk p44/42 4370 Cell signalling 1:1000 
I Mouse monoclonal Pan ERK 610124 BD Transduction laboratories 1:1000 
II Goat polyclonal-HRP conjugated Mouse IgG HAF007 R&D 1:1000 
II Goat polyclonal-HRP conjugated Rabbit IgG HAF008 R&D 1:1000 
Table 2-4: List of antibodies for Western Blot. I=primary antibody, II= secondary antibodies 
 
2.3 Immunofluorescence  
2.3.1 Antibodies  
 Type Target Reference Manufacturer Dilution 
I Rabbit polyclonal Flag tag DYKDDDDK 2368 Cell signalling 1:800 
I Mouse polyclonal GM130 ab 169276 Abcam  1:70 
I Rabbit polyclonal HB EGF ab 192545   Abcam  1:200 
I Phage display VSV HS-3-0-sulfation HS4C3 Prof van Kuppevelt 1:5 
I Rabbit polyclonal Fibronectin sc-8422 Santa Cruz 1:100 
I Mouse monoclonal E-cadherin 610181 BD Biosciences 1:100 
I Mouse monoclonal smooth muscle α-Actin sc-32251 Santa Cruz 1:100 
II Mouse monoclonal Cy3  VSV glycoprotein C7706 Sigma 1:200 
II Goat Polyclonal Alexa fluor 488 Mouse IgG A11001 Thermo Fisher 1:100 
II Goat Polyclonal Dylight 550  Rabbit IgG GtxRb-003-D550NHSX Immunoreagents 1:100 
Table 2-5: List of antibodies used for immunofluorescent staining 
I=primary antibody, II= secondary antibodies 
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Techniques of immunofluorescence are a great asset for tissue imaging and to localise and track 
molecules within the matrix, the basal membrane and within the cell. Images were taken with Leica 
LCM microscope, Zeiss Axioimager, Nicon A1R confocal microscope. For tissue culture images, 
pictures were taken by Carl Zeiss 40CFL microscope. Immunofluorescent images were analysed 
using Fiji and Zen softwares. 
 
2.3.2 Chamber slides staining  
All antibodies references and dilutions can be found Table 2-5. 
For protein staining: 
HK2 and HKC8 cell lines were cultured in complete media into 8-well chamber slides (Falcon, 
corning). Cells were 60-80% confluent when starting the staining in order to have some space 
between the cells and therefore a better staining. Cells were fixed in ice-cold methanol for 5 minutes 
at -20°C and gradually rehydrated with PBS. To avoid unspecific binding, 5% BSA in PBS was 
added into each well at room temperature for 2h. Albumin binds widely to the proteins on the cells. 
Primary antibodies were diluted in PBS (see Table 2-5) and incubated overnight at 4°C to allow a 
slow, specific and high binding of the primary in a humidified chamber to prevent the slides from 
drying. The next day, slides were washed 3 times for 5 minutes with PBS and incubated 2h at room 
temperature with the corresponding secondary antibody in the dark to avoid photo bleaching. 
Finally, slides were washed 3 times for 5 minutes in PBS and mounted with liquid mounting 
medium containing DAPI (Vectashield) and stored in the dark at 4°C until imaging. 
 
2.3.3 Paraffin embedded staining  
Mouse kidneys were dissected and fixed in 4% formalin solution and embedded in paraffin by the 
Royal Victoria Infirmary pathology services. Serial tissue sections of 4µm thickness were cut and 
mounted onto slides. Sections were dewaxed for 5 minutes in xylene and gradually rehydrated with 
incubation in decreasing alcohol concentration solution of 99%, 95%, 75% and finally tap water. 
Peptide retrieval was performed by microwaving the slides in 200 mL of EDTA buffer two times 
5 minutes on high power then cool down for 20 minutes. Sections were blocked 10 minutes with 
2% fetal bovine serum in PBS to block non-specific binding sites at room temperature. Sections 
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were incubated overnight in the dark at 4°C with primary antibodies. The next day sections were 
washed 3 times 5 minutes with PBS then incubated with secondary antibody diluted in PBS for 1-
2h at room temperature. Sections were then washed 3 times 5minutes in PBS, incubated with Sudan 
Black for 20minutes in the dark at room temperature and finally washed 3 times in PBS before 
mounting with VECTA shield DAPI liquid mounting medium. Sudan black was used to remove 
any background of fluorescence. 
 
2.4 Flow cytometry 
2.4.1 Principles 
Flow cytometry is a powerful tool for analysing single cells. It can distinguish different cell 
population by examining how a cell scatters a known wavelength light. Cell’s size is determined 
by a Forward Scatter Channel (FSC) that collects light scattered in the forward direction. Internal 
structure and granulosity are determined by a Side Scatter Channel (SSC) that collects light 
scattered at 90°. Additionally, cells can be fluorescently labelled to quantify extracellular and 
intracellular molecules. A laser beam stimulates the fluorophore and a detector collects the emitted 
fluorescence. All measurements collected by a detector correspond to a parameter. For this study 
Fluorescein isothiocyanate (FITC) was used with an excitation wavelength of 488nm and a 
fluorescence emission detectable by a 530/30 filter. An example of excitation-emission spectra can 
be found Figure 2-5.  
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Figure 2-5: FITC laser excitation and emission spectra 
Using the FACS Canto II, FITC is excited at 488nm. Fluorescence is detected with a 530/30 filter. 
Source: BD-biosciences. 
 
2.4.2 FGF2 binding 
FGF2 binding was studied with the Human FGF basic biotinylated Fluorokine Flow Cytometry kit 
(R&D). The use of a biotinylated FGF2 allowed a very strong binding with the associated Avidin-
FITC that enables an amplified signal. Cells cultured in T75 flasks were detached with Accutase 
(Biolegend) or cell dissociation solution (Sigma). Trypsin could not be used as it alters the heparan 
sulfate proteoglycan present on cell surfaces. Cells suspension was washed twice with PBS and 
resuspended in PBS containing 2% BSA at a concentration of 4x106 cells/mL. In 2mL tubes, 25μL 
of the cell suspension (100 000 cells) was incubated with 10μL of 1mg/mL of biotinylated FGF2 
or with a biotinylated negative control (a soybean trypsin inhibitor that does not bind to cells) for 
1h at 4°C. In the same tube, 10μL of Avidin-FITC conjugated secondary were added for 30 minutes 
in the dark at 4°C. The cells were washed twice with 2mL of 1X RDF1 (a buffered saline-protein 
solution specifically designed to minimise background staining and stabilise specific binding) to 
remove unbound avidin-FITC. Finally, cells were suspended in 0.2mL of 1X RDF1 for flow 
cytometry analysis with FACS Canto II. 
For peptides and peptoids treatments, time of incubation and concentration are specified in the 
specific method sections. 
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2.5 Software and statistics 
Graphs were created using Microsoft Excel and GraphPad Prism 6.0. Diagrams were generated 
using Microsoft PowerPoint and Servier Medical Art images (http://servier.com/Powerpoint-
image-bank). Chemical compounds were drawn with ChemDraw. Plasmids were designed using 
ApE (Universal).  
Results are expressed as mean±SD. Statistical evaluations were performed using GraphPad Prism 
6.0. Significant results were considered when P<0.05 (*), P<0.01 (**) and P<0.001 (***). Unless 
specified, P values were calculated using one way ANOVA with Bonferonni’s correction and two 
tailed unpaired student’s t-test with Welch’s correction for in vitro treatments and two tailed 
unpaired student’s t-test with Welch’s correction for the in vivo work. 
Heparan sulfate modulation in vivo 
 
62 
 Heparan sulfate modulation in vivo 
 
3.1 Introduction 
3.1.1 Heparan sulfate in human kidney diseases 
The study of HS and its modifications is more complex than studying proteins for which antibodies 
can be generated and used. Fortunately, in the 1990s, HS antibodies were created to study the 
number of HS chains attached to a core protein (antibody 3G10), the amount of HS (antibody 10E4) 
(David et al., 1992), and the different degree of sulfation (phage display antibodies, (van Kuppevelt 
et al., 1998)). Furthermore, the synthesis of HS disaccharide standards have allowed the 
development of HS sequencing techniques by high performance liquid chromatography and mass 
spectrometry (Hart and Varki, 2015).  
Because these tools have been newly developed and used, only recent research has examined HS 
in renal diseases. HS has previously been studied by indirect immunofluorescence in patients with 
lupus nephritis, membranous glomerulonephritis, minimal change disease and diabetic 
nephropathy where glomerular staining was decreased (Van Den Born et al., 1993). In the same 
study, renal biopsies from Alports syndrome and IgA nephropathy showed similar staining to 
control kidneys. However, when analysing not only HS but HS sulfation, patients with proliferative 
lupus nephritis had a significant increase of HS N, 2 and 6-O-sulfation in their glomeruli (Rops et 
al., 2007). Furthermore, human renal allograft biopsies showed an increase in HS 2-O and 6-O-
sulfation staining compared to normal human kidney (Alhasan et al., 2014). In contrast, 
disaccharide analysis of the glomerular basement membrane of diabetic patients revealed a 
decrease in 3-O-sulfation (Edge and Spiro, 2000).  
Another way to study HS sulfation is to analyse HS modifying enzyme expression. To date very 
little research has analysed the expression of HS sulfotransferases in human kidney diseases. 
Recent studies have looked at HS3ST1 expression in transplanted patients. One study found 
HS3ST1 expression increased in the blood of tolerant patients (Sagoo et al., 2010) while  another 
one found it increased in the kidneys of failing grafts (Einecke et al., 2010). Additionally, HS3ST1 
expression was found negatively correlated with glomerular filtration rate (Bunnag et al., 2009). 
No mechanistic explanations were given to determine the significance of HS3ST1 expression for 
renal function. 
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Taken together these data indicate that HS sulfation is complex in the way that a decrease in HS 
does not necessary correlate with a decrease in HS sulfation. Furthermore, depending on the type 
of disease, HS sulfation can be decreased or increased. Additional studies and in vivo models can 
help elucidate how HS changes during renal fibrosis and what modulates HS with time. 
 
3.1.2 Animal models of renal diseases  
The use of animal models is important for understanding the mechanisms of disease development, 
signalling, testing new drugs and finding biomarkers. There are many different models of renal 
diseases in rat, pigs and mice. The risk factors for CKD development can be study with the use of 
genetically modified or selected animals with obesity (ob/ob mice, New Zealand obese Mice, db/db 
mice, etc), insulin resistance (KK-Ay mouse, Zucker diabetic fatty rat) and also hypertensive 
animals. However here I will focus on acute injury models that can lead to the development of 
renal fibrosis. 
 
3.1.2.1 Pre-renal acute injury 
Ischemia Reperfusion Injury (IRI) can be studied in vivo by clamping a renal artery to generate 
ischemia and then restoring blood flow to cause reperfusion damage. In this model, a longer 
ischemic period can induce more damage (Hesketh et al., 2014). The IR procedure can be 
performed in one or both kidneys. However unilateral ischemia does not allow the study of renal 
function as the contralateral kidney remains functional. IR can be performed on one kidney and a 
nephrectomy on the non-ischemic kidney to allow functional measurement. IRI can vary with body 
temperature, animal strain, age and sex (Wei and Dong, 2012). Various anesthetics can be used but 
volatile agents such as isoflurane have been found to be protective (Erturk, 2014). This model 
generates cell death, mitochondrial and ER stress, inflammation and fibrosis. The IRI model is a 
good tool to understand what happens during organ transplantation as the organ is subjected to IRI 
and can be used to test drugs to prevent injury. HSPGs such as syndecan-1 can sometimes protect 
from fibrosis development with Syndecan-1 -/- mice showing increased tubular injury following 
bilateral IRI (Celie et al., 2012). 
Another model of ischemic injury is induced by creating arterial stenosis with the use of a stent to 
reduce blood flow. Compared to IR surgery, the arterial stenosis model can be less invasive 
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(Lerman et al., 1999). However, this model only reduces blood flow and does not stop it. 
Additionally, invasive procedures using clip on one or both arteries to study arterial stenosis can 
be done.  
 
3.1.2.2 Intrinsic acute injury 
The use of drugs to treat disease can damage kidneys. For example, aminoglycoside antibiotics 
such as gentamicin can accumulate within tubules and trigger necrosis and generate acute injury. 
Models can be used to understand the toxicity and develop drugs that reverse the side effects (Li et 
al., 2009). The injection of Adriamycin, a chemotherapy drug, generates podocyte effacement, 
glomerular hypertrophy and the development of fibrosis accompanied with protein excretion (Lee 
and Harris, 2011). Adriamycin was found to increase glomerular heparanase expression and 
decrease HS (Kramer et al., 2006b), indicating a potential role for HS loss in disease progression. 
Drugs used in renal transplant patients can be nephrotoxic. Calcineurin inhibitors, which inhibit T 
cell activation, can disrupt endothelial function (Oflaz et al., 2003). The use of animal models to 
study nephrotoxic drugs is important for the development of improved molecules with fewer side 
effects. 
Finally, there are models of sepsis that can be used. This includes the intraperitoneal injection of 
lipopolysaccharides (LPS), the ligation into the ileocecal valve (a muscle that separates the small 
and the large intestine) and puncture of the caecum (Rittirsch et al., 2009) or the insertion of a stent 
into the ascending colon to allow bacteria to migrate into the peritoneal cavity (Traeger et al., 
2010). In this model, a loss of HSPG on the endothelium together with an increase of heparanase 
within the glomerulus was observed (Xu et al., 2014). The loss of HS could be linked to disease 
progression and should be further studied. Once again studying these models can help generate 
new drugs or biomarkers for sepsis.  
 
3.1.2.3 Postrenal acute injury 
As discussed in chapter 2, postrenal injury is due to the obstruction of the urinary tract. To date, 
only two models have been developed. In rats, kidney stones can be generated by injection of 
vitamin B6, sodium oxalate, ammonium oxalate, hydroxyl-L-proline, ethylene glycol, glycolic acid 
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and glyoxalate (Khan, 2010). HSPG are thought to play a role in crystal formation  with syndecan-
1 expression increasing in rat kidneys with stone formation (Iida et al., 1997). 
The other model, which is studied in this chapter, is Unilateral Ureteral Obstruction (UUO). The 
UUO model can be used to study reversible injury if the obstruction is removed or chronic 
irreversible injuries when the obstruction is definitive (Chevalier et al., 2009). It induces tubular 
dilatation, immune cells infiltration and the development of interstitial fibrosis. The contralateral 
kidney can be used as a control even though some changes can occur in response to the other 
damaged kidney. In this model, renal function can only be assessed if the UUO is performed 
together with re-implantation and a nephrectomy of the contralateral kidney. This model can be 
used to study recovery when the obstruction is removed. The first functional damage can be 
observed within 24h (Vaughan et al., 2004). The obstructed kidney shows increased staining of 
interstitial col I, col III, fibronectin and perlecan between 3 to 7 days of UUO (Sharma et al., 1993). 
This model is adequate for the study of interstitial fibrosis, a disease which is currently irreversible. 
Hence the importance and the use of UUO for this project. 
Taken together, the review of the different models of kidney diseases and the lack of information 
regarding HS 3-O-sulfation raised interest about the potential changes in sulfation. The aims of this 
chapter are: 
-To identify if the UUO model was suitable for assessing HS sulfation changes during the 
development of interstitial fibrosis 
-To analyse the changes in HS 3-O-sulfation with renal fibrosis 
-To identify new HS binding growth factors possibly modulated by HS 3-O-sulfation 
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3.2 Specific material and methods  
3.2.1 Unilateral Ureteral Obstruction experiment  
The UUO model was selected to analyse the changes in HS during renal fibrosis. In order to observe 
the changes with the severity of disease, three different time points were selected. Mice were 
subjected to UUO for 5, 10 and 15 days. All experiments were carried out under UK Home Office 
regulations (PPL60/4521) at the Comparative Biology Centre (CBC), Newcastle University. Mice 
were housed in cages of 6 animals and had free access to food and water throughout the experiment.  
C57BL/6 female mice aged 8-10 weeks were anaesthetised (ketamine/medetomidine), shaved 
around their lower abdomen and injected subcutaneously with the pain killer buprenorphine. To 
access the left kidney, a laparotomy incision in the lower abdomen was made. Once the ureter was 
isolated, it was tied from 1cm of the kidney with Mersil 6.0. A second knot was made at 
approximately 3mm from the first one and the ureter was cut in-between the two knots. The 
abdomen was then closed with 5.0 vicryl. The right kidney was not manipulated and used as a 
control. At the end of the surgery, mice were injected with the reversal atipamezole. Eye ointment 
was applied to all animals to avoid eye dryness.  
 
 
Figure 3-1: UUO plan of experiment 
 
3.2.2 Samples collection 
At D5, D10 and D15 after UUO, blood, urine, spleen and kidneys were retrieved. However, urine, 
blood and spleen samples were not used for this study. Kidneys were dissected into 4 parts. Half 
of the kidney was directly put into a cassette and placed in 4% formalin for paraffin embedding. 
The other half was cut into three pieces, one was left in RNAlater for RNA extraction, the two last 
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pieces were snap frozen for disaccharide analysis and cryosections. The experimental plan is 
illustrated Figure 3-2. 
RNAs extraction and staining on mice kidneys were described in section 2. 
 
Figure 3-2: Samples collection and analysis following UUO 
 
3.2.3 HS disaccharides analysis from mice kidney 
HS disaccharides analysis was performed at the “Institut de Biologie Structurale”, Grenoble France 
by Dr Romain R Vives and the PhD student Rana el Masri as described previously (Hijmans et al., 
2017). 
 
3.2.4 Paraffin embedded sections staining 
Paraffin embedded kidney tissues were cut at 4µm thickness and mounted onto slides. All staining 
started with a dewax and rehydration step. Sections were dewaxed 5 minutes in xylene and 
rehydrated in decreasing concentration of ethanol. First slides were incubated for 10 seconds in 
99% ethanol, then 10 seconds in 95% ethanol, 10 seconds in 70% ethanol and finally 1 minute in 
tap water. 
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Haematoxylin and Eosin (H&E) staining was performed on paraffin embedded sections. Following 
dewaxing and rehydration, slides were incubated for 80 seconds in Mayers haematoxylin and 
washed for 1 minute under tap water. The Mayers haematoxylin solution is composed of hematein 
(oxydised haematoxylin) complexed to metal ions (usually Al+3) providing an overall positive 
charge. The complex binds negatively charged molecules such as chromatin and may bind to mucin 
and proteoglycans. In general, hematein Al+3 gives a red/purple nuclear coloration, to turn the 
nuclear coloration into blue, slides were incubated in Scott’s solution 30 seconds and washed in 
tap water. Slides were incubated 30 seconds in alcoholic eosin and washed briefly in tap water. 
Eosin is a negatively charged synthetic dye and therefore binds positively charged proteins within 
the tissue. Red blood cells are colored red and muscle, collagen, cytoplasm pink. Slides were 
dehydrated by 10 seconds incubation in 70%, 90%, 95% ethanol and finally xylene. Slides were 
mounted with DPX and imaged using Zeiss Axioimager. 
For Sirius red staining, nuclei were stained 8 minutes in Weigert’s haematoxylin and washed in tap 
water. Slides were then incubated for 1 hour in 0.1% solution picro Sirius red and washed twice in 
acidified water (5mL of glacial acetic acid into 1L of water). Sirius red sulfonic acid groups can 
bind to basic amino acids and gives a pink/red color. It can stain collagen I and III but also amyloid 
fibrils. The acidified water removes any excess of staining. Finally, samples were dehydrated in 
three quick washes of ethanol 100% and mounted. Images were analysed using LeicaQWin 
analysis software with 10 cortex fields analysed per section for each kidney. 
Peptide retrieval was performed by microwaving the slides in EDTA buffer. Sections were blocked 
10 minutes with 2% FBS in PBS and incubated overnight at 4°C with primary antibody (HB-EGF 
ab192545 Abcam 1:200, HS4C3 1:5 given by Toin van Kuppevelt, Radboud University, 
Netherlands). The next day, sections were washed in PBS, then incubated with secondary antibody 
(anti VSV C7706 sigma, Dylight 550 Immunoreagent) diluted in PBS for 1-2 hours at room 
temperature. Sections were then washed in PBS, incubated with Sudan Black for 20 minutes in the 
dark at room temperature and finally washed in PBS before mounting with VECTA shield DAPI 
liquid mounting medium.   
Immunofluorescence images were analysed using Fiji and Zen softwares.   
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3.2.5 Cryosection staining  
3.2.5.1 Generating fluorescently labelled AT 
Fluorescently labelled Antithrombin III (AT) was generated using Alexa fluor 647 labelling kit 
from ThermoFisher Scientific, A20173. The procedure is shown Figure 3-3. A quantity of 1mg of 
AT (Calbiochem, 169756) was suspended in PBS and dialysed twice with 6mL of PBS to remove 
any Tris that could interfere with the labelling as the dye binds to amine residues. Alexa fluor 647 
is a succinimidyl ester that reacts best at pH 7.5-8.5. Therefore, a volume of 50µL of 1M 
bicarbonate was added to 450µL of the dialysed AT to increase the pH. The solution of AT was 
then incubated for 2h at room temperature with Alexa fluor 647 and gently mixed with a magnetic 
stirrer. A BioGel P30 column was used to separate the labelled AT from the free dye. Labelled AT 
was eluted by gradually adding elution buffer (10mM potassium phosphate, 150mM NaCl, pH 7.2, 
0.2mM sodium azid). The labelled AT was collected into a final volume of 1.2mL. The final 
labelled protein was diluted 1 in 5 and absorbance values at A280, A650 were taken to determine 
the degree of labelling using the formula: 
Protein concentration (M)=
(𝑨𝟐𝟖𝟎−(𝑨𝟔𝟓𝟎×𝟎.𝟎𝟑))× 𝒅𝒊𝒍𝒖𝒕𝒊𝒐𝒏 𝒇𝒂𝒄𝒕𝒐𝒓
𝟑𝟕 𝟕𝟎𝟎
 
37 700 cm-1M-1 is the molar extinction coefficient of AT. 
Moles dye per mole protein =
𝑨𝟔𝟓𝟎× 𝒅𝒊𝒍𝒖𝒕𝒊𝒐𝒏 𝒇𝒂𝒄𝒕𝒐𝒓
𝟐𝟑𝟗 𝟎𝟎𝟎× 𝒑𝒓𝒐𝒕𝒆𝒊𝒏 𝒄𝒐𝒏𝒄𝒆𝒏𝒕𝒓𝒂𝒕𝒊𝒐𝒏 (𝑴)
  
239 000 cm-1M-1 is the molar extinction coefficient of the Alexa fluor dye. 
The degree of labelling was about 25.5 moles of dye per mole of protein. This can be considered 
as over-labelling. Overlabel can cause aggregation, dye quenching and unspecific staining. 
Therefore, optimisation and assessment of the staining quality and specificity was required. 
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Figure 3-3: Antithrombin III labelling with Alexa fluor 647 
AT was purchased from Calbiochem and labelled with Alex fluor 647 (ThermoFisher Scientific). 
 
3.2.5.2 Antithrombin III staining 
The use of labelled AT to detect HS 3-O-sufation has been previously described (Girardin et al., 
2005) and this method was followed for staining. Cryosections of 7m thickness were fixed in 
acetone and hydrated 15 minutes in PBS. Slides were blocked with 1% BSA in PBS for 20 minutes 
at room temperature and incubated for 1h with 1:5 labelled AT (lb AT) in the dark. Sections were 
then washed 3 times with blocking buffer and 1 time in PBS. Slides were mounted using 
Vectashield containing DAPI. As observed Figure 3-4, the staining with lb AT showed positive 
staining on the tubules basement membrane and blood vessels. Due to the faint DAPI staining, 
glomerular staining was difficult to assess. Therefore, a second optimisation was performed using 
a different mounting medium. The second time slides were mounted with Prolong Diamond 
antifade containing DAPI (ThermoFisher Scientific) mounting medium and were incubated for 24h 
at room temperature in the dark before imaging. As observed Figure 3-5, the staining was localised 
at the tubular basement membrane, on vessels and within the glomerular vascular structures. This 
staining was similar to what was observed before (Girardin et al., 2005). However, to make sure 
the staining was specific for heparan sulfate, a competition assay was performed with heparin. 
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Figure 3-4: First staining with labelled antithrombin III 
Representative images of labelled AT staining. Control kidney cryosections were blocked for 20 
minutes in 1% BSA and incubated for 1h with 1:5 labelled AT or with blocking buffer (negative 
control). Slides were mounted with Vectashield containing DAPI. Scale bars represent 100µm. 
 
Figure 3-5: Second staining with labelled antithrombin III staining 
Representative images of labelled AT staining. Cryosections from control kidney were blocked for 
20 minutes in 1% BSA and incubated for 1 hour with 1:5 labelled AT or blocking buffer (negative 
control). Slides were mounted with prolong diamond antifade containing DAPI and were stored 
24h at room temperature before imaging. Scale bars represent 100µm. 
 
 
3.2.5.3 Testing AT staining specificity 
Slides were blocked for 20 minutes at room temperature in 1% BSA in PBS and incubated for 1 
hour with 1:5 lb AT ± 20-200µM heparin. Slides were then washed three times with blocking 
buffer, mounted with prolong diamond antifade with DAPI 24 hours before imaging. As seen 
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Figure 3-6, the staining was completely abolished with the addition of heparin, confirming 
specificity of the labelled AT binding. 
 
Figure 3-6: Assessing labelled AT staining specificity with heparin competition 
Representative images of labelled AT staining. Cryosections from control kidney were blocked for 
20 minutes in 1% BSA and incubated for 1 hour with 1:5 labelled AT ± Heparin (20-200µM) or 
blocking buffer (negative control). Slides were mounted with prolong diamond antifade containing 
DAPI and were stored 24 hours at room temperature before imaging. Scale bars represent 100µm. 
N=3 
 
 
3.3 Results 
3.3.1 Anatomical changes during UUO  
As seen Figure 3-7, H&E staining of control, D5, D10 and D15 UUO kidney tissues showed 
morphological changes with the development of fibrosis. The staining was different in ureteral 
obstructed kidneys compared to control due to the increase in infiltrating cells and the excess 
deposition of ECM. Additionally, tubular structures were dilated at D5, D10 and predominantly at 
D15. At D15 UUO, the cortex was very damaged and narrow making it difficult to analyse. 
Therefore, further experiments focused on D5 and D10 UUO. 
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Figure 3-7: Haematoxylin and Eosin staining of control, D5, D10 and D15 UUO 
Representative images of Haematoxylin and Eosin staining of cortex from control unobstructed 
kidney, D5, D10 and D15 UUO. Paraffin embedded sections of 4µm were dewaxed, rehydrated, 
stained for H&E and mounted with DPX. UUO generates tubular dilatation which was found to be 
very severe at D15 UUO. Images were taken by Zeiss Axioimager. Scale bars represent 100 µm. 
N≥5 per group with 3 cortical fields captured per section. 
 
In order to estimate the level of fibrosis, slides were stained with Sirius red, a dye that stains 
collagen fibers red. In control tissue, glomerular capillaries, vessels and some interstitial tissues 
displayed a red staining. At D5 and D10 UUO, the staining was different to control with an increase 
in collagen deposition in the interstitium as seen Figure 3-8. Sirius red quantification showed 
significantly increased staining at D5 (p<0.05) and D10 (p<0.001) UUO.  
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Figure 3-8: Sirius red staining and quantification  
Paraffin embedded sections of 4µm were dewaxed, rehydrated, stained with Sirius red and mounted 
with DPX. Interstitial fibrosis was quantified by Sirius red staining (graph). N=6 per group with 
10 cortex fields analysed per section for each kidney. Collagens are stained in red. Images were 
analysed using LeicaQWin analysis software. Two-tailed unpaired t test, p<0.05 (*), p<0.001 
(***). 
 
3.3.2 Heparan sulfate 2-O and 6-O-sulfation changes in renal fibrosis 
The changes in the ECM with the development of fibrosis is well-described in the literature. 
However, not much is known about HS sulfation changes. To assess if there was an alteration in 
HS sulfation in the UUO model of fibrosis, HS sulfation and disaccharide sequencing analyses 
were performed in collaboration with the institute of structural biology in Grenoble.  
N-acetylation and N-sulfation were not changed at D5 UUO (Figure 3-9). However, a decrease of 
12.6% in N-acetylation together with an increase of 14.4% in N-sulfation was observed at D10 
UUO. 
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Figure 3-9: Total N-acetylation and N-sulfation in control and D5, D10 UUO 
HS sulfation of 6 pooled control unobstructed kidney, D5 UUO and D10 UUO is represented as 
percentage of total disaccharides with error bars from three technical replicates. A represents N-
acetylation and B N-sulfation. Results are represented as mean ±SD. 
As observed Figure 3-10, total HS 2-O-sulfation was increased at D5 and D10 UUO by 45.3% and 
19.2% respectively compared to control. In contrast, there was a slight decrease in total HS 6-O-
sulfation in UUO at D5 (-6.4%) and D10 (-4.4%).  
 
Figure 3-10: Total HS 2-O and 6-O-sulfation in control and D5, D10 UUO 
HS sulfation of 6 pooled control unobstructed kidney, D5 UUO and D10 UUO is represented as 
percentage of total disaccharides with error bars from three technical replicates. A represents HS 
2-O-sulfation and B HS 6-O-sulfation. Results are represented as mean ±SD. 
 
For a deeper understanding of disaccharide changes responsible for the changes in total sulfation, 
HS disaccharide composition was studied. The proportion of monosulfated disaccharides are 
shown in Figure 3-11. At D5 UUO, N-sulfated and 6-sulfated monosaccharides were decreased by 
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24% and 11.2% while there was three times more ΔUA2S-GlcNAc compared to control. At D10 
UUO, the 6-O monosulfated disaccharides was still decreased by almost 30% compared to control 
while ΔUA-GlcNS increased by 14.4% and ΔUA2S-GlcNAc decreased by nearly 50%. 
Regarding disulfated disaccharide (Figure 3-12), ΔUA2S-GlcNS was increased at both time points 
with a 43% increase at D5 and 29.5% at D10 UUO compared to control. In contrast, ΔUA-GlcNS6S 
decreased by 43.5% at D5 and 14.4% at D10. 
The unsulfated disaccharide ΔUA-GlcNAc was not changed with UUO. However, the trisulfated 
disaccharide ΔUA2S-GlcNS6S showed an increase by 23.4% at D5 and 17.4% at D10 UUO 
(Figure 3-13). Together, these data revealed an increase in HS 2-O-sulfation with a decrease in HS 
6-O-sulfation with the UUO model. 
 
 
Figure 3-11: Monosulfated disaccharides analysis in control and at D5 and D10 UUO 
HS monosulfated disaccharides analysis of 6 pooled control unobstructed kidney, D5 UUO and 
D10 UUO is represented as percentage of total disaccharides with error bars from three technical 
replicates. The monosulfated disaccharides ΔUA-GlcNS is represented in A, ΔUA2S-GlcNAc is 
represented in B and ΔUA-GlcNAc6S in C. Results are represented as mean ±SD.  
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Figure 3-12: Disulfated disaccharides analysis in control and at D5 and D10 UUO 
HS disulfated disaccharides analysis of 6 pooled control unobstructed kidney, D5 UUO and D10 
UUO is represented as percentage of total disaccharides with error bars from three technical 
replicates. The disulfated disaccharides ΔUA2S-GlcNS is represented in A and ΔUA-GlcNS6S in 
B. Results are represented as mean ±SD. 
 
Figure 3-13: Unsulfated and trisulfated disaccharides analysis in control, D5 and D10 UUO 
HS disulfated disaccharides analysis of 6 pooled control unobstructed kidney, D5 UUO and D10 
UUO is represented as percentage of total disaccharides with error bars from three technical 
replicates. The unsulfated disaccharides ΔUA-GlcNAc is represented in A and the trisulfated 
disaccharides ΔUA2S-GlcNS6S in B. Results are represented as mean ±SD.  
 
HS sulfation analysis was also performed in samples from D15 UUO. These data are presented 
separately as the results were unexpected, with a very high level of trisulfated disaccharides 
potentially due to an incomplete digestion. However, it is possible that there is an increase in 
sulfation at D15 but caution should be taken when analysing these data (Figure 3-14). 
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Figure 3-14: HS sulfation increase at D15 UUO 
HS disulfated disaccharides analysis of 6 pooled control unobstructed kidney, D5 UUO, D10 UUO 
and D15 UUO are represented as percentage of total disaccharides with error bars from three 
technical replicates. A is the total 2-O-sulfation, B 6-O-sulfation and C is the trisulfated 
disaccharides ΔUA2S-GlcNS6S. Results are represented as mean ±SD. 
 
To assess if HS sulfation was correlated with the expression of HS sulfation modulating enzymes, 
HS O-sulfotransferases and sulfatase 1 and 2 expression were analysed by RT-qPCR.  
First, the HS 2-O-sulfation increase was mirrored by HS2ST1 expression which was significantly 
increased by 4-fold at D10 UUO (p<0.01) (Figure 3-15). HS2ST1 expression correlated 
significantly (p<0.001) to the Sirius red quantification with r=0.6750.  
Regarding HS6ST1 expression, the level of expression detected by RT-qPCR was not sufficient to 
be interpreted. As the expression of the 6-O-sulfotransferase could not be detected, the expression 
of the endosulfatases SULF1 and SULF2 which cleave 6-O-sulfation were analysed. As seen 
Figure 3-16, SULF1 expression was increased at D5 by 4.4-fold and D10 UUO by 6 fold but only 
significantly at D5 (p<0.05). Additionally, SULF1 expression was significantly correlated to Sirius 
red quantification (p<0.01) with r=0.5643. In contrast, SULF2 expression was not changed with 
UUO and did not correlate with Sirius red staining (Figure 3-17). 
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Figure 3-15: HS2ST1 expression and correlation to Sirius red staining 
Expression was adjusted to HPRT1 expression and normalised to the mean of controls (MC) N=6. 
RT-qPCR data are displayed in A and HS2ST1 correlation to Sirius red staining is shown in B. 
Two-tailed unpaired t test with Welch’s correction with p<0.01 (**). The Pearson’s correlation 
coefficient was generated with the data from HS2ST1 expression and results from Sirius red 
staining. 
 
 
Figure 3-16: SULF1 expression and correlation to Sirius red staining 
Expression was adjusted to HPRT1 expression and normalised to the mean of controls (MC) N=6. 
RT-qPCR data are displayed in A and SULF1 correlation to Sirius red staining is shown in B. Two-
tailed unpaired t test with Welch’s correction with p<0.05. The Pearson’s correlation coefficient 
was generated with the data from SULF1 expression and results from Sirius red staining. 
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Figure 3-17: SULF2 expression and correlation to Sirius red staining 
Expression was adjusted to HPRT1 expression and normalised to the mean of controls (MC) N=6. 
RT-qPCR data are displayed in A and SULF2 correlation to Sirius red staining is shown in B. Two-
tailed unpaired t test with Welch’s correction. The Pearson’s correlation coefficient was generated 
with the data from SULF2 expression and results from Sirius red staining. 
 
3.3.3 Heparan sulfate 3-O-sulfation changes in renal fibrosis 
The technique used to analyse HS sulfation and disaccharide composition could not provide any 
data about HS 3-O-sulfation as no standard for this particular pattern of sulfation was available. 
Therefore, HS 3-O-sulfation was analysed by immunofluorescence. The phage display antibody 
HS4C3 recognises a highly-sulfated pattern of HS including 3-O-sulfation. Interestingly, HS4C3 
staining was found decreased in the tubular basement membrane and glomerular capillaries of all 
UUO samples (Figure 3-18). Only blood vessels maintained a strong staining within all tissues.  
To assess if the decrease in HS 3-O-sulfation was accompanied by a decrease in HS3STs 
expression, HS3ST3A and HS3ST1 expression in control, D5 and D10 UUO were analysed by RT-
qPCR. HS3ST3A was decreased in UUO with a significant drop by 0.6-fold in expression at D5 
(p<0.05). Additionally, HS3ST3A was significantly correlated with Sirius red staining (p<0.05, r=-
0.4429) (Figure 3-19). In contrast, HS3ST1 was significantly increased at D5 and D10 UUO by 
2.7 fold and 4.5 fold respectively (p<0.001). Regarding HS3ST1 correlation to Sirius red staining 
it was the best-correlated enzyme with r=0.7881 and p<0.001 (Figure 3-20). 
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Figure 3-18: Highly sulfated HS staining on control, D5 and D10 UUO kidneys 
Representative images of HS4C3 staining on paraffin embedded sections of control tissues, D5 
UUO and D10 UUO. Paraffin embedded sections of 4µm were dewaxed, rehydrated. Peptide 
retrieval was performed by microwaving the slides in EDTA buffer. Sections were blocked for 10 
minutes with 2% FBS in PBS and incubated overnight at 4°C with primary antibody HS4C3 1:5 
given by Toin van Kuppevelt, Radboud University, Netherlands. The next day, sections were 
washed in PBS, then incubated with secondary antibody. Sections were then washed in PBS, 
incubated with Sudan Black for 20 minutes in the dark at room temperature and finally washed in 
PBS before mounting with VECTA shield DAPI liquid mounting medium. HS4C3 antibody, which 
stains heavily sulfated HS, showed glomerular, vascular and tubular staining. N=6 with 10 cortex 
fields analysed per section for each kidney. Scale bars represent 100 µm. 
 
Figure 3-19: HS3ST3A expression and correlation to Sirius red staining 
Expression was adjusted to HPRT1 expression and normalised to the mean of controls (MC) N=6. 
RT-qPCR data are displayed in A and HS3ST3A correlation to Sirius red staining is shown in B. 
Two-tailed unpaired t test with Welch’s correction with p<0.05 (*). The Pearson’s correlation 
coefficient was generated with the data from HS3ST3A expression and results from Sirius red 
staining. 
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Figure 3-20: HS3ST1 expression and correlation to Sirius red staining 
Expression was adjusted to HPRT1 expression and normalised to the mean of controls (MC) N=6. 
RT-qPCR data are displayed in A and HS3ST1 correlation to Sirius red staining is shown in B. 
Two-tailed unpaired t test with Welch’s correction with p<0.001 (***). The Pearson’s correlation 
coefficient was generated with the data from HS3ST1 expression and results from Sirius red 
staining. 
To better understand the impact of H3ST1 in UUO, slides were stained with a fluorescently labelled 
antithrombin III (lbAT). HS3ST1 and HS3ST5 are known to generate the HS binding site for AT. 
HS3ST5 has a very low expression in kidney. Therefore, detecting AT binding would give an 
indication on HS3ST1 activity within the kidney. As seen Figure 3-21, lbAT stained the tubular 
basement membrane, the vessels, the Bowman’s capsule and within the vascular structure of the 
glomerulus in both control and D5 UUO. Remarkably, lbAT also stained some interstitial tissue in 
D5 UUO. This staining was not seen in control kidney. Overall tubular lbAT staining decreased in 
all sections from D5 UUO while vascular structure remained unchanged. Unfortunately, D10 UUO 
tissues were of poor quality and could not be analysed. The sections were stained and from the 
experimenter, the staining decreased too at D10 UUO (data not shown). 
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Figure 3-21: Antithrombin III staining in control and D5 UUO cryosections 
Representative images of antithrombin III (AT) staining on cryosections from control kidney (A, 
C) and D5 UUO (B, D). Sections were blocked for 20 minutes in 1% BSA in PBS and incubated 
for 1h in fluorescently labelled AT. Slides were mounted with prolong diamond antifade with dapi. 
AT binding was detectable around Bowman’s capsule (⤏), on blood vessels (❍), on the tubular 
basement membrane (➝), at the vascular pole of the glomerulus (△) and in the expanded 
interstitium at D5 UUO (✩). N=6 with at least 5 cortex fields analysed per section for each kidney. 
Scale bars represent 100 and 50µm. 
 
 
3.3.4 Heparin Binding-EGF localisation in renal fibrosis  
Heparin Binding Epidermal Growth factor like (HB-EGF) is a protein that binds strongly to heparin 
and was found overexpressed after ischemia reperfusion in rats (Homma et al., 1995) with a 
predominant staining in distal tubules (Sakai et al., 1997). Furthermore, HB-EGF staining was 
found increased in basolateral tubular epithelial cells of renal allograft biopsies with minor 
histological alteration (Celie et al., 2012). I hypothesised that potentially HB-EGF binding could 
require HS 3-O-sulfation and therefore studied if HB-EGF staining was changed in fibrosis. 
Paraffin embedded sections were stained for HB-EGF and analysed in control, D5 and D10 UUO 
sections (Figure 3-22). HB-EGF staining was localised mainly on the basolateral pole of tubules. 
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Surprisingly, not all tubules were stained and the staining was heterogeneous. It is possible that the 
staining is present on only proximal or distal tubules. The staining decreased at D5 and D10 UUO. 
 
Figure 3-22: HB-EGF staining on control, D5 and D10 UUO kidneys 
Representative images of HB-EGF staining on paraffin embedded sections of control tissues, D5 
UUO and D10 UUO. Paraffin embedded sections of 4µm were dewaxed and rehydrated. Peptide 
retrieval was performed by microwaving the slides in EDTA buffer. Sections were blocked for 10 
minutes with 2% FBS in PBS and incubated overnight at 4°C with primary antibody. The next day, 
sections were washed in PBS, then incubated with secondary antibody Dylight 550 PBS for 1-2 
hours at room temperature. Sections were then washed in PBS, incubated with Sudan Black for 20 
minutes in the dark at room temperature and finally washed in PBS before mounting with VECTA 
shield DAPI liquid mounting medium.  HB-EGF staining was mainly present on the tubular 
basement membrane. N=6 with 10 cortex fields analysed per section for each kidney. Scale bars 
represent 100 µm. 
 
3.4 Discussion  
To date, renal fibrosis is irreversible. The use of in vivo murine models such as UUO has generated 
in recent years a better understanding of disease development (Stefanska et al., 2016), identified 
new biomarkers (Yuan et al., 2015) and new promising therapeutics (Fox et al., 2016).  
Results presented in this chapter showed that the obstruction of one ureter led to a significant 
increase in collagen deposition within the cortex. Additionally, tubules were found dilated and the 
interstitium expanded. These are characteristics of fibrosis and proved that the surgical procedure 
was successful. The analysis of HS sulfation showed a minor change in N-acetylation/N-sulfation 
at D10 with an increase in sulfation. These findings are consistent with what was found in 
idiopathic pulmonary fibrosis, where N-sulfation was also increased (Lu et al., 2014; Westergren-
Thorsson et al., 2017). During inflammation and fibrosis, N-sulfated/acetylated/sulfated patterns 
are important in attracting immune cells as they play a role in HS binding to cytokines such as 
interferon-γ (Lortat-Jacob et al., 1995) and Interleukin 8 (Spillmann et al., 1998). Therefore, the 
changes in N-acetylation and N-sulfation observed in UUO could either enhance or decrease pro-
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inflammatory cytokines binding. Additionally, N-sulfation is essential for the activity of other 
sulfotransferases. Therefore, another explanation of the increase in N-sulfation is the drive to 
increase the general sulfation status of the cell surface and ECM. Increasing N-sulfation, is 
permissive to sulfotransferase and sulfatase activity (Rong et al., 2001; Sheng et al., 2011) 
changing the whole GAGs sulfation pattern. 
The N-sulfation was not the only sulfation increased with UUO. Indeed, the most noticeable 
changes in the disaccharides analysis was an increase in the monosulfated disaccharide ΔUA2S-
GlcNAc and an increase in the disulfated disaccharide ΔUA2S-GlcNS. These results are consistent 
with the increase in trisulfated disaccharides ΔUA2S-GlcNS6S seen in lung fibrosis (Lu et al., 
2014). The increase in HS 2-O-sulfation mirrored by HS2ST1 overexpression in D10 UUO 
suggests the importance of this pattern in fibrosis. In fact, 2-O-sulfation plays an important role in 
the pro-fibrotic FGF family binding to HS (Turnbull et al., 1992; Ashikari-Hada et al., 2004). FGF7 
was increased in UUO (Girshovich et al., 2012) and FGF2 staining was increased in chronic 
rejection (Alhasan et al., 2014). Consequently, the change in 2-O-sulfation could trigger more FGF 
binding and signalling during the development of fibrosis.  
No increase was observed in the level of 6-O-sulfation in UUO. It has been previously published 
that HS 6-O-sulfation increased in idiopathic fibrosis (Lu et al., 2014; Westergren-Thorsson et al., 
2017) and HS staining with antibodies recognising 6-O-sufation increased in UUO  (Alhasan et al., 
2014). One can suggest that HS sequencing is more accurate than staining, therefore the increase 
previously seen in UUO can be related to an increase in total HS. Second, lungs and kidneys are 
two different organs and the 6-O-sulfation seems to be important for lung development, with 
HS6ST1-/- mice showing abnormal lung development with an increased intra alveolar space whilst 
kidney development is normal (Habuchi et al., 2007). The decrease in 6-O-sulfation could have 
been attributed to the overexpression of SULF1 in the fibrotic kidneys, an endosulfatase that 
cleaves 6-O residues. However, the preferential substrate of SULF1 is the trisulfated disaccharides 
ΔUA2S-GlcNS6S, which was actually increased. One explanation could be that the increase in the 
trisulfated disaccharides is being regulated by the cells to prevent an oversulfation of the cell 
surface and ECM. The fact that disulfated ΔUA2S-GlcNS, a product of the SULF1 activity, 
increased suggests that this could be the case.  
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The change in HS modulating enzymes was remarkable, with most enzymes being significantly 
correlated to the Sirius red staining and therefore to the degree of fibrosis. This is not the first time 
that HS modifying enzymes are found modulated during the development of fibrosis. In idiopathic 
pulmonary fibrosis HS3ST1 and HS6STs were overexpressed (Lu et al., 2014; DePianto et al., 
2015) and in liver fibrosis, heparanase, SULF1, SULF2 and HS3ST1 were overexpressed in fibrotic 
tissue compared to non-fibrotic liver (Tátrai et al., 2010). The increase in SULF1 in fibrotic kidneys 
is potentially due to the presence of TGF1, a pro-fibrotic factors that stimulate SULF1 expression 
(Yue et al., 2008).  
In fibrotic liver, amongst all HS modulating enzymes studied, HS3ST1 showed the highest fold 
change increase (Tátrai et al., 2010). These results, together with the finding that HS3ST1 
correlated with glomerular filtration rate and graft survival (Bunnag et al., 2009; Einecke et al., 
2010; Sagoo et al., 2010), suggest the potential of HS3ST1 as a biomarker of disease progression. 
It was not possible to identify any changes in 3-O sulfated disaccharides due to the lack of standard 
for 3-O-sulfated residues. Because of the promising results obtained with the enzyme expression, 
immunofluorescence staining for total 3-O-sulfation (HS4C3 staining) and 3-O sulfation specific 
of HS3ST1/5 (AT) was performed. 
HS 3-O-sulfation was mainly found on blood vessels, Bowman’s capsule, glomerular vasculature 
and tubular basement membrane as observed in previous studies (Girardin et al., 2005). 
Unexpectedly, the increase in HS3ST1 expression did not lead to an increase in HS 3-O-sulfation 
in D5 and D10 UUO. HS 2-O residues are known to inhibit the activity of HS3ST1. Therefore HS 
3-O-sulfation decrease could be explained by a lack of HS precursor. The decrease of staining was 
mainly observed on the tubular basement membrane. There was no change in the blood vessels 
staining. It is possible that the increase in HS3ST1 expression is mainly found in endothelial cells, 
which are known to produce HS with 3-O-sulfation (Marcum et al., 1986). Additionally, infiltrating 
cells could express HS3ST1 as macrophages do express high levels of expression (Martinez et al., 
2015). While the increase in 2-O-sulfation could be a pro-inflammatory mechanism to increase 
pro-fibrotic factors binding, HS3ST1 could be a defensive mechanism. Smits et al. found that 
HS3ST1 -/- mice are more susceptible to death following acute septic shock (Smits et al., 2017). 
Hence HS3ST1 may be involved in tissue recovery. All changes in HS N-acetylation, sulfation and 
modifying enzymes expression with UUO are summarised Table 3-1. 
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Table 3-1: HS modification and modifying enzymes expression at D5 and D10 UUO 
An increase is represented by “↑”and a decrease by “↓”no change by “−“. 
The changes in HS sulfation observed in the UUO model can lead to a change in growth factor 
binding. The analysis of HB-EGF staining revealed a decrease in all fibrotic tissues. In previous 
studies, HB-EGF signalling was decreased by SULF1 expression (Lai et al., 2003). Therefore, the 
drop in HB-EGF staining can be explained by the increase in SULF1 activity. Additionally, the 
decrease in 3-O-sulfation could be related to the decrease in HB-EGF binding but this would need 
further experiments. HB-EGF was found expressed following acute injury in an ischemia 
reperfusion model. The authors suggested that it was a protective mechanism of distal tubules to 
stimulate regeneration (Sakai et al., 1997). Additionally, in a recent study, HB-EGF staining was 
increased in basolateral tubular epithelial cells of renal allograft biopsies with minimal histological 
alteration while IFTA biopsies showed similar staining score to control tissues (Celie et al., 2012). 
Therefore, HB-EGF could be secreted in the initial events of tissue damage as an homeostatic 
regulation to resolve minimal damage. Conversely, the decrease in staining in chronic stages could 
be due to the changes in HS sulfation not allowing the growth factor to bind to the cells. In the 
intestine, HB-EGF has shown to have protective capacities by protecting pericytes, decreasing level 
of cytokines and decreasing cell death (Yang et al., 2014). Hence, there might be a potential link 
between HB-EGF, HS 3-O-sulfation and renal healing that should be further explored. 
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In conclusion, unilateral ureteral obstruction in mice is an excellent model to study HS sulfation 
changes during the development of interstitial fibrosis with major changes in 2-O and 3-O-
sulfation. Additionally, HS sulfotransferases have a great potential to be used as biomarkers with 
HS3ST1 being the most promising. Hence these results raised a lot of questions and curiosity 
regarding what can modulate HS3STs enzymes within the kidney and during fibrosis and what role 
they play in binding pro-fibrotic growth factors. These questions will be discussed in-depth in the 
next section of this thesis. 
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 Heparan sulfate 3-O-sulfotransferases expression: 
modulation and effect on growth factors signalling 
 
4.1 Introduction 
4.1.1 Control of HS3ST expression 
In the last decade, several studies have described factors that modulate the expression of HS3ST 
enzymes. Remarkably, HS3STs modulation differs between cell types and origin. In epithelial 
cells, it was found that IL-4 and IL-13 treatment increased HS3ST1 expression in intestinal 
epithelial cells (Takeda et al., 2010). Moreover, FGF10 treatment of salivary gland epithelia 
increased HS3ST1 and HS3ST6 expression at 4 hours and HS3ST3A and HS3ST3B at 2 and 4 
hours (Patel et al., 2014).  
 
Additionally, HS3STs expression in endothelial cells is of big interest as HS integrity and sulfation 
on the surface of the vascular system is important for inflammation. A preliminary study from 
Krenn et al., showed that 20 hours treatment of TNFα downregulated HS3ST1 and HS3ST4 and 
upregulated HS3ST3B in human microvascular endothelial cells (Krenn et al., 2008). In the same 
study, LPS treatment for 4h decreased HS3ST1, 2,3B and HS3ST4. Furthermore, the authors 
observed a decrease in HS4C3 staining on the cells treated with TNFα. Unfortunately, this study 
did not do any statistical tests on these results and therefore caution should be taken when 
interpreting these data. Especially as the study from Takeda et al. showed no difference in HS3ST1 
expression after 24h treatment with TNFα and LPS treatment on intestinal epithelial cells (Takeda 
et al., 2010). The difference in results could also be explained by the difference in treatment 
concentration and cell types.  
 
Because of the role of HS3STs in cancer development, HS3STs modulation in immune cells has 
recently been studied. LPS treatment increased HS3ST1, HS3ST3A, and HS3ST3B in human 
primary monocytes and only HS3ST3A-B in human monocytic leukemia cells. Furthermore TNFα, 
IL6, IL4, IFNγ, PGN all increased HS3ST3B expression in the human leukemia cells together with 
an increase in HS4C3 staining (Sikora et al., 2016). HS3STs expression have also been studied in 
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activated macrophages. While HS3ST1, HS3ST2 are expressed at higher levels in M2 
macrophages, HS3ST3B is more highly expressed in M1 (Martinez et al., 2015). 
 
4.1.2 HS 3-O-sulfation binding proteins 
There are very few proteins known to require HS 3-O-sulfation for binding to HS.  
The most studied is antithrombin (AT). Its binding motif is created by the activity of HS3ST1 and 
HS3ST5. AT inhibits thrombin, factor IXa and factor Xa and its binding to heparin enhances its 
catalytic activity (Rosenberg and Damus, 1973). For this reason, low molecular weight heparin 
(LMWH) is used in clinics to prevent clot formation. Initially, anticoagulant HSPG (aHSPG) were 
first studied on endothelial cells (Marcum et al., 1986; De Agostini et al., 1990; HajMohammadi 
et al., 2003) but were also found in many other structures such as the genital tract within the uterus 
e.g. the oviduct, follicular fluid (De Agostini, 2006); in fibroblasts (Marcum and Rosenberg, 1984) 
and epithelial cells (Pejler et al., 1987; Berry et al., 1991). Additionally, within the kidney aHSPG 
can be found on vessels, glomerular basement membrane and tubules (Girardin et al., 2005).  
 
HS3ST activity also generates a binding sequence for Herpes Simplex virus type 1 (HSV-1). In 
order to be able to enter the host cells, the viral glycoprotein of HSV-1, glycoprotein D has to bind 
to HS 3-O sulfation of the cell surface. Chinese Hamster Ovarian-K1 (CHO-K1) cells that do not 
have HS 3-O-sulfation are protected against HSV-1 infection but become infected when expressing 
HS3ST2  (O’Donnell et al., 2006), 3A, 3B (Shukla et al., 1999), 4 (Tiwari et al., 2005), 5 (Xia et 
al., 2002) and 6 (Xu et al., 2005). 
 
The implication of HS 3-O-sulfation in the binding of FGF family members to their receptors has 
also been well studied. FGF7 was protected from proteases by decasaccharides and tetrasaccharides 
containing 3-O-sulfation (Ye et al., 2001) and AT binding fraction of heparin can bind strongly to 
FGF2 receptor 1  (McKeehan et al., 1999). Additionally, Li et al. studied the interaction between 
FGF-2 and multiple HS disaccharides (Li et al., 2014). They found that the disaccharide with N-, 
3-O-sulfated GlcN and 2-O-sulfated IdoA had the highest affinity (KD= 1.73±0.31µM), showing 
that the 3-O sulfation might be implicated in the interaction between FGF2 and HS. However, a 
recent study on HS isolated from CHO cells transfected with HS3ST1 or HS3ST2 did not find any 
difference in FGF2 binding with HS 3-O-sulfation (Thacker et al., 2016b). This same study found 
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Neuropillin 1 binding to HS to be increased with 3-O-sulfation, a growth factor implicated in 
axonal growth and angiogenesis. 
 
Another protein of interest, cyclophilin B, which has chemotactic properties and is important for 
leukocytes recruitment to injured sites might require HS 3-O-sulfation. It was shown in vitro that 
the knock down of HS3ST3B in Jurkat T cells led to a decrease in cyclophilin B binding and P-
ERK signalling  (Vanpouille et al., 2007).  
 
Finally, the clearance of heparin in the liver by stabilin is increased by its 3-O-sulfation. In vitro 
data showed that heparin endocytosis by Flp-In-293 cells (transformed human embryonic kidney 
cells) overexpressing stabilin receptors was at the highest rate when HS polysaccharides were 3-O 
sulfated. In vivo the retention of heparan sulfate in the liver of mice was decreased when 3-O-
desulfated (Pempe et al., 2012). 
 
Taken together, this literature shows how very little is known about HS 3-O-sulfation. The lack of 
information on the factors influencing HS3ST expression in renal cells prevents us from 
understanding what modulates HS 3-O-sulfation in kidney fibrosis. 
 
The aims of this chapter are: 
 
-To discover new regulators of HS3ST expression in renal epithelial cells and fibroblasts.  
 
-To identify the impact of HS 3-O-sulfation on growth factors binding in renal epithelial cells by 
generating an in vitro model of renal epithelial cells overexpressing one isoform of HS3STs. 
 
4.2 Specific material and methods  
4.2.1 Cells starvation and treatments 
All cytokines were from PeproTech unless specified. FGF2 (SRP4037) and HB-EGF (E4643) were 
from Sigma. As seen Figure 4-1, cells were seeded with complete medium and starved when 
reaching 80% confluence with medium supplemented with only 0.5% FBS. Starvations were 
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treatment dependent (between 16 to 24h) and are specified in the results sections. Cells were treated 
with either 5ng/mL TGFβ1, 10ng/mL TGFβ2 + 10ng/mL IL1β, 10ng/mL FGF2 or 10ng/mL HB-
EGF. RNAs extractions were performed at different time points after treatment. The UG student 
Imogen L Wilson supervised by Laura Ferreras contributed in part to the work assessing HS3ST 
expression. 
 
Figure 4-1: Treatments experimental design 
Cells were seeded on the first day, incubated with 0.5% FBS between 16 to 24h when 80% 
confluent and treated with different factors (time and concentration are specified in results 
sections). 
 
4.2.2 Transfection: G418 killing curve 
Cells were transfected with a plasmid coding for neomycin gene which confers resistance to 
geneticin (G418), a prokaryote and eukaryote antibiotic. G418 (Invitrogen) is an aminoglycoside 
antibiotic toxic for both prokaryotes and eukaryotes cells as it blocks polypeptide synthesis. In 
eukaryotic cells peptide synthesis is disrupted by irreversible binding to the 80S ribosomes. 
Therefore, stably transfected cell lines were selected and maintained in media supplemented with 
G418. Prior to transfection, the concentration used was determined with a killing curve titration to 
determine the conditions of cell selection.  
HKC8 cells were seeded in 24-well plates with 2.5x104 cells per well. When cells reached 60% 
confluence they were treated in duplicate with different concentrations of G418 (0, 50, 100, 200, 
300, 400, 500, 600, 700, 800, 900 and 1000 µg/ml) in complete media. Antibiotic supplemented 
media was changed every two days and cell confluency was assessed every day for a week. The 
lowest concentration at which all cells died was used for selection.  
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As seen Figure 4-2, HKC8 cells were treated with different concentration of antibiotics ranging 
from 0 to 300µg/mL. The concentration of 300 µg/mL and 200µg/mL successfully killed the cells. 
The lowest of the two, 200µg/mL was chosen for further experiments. 
 
Figure 4-2: Killing curve for HKC8 cells with G418 
HKC8 cells were seeded at 2.5x104 cells per well in 24-well plate and treated with G418 
concentration ranging from 0 to 300 µg/mL when 60% confluence was reached. Cells were imaged 
at 48 hours and 72 hours respectively after transfection with a Carl Zeiss 40CFL microscope, 
magnification x100. 
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4.2.3 Transfection: optimising transfection method 
Cells transfection can affect cells integrity and generate damage. Furthermore, the ratio DNA to 
Effectene is important to provide a general positive charge complex to allow binding to negatively 
charged cell surface glycoproteins. Therefore, different transfection conditions were assessed. 
HKC8 cells were seeded at different cell densities and transfected with a 1:10 or 1:25 ratio of 
effectene complexed with 400ng of plasmid DNA. As observed in Figure 4-3, cell death and cell 
fragmentation could be observed at low seeding density with high concentration of effectene while 
cells remained healthy at the lower dose and with a seeding of 3x105cells per well in a 6-well plate. 
Therefore, cells had to be 80 to 90% confluent to allow the cells to remain healthy after transfection. 
 
Figure 4-3: Transfection optimisation  
HKC8 cells were seeded in 6-well plate at concentrations ranging from 105 to 3x105 and transfected 
with 400ng of DNA mixed with enhancer and with 1:10 or 1:25 of effectene. Cells were imaged 
before transfection and 24h after transfection with a Carl Zeiss 40CFL microscope, magnification 
x200. 
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4.2.4 Transfection: generating stable cell line 
Cells were seeded in 10cm petri dishes and grown until 80-90% confluent. First 2µg plasmid DNA 
was condensed by interaction with the Enhancer (16 µL) in 279µL of buffer. The condensed 
plasmid solution was then vortexed for 1 second and left 3 minutes at room temperature. A volume 
of 60 µL of Effectene Reagent was then added to the condensed DNA to produce condensed 
Effectene–DNA complexes. The complex was vortexed for 10 seconds and left for 7 minutes at 
room temperature. While incubating, media was removed from the 10cm dish, cells were washed 
with PBS and 7mL of complete media added. The Effectene–DNA complexes were finally mixed 
with 3mL of complete medium and directly added to the cells in a drop wise manner. The plasmid-
effectene complex is taken up by endocytosis and reaches the cytoplasm and for some cells 
integrates in the genome. The antibiotic selection selects stable transfectants. The following day, 
fresh media containing 200µg/mL of G418 was added to the transfected cells. Two to three days 
after transfection, cells were split in 1:5 in media complemented with 200µg/mL of G418. Colonies 
were isolated by using cloning cylinders where 200µl of pre-warmed trypsin was added to detach 
the cells. Cells were then cultured in 24-well plates, one well corresponding to an individual colony. 
Once confluent cells were grown in 6-well plates, T25 and finally T75 flasks. Gene expression for 
each colony was assessed by RT-qPCR. 
 
4.2.5 GAG sequencing 
The isolation of radiolabelled Heparan Sulfate from cultured cells is a sensitive method that should 
be carried out with extra care. Bergen University policies were followed for handling radioactivity 
substances. Experiments with dangerous goods and gas were carried out in a fume hood. Figure 
4-4 shows a simplified plan of experiment for disaccharides isolation. 
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Figure 4-4: Disaccharide isolation 
GAGs were radiolabeled with 35S and isolated from proteins by alkali treatment. Different column-
based isolation and acidic treatments were required to isolate disaccharides from the initial cell 
lysate. 
 
4.2.5.1 Cell labelling and proteoglycans isolation  
In a T75 flask, 80% confluent cells were labelled with 200 µCi/ml Na235SO4 (Perkin Elmer) diluted 
in fresh medium at 37°C for 24 hours. Cells were incubated for a day to allow them to generate 
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new HS with labelled sulfate. The media contained labelled GAGs on proteoglycans released to 
the medium (secreted or shredded). Cells were carefully washed 2 times with PBS and incubated 
on a rotating platform for 1 hour at 4°C with 3mL of solubilisation buffer (1% Triton TX-100, 
50mM Tris/HCl pH (7.4), 0,15M NaCl). This solution lyses the cells but also preserves the integrity 
of the proteoglycans and their GAG chains. Cells were then scraped, collected in labelled tubes 
and centrifuged at 2000rpm for 15 minutes. The pellet contains cells debris and the supernatant 
proteins and GAGs. A volume of 100μL of this supernatant was kept for determining protein 
concentration. 
 
4.2.5.2 Isolating the GAGs chains from the core protein 
HS and CS chains are coupled to a core protein. Alkali treatment releases the GAG chains from 
the proteins. The final supernatant (minus 100μL) volume was measured and 4M NaOH was added 
to it to obtain a final concentration of 0.5M. 
The samples were then left at 4ºC overnight for the alkali treatment to be effective. The next day, 
10M HCl was used to adjust the pH to 8. This was required before applying to a DEAE-Sephacel 
column equilibrated at pH 8. DEAE Sephacel is a weak anion exchanger based on beaded cellulose 
(ion exchange group is diethylaminoethyl) which was used to isolate GAGs from any proteins or 
other compounds in the supernatants. Samples were diluted to a final concentration of 0.15M Cl- 
(same concentration of the equilibration buffer for the column) with 0.02M Tris/HCl pH8. Initially 
samples were estimated to contain 0.5M NaCl. 
DEAE columns were brought at room temperature and 500μL of DEAE sephacel was added on top 
of the column and equilibrated with 0.05M Tris/HCl pH8; 0.15M NaCl; 0.1% TX-100. Samples 
were added on top of the column followed by washes with 500μL of equilibration buffer. The flow 
through was kept in a 15mL tube in case the sample does not bind properly to the column. 
To elute the proteins, 5mL (in 500µL aliquots) of 0.05M Acetate pH4, 0.15M NaCl, 0.1% TX-100 
was added on top of the column. The drop in pH releases most proteins from the column. Each 
time 500μL was added, the elute was collected in a new Eppendorf tube. To increase pH and wash 
away Triton, ten times 500μL of 0.05M Tris/HCl pH 7.4, 0.15M NaCl was applied to the column. 
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Finally, GAG elution was performed by adding ten aliquots of 500μL of 1.5M NaCl. Five μL of 
each fraction was collected and added to 1mL of scintillation fluid to assess the level of 
radioactivity in each fraction. The fractions with the most radioactivity were pooled and checked 
for radioactivity level.  
 
4.2.5.3 Desalting step. 
Because the elution was performed with 1.5M NaCl it was required to remove the salt from the 
isolated GAGs. Samples volumes were adjusted to a final volume of 2.5mL with water and twelve 
1.5 mL Eppendorf labelled. A PD 10 column eluted with H2O was used for desalting, 1mg of 
heparin was added followed by another 50mL wash. Samples were applied to the column and eluted 
12 times with 500μL water. Each elute was collected in a fresh tube and analysed by beta counting. 
Salt-free fractions with the most radioactivity were pooled and freeze-dried. 
 
4.2.5.4 Deamination and reduction 
The procedure was carried out in a fume hood as strong acids and bases were used.  The samples 
were dissolved in 20μL of H2O and the deamination was performed with HNO2 at pH1.5. 
Deamination removes N-S groups leading to breaking of glycosidic bond. The reaction was stopped 
by adding 40μL of 2M Na2CO3, pH was checked and adjusted to 7-9 (8.5 ideally). 
Following deamination, the samples were reduced with 50μL of NaBH4 (solution 20mg/mL 10mM 
NaOH) for 3h at room temperature. To neutralise borohydride, samples were incubated with 60μL 
of 4M HAc for 10 minutes at room temperature. H2 gas will be released during the reaction. 
 
4.2.5.5 Disaccharides isolation and analysis 
The disaccharides were desalted and isolated by gel chromatography on a long G15 column in 
0.5M NH4HCO3, 0.5mL/min/fraction with 60 fractions. Radioactivity was assessed for each 
fraction and the ones containing the disaccharides were pooled, freeze-dried and diluted in water 
for compositional analysis. The disaccharide analysis was performed by strong anion exchange 
HPLC (SAX-HPLC). All buffers were degassed prior to use. In principle, the disaccharides bind 
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to the column. The elution occurs with aqueous KH2PO4 by stepwise increasing concentration at a 
rate of 1 ml/min therefore the retention time is proportional to the number and orientation of sulfate 
groups. Finally, fractions were collected and analysed for radioactivity. The disaccharide 
composition of the samples and more specifically the amount of sulfate group was assessed by 
analysing the amount of radioactivity for each fraction. 
 
4.2.6 Cell proliferation and wound healing 
Cell proliferation was measured with WST-1 test (Roche) following manufacturer’s instructions. 
WST-1 test is dependent of the quantity of NADPH produced by the cells and is therefore 
correlated with the metabolic activity of the cells. 
The capacity of the cells to migrate was assessed by a wound-healing assay. In this assay the cells 
are grown in an insert that generates an empty space within the cell layer. Ibidi inserts are silicone 
made with two gaps to allow cell growth and the generation of a well-defined scratch once removed 
(Figure 4-5). The cell velocity is determined by analysing the distance traveled by the cells at 
different intervals. In each well of a 12-well plate, cells were suspended at 21 000 cells/reservoir 
of Ibidi insert in complete media or with 0.5% FBS media for FGF2 stimulation studies. The next 
day, inserts were removed with sterile tweezers, washed with complete media or 0.5% FBS media 
supplemented with 10ng/mL FGF2 and a final volume of 2mL was added before starting imaging. 
Images for cell migration was acquired every hour in a Nikon Biostation.  
Cell velocity was determined during the linear growth when the speed of closure is constant. 
Cell velocity= (area of the wound/height of the picture/2 (two cell front))/ time B-time A 
With time A= starting time of linear growth, time B= ending time of linear growth. 
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Figure 4-5: Wound healing assay 
Cells were seeded at 3x105cells/mL with 70µL per Ibidi insert in 12-well plate. The next day, 
inserts were removed with sterile tweezers and complete media or 0.5% FBS media ± 10ng/mL 
was added to the cells. Images were acquired by Nikon Biostation every hour. Image adapted from 
http://animalab.eu/products/culture-insert-2-well. 
 
4.3 Results 
4.3.1 Cell characterisation 
In order to characterise the cell lines and making sure of their authenticity, the cells studied in this 
chapter were stained for different markers such as a cell surface marker E-cadherin, a cytoskeleton 
fiber marker α-Smooth Muscle Actin (α-SMA) and the ECM protein, fibronectin. As seen Figure 
4-6, HK2 and HKC8 cells which are epithelial cells showed a positive staining of extracellular 
fibronectin. Fibronectin staining was seen as a well-defined network around the cells. E-cadherin 
expression was found to be heterogeneous. Not all HK2 and HKC8 cells expressed E-cadherin and 
fibronectin seemed to be more expressed in these cells. In contrast, the NRK-49F cells which are 
rat renal fibroblasts did not express E-cadherin and showed low expression of fibronectin. NRK-
49F cells were further stained with α-Smooth Muscle Actin (α-SMA) which is a marker of activated 
fibroblasts. Less than 5% of the cells were positive but those cells that were positive displayed a 
very strong staining with α-SMA located on contractile fibers.  
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Figure 4-6: Cells characterisation 
HK2, HKC8 and NRK-49F cells were seeded in 8 well-chamber slides and grown until 60-80% confluent. Cells were fixed for 10 
minutes in ice cold methanol at -20°C and incubated for 1 hour at room temperature in 1% BSA to avoid unspecific binding. Slides were 
incubated with the primary antibodies overnight at 4°C. The next day slides were washed with PBS and incubated for 2h at room 
temperature with the corresponding secondary antibody. Slides were mounted in Vectashield with DAPI. Cells incubated with only 
secondary (no primary) were used as negative control. Scale bar represents 100µm. N≥2. UG student Imogen L Wilson and MRes student 
Hanna Lane contributed to the staining under supervision of Laura Ferreras. 
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Very little is known about the HS3STs in kidney tissue and in view of the results observed in vivo 
with HS3ST1 expression in fibrosis, this project studied what growth factors could modulate their 
expression. The three different cell types described above, and two pro-fibrotic treatments were 
used. 
 
4.3.2 The effect of TGFβ1 on HS3STs expression in renal epithelial cells 
As described in section 1, TGFβ1 is one of the most studied pro-fibrotic factors. However, to the 
best of our knowledge, its role in HS3ST expression has never been described before. Therefore, 
HK2 and HKC8 cells were treated with 5ng/mL TGFβ1 for different time periods to identify a 
potential action of TGFβ1 on renal epithelial cells HS3ST expression. 
 
4.3.2.1 HS3ST in HK2 cells 
HK2 cells were seeded in 6-well plates with 2x105cells per well. After 24h incubation in 0.5% FBS 
media, cells were treated with TGFβ1 (5ng/mL) for 3, 6, 24, 48 hours. HS3ST1 and HS3ST3B 
expression was analysed by RT-qPCR. HS3ST1 was decreased but only significantly at 6 hours 
and 48 hours after treatment (p<0.05) (Figure 4-7). In contrast, HS3ST3B expression was increased 
after TGFβ1 treatment. The upregulation of HS3ST3B was time dependent and significant at 24 
hours (p<0.01) and 48 hours (p<0.01) (Figure 4-8). 
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Figure 4-7: HS3ST1 expression in HK2 cells treated with TGFβ1 (5ng/mL) 
HK2 cells were seeded in 6-well plates with 2x105cells per well. Cells were incubated with 0.5% 
FBS medium 24 hours before being treated with 5ng/mL TGFβ1 or only buffer (CTL) for 3, 6, 24, 
48 hours. Results are expressed as mean ± SD. Results were normalised to the house keeping gene 
HPRT1 and compared to the average of the mean of controls (MC). Two-tailed unpaired t test with 
Welch’s correction, p<0.05 (*) N=3.  
 
 
Figure 4-8: HS3ST3B expression in HK2 cells treated with TGFβ1 (5ng/mL) 
HK2 cells were seeded in 6-well plates with 2x105cells per well. Cells were incubated in 0.5% FBS 
medium for 24 hours and treated with 5ng/mL TGFβ1 or only buffer (CTL) for 3, 6, 24, 48 hours. 
Results are expressed as mean ± SD. Results were normalised to the house keeping gene HPRT1 
and compared to the average of the mean of controls (MC). Two-tailed unpaired t test with Welch’s 
correction, p<0.01 (**) N≥3.  
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Two other isoforms of HS3STs, HS3ST3A and HS3ST6 were analysed at 24h and 48h treatment 
with 5ng/mL TGFβ1 but no significant changes were observed (Figure 4-9). HS3ST2, 4 and 5 were 
not analysed considering their low or non-existent expression in kidney tissue (Shworak et al., 
1999; Mochizuki et al., 2008). 
 
Figure 4-9: HS3ST3A and HS3ST6 expression in HK2 cells treated with TGFβ1 (5ng/mL) 
HK2 cells were seeded in 6-well plates with 2x105cells per well. Cells were incubated in 0.5% FBS 
medium for 24 hours and treated with 5ng/mL TGFβ1 or only buffer (CTL) for 24 and 48 hours. 
HS3ST3A expression is displayed in A, HS3ST6 expression is displayed in B. Results are 
expressed as mean ± SD. Results were normalised to the house keeping gene HPRT1 and compared 
to the average of the mean of controls (MC). N≥2.  
 
4.3.2.2 HS3STs in HKC8 cells 
HKC8 cells were seeded in 6-well plates with 2.4x105cells per well and incubated in 0.5%FBS for 
24 hours media prior to treatment with 5ng/mL TGFβ1 for 3, 6, 24, 48 hours. HS3STs expressions 
were analysed by RT-qPCR. HS3ST1 expression was very low in HKC8 cells and therefore this 
isoform expression was not studied in these cells (CT values between 36 and undetermined). 
Overall, TGFβ1 (5ng/mL) treatment did not induce any significant change in HS3STs expression 
as seen in Figure 4-10 and Figure 4-11. 
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Figure 4-10: HS3ST3B expression in HKC8 cells treated with TGFβ1 (5ng/mL) 
HKC8 cells were seeded in 6-well plates with 2.4x105cells per well. Cells were incubated in 0.5% 
FBS medium for 24 hours and treated with 5ng/mL TGFβ1 or only buffer (CTL) for 3, 6, 24, 48 
hours. Results are expressed as mean ± SD. Results were normalised to the house keeping gene 
HPRT1 and compared to the average of the mean of controls (MC). N≥2. 
 
Figure 4-11: HS3ST3A and HS3ST6 expression in HKC8 cells treated with TGFβ1 (5ng/mL) 
HKC8 cells were seeded in 6-well plates with 2.4x105cells per well. Cells were incubated in 0.5% 
FBS medium for 24 hours and treated with 5ng/mL TGFβ1 or only buffer (CTL) for 24 and 48 
hours. HS3ST3A expression is displayed in A, HS3ST6 expression is displayed in B. Results are 
expressed as mean ± SD. Results were normalised to the house keeping gene HPRT1 and compared 
to the average of the mean of controls (MC) N≥2. 
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4.3.3 HS3STs modulation by TGFβ2 and IL1β in renal epithelial cells 
The combination of treatment of TGFβ2 and IL1β has been shown to promote endothelial to 
mesenchymal transition and this study addressed if the treatment could have an effect on renal 
epithelial cells. The same seeding condition as in TGFβ1 treatment was used for these experiments. 
 
4.3.3.1 HK2 cells 
After 24h incubation in 0.5% FBS followed by TGFβ2 and IL1β treatment (10ng/mL) for 3, 6, 24, 
48h, HS3ST1 expression decreased in HK2 cells. This decrease was only significant at 6 hours and 
24 hours after treatment with TGFβ2 and IL1β (p<0.05, p<0.01 respectively) (Figure 4-12). In 
contrast, HS3ST3B was increased after TGFβ2 and IL1β treatment. The upregulation of HS3ST3B 
was time dependent and significant at 24 hours (p<0.001) and 48 hours (p<0.01) as seen Figure 
4-13. The expression of HS3ST3A and HS3ST6 after TGFβ2 and IL1β treatment of HK2 cells was 
variable and no clear changes in expression as observed Figure 4-14. 
 
 
Figure 4-12: HS3ST1 expression in HK2 cells treated with TGFβ2 and IL1β (10ng/mL) 
HK2 cells were seeded in 6-well plates with 2x105cells per well. Cells were incubated in 0.5% FBS 
medium for 24 hours and treated with 10ng/mL TGFβ2 and IL1β or only buffer (CTL) for 3, 6, 24, 
48 hours. Results are expressed as mean ± SD. Results were normalised to the house keeping gene 
HPRT1 and compared to the average of the mean of controls (MC). Two-tailed unpaired t test with 
Welch’s correction, p<0.05 (*) and p<0.01 (**) N=3.  
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Figure 4-13: HS3ST3B expression in HK2 cells treated with TGFβ2 and IL1β (10ng/mL) 
HK2 cells were seeded in 6-well plates with 2x105cells per well. Cells were incubated in 0.5% FBS 
medium for 24 hours and treated with 10ng/mL TGFβ2 and IL1β or only buffer (CTL) for 3, 6, 24, 
48 hours. Results are expressed as mean ± SD. Results were normalised to the house keeping gene 
HPRT1 and compared to the average of the mean of controls (MC). Two-tailed unpaired t test with 
Welch’s correction, p<0.01 (**) and p<0.001 (***) N≥3.  
 
Figure 4-14: HS3ST3A and HS3ST6 expression in HK2 cells treated with TGFβ2 and IL1β 
(10ng/mL) 
HK2 cells were seeded in 6-well plates with 2x105cells per well. Cells were incubated in 0.5% FBS 
medium for 24 hours and treated with 10ng/mL TGFβ2 and IL1β or only buffer (CTL) for 24 and 
48 hours. HS3ST3A expression is displayed in A, HS3ST6 expression is displayed in B. Results 
are expressed as mean ± SD. Results were normalised to the house keeping gene HPRT1 and 
compared to the average of the mean of controls (MC). N≥2. 
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4.3.3.2 HKC8 cells 
HKC8 showed the same response as HK2 cells to TGFβ2 and IL1β with an increase in HS3ST3B 
expression. However, this increase was not significant (Figure 4-15). Additionally, HS3ST3A was 
increased at 24 hours and 48 hours but not significantly and HS3ST6 expression was not affected 
by TGFβ2 and IL1β treatment (Figure 4-16). 
 
Figure 4-15: HS3ST3B expression in HKC8 cells treated with TGFβ2 and IL1β (10ng/mL) 
HKC8 cells were seeded in 6-well plates with 2.4x105cells per well. Cells were incubated in 0.5% 
FBS medium for 24 hours and treated with 10ng/mL TGFβ2 and IL1β or only buffer (CTL) for 3, 
6, 24, 48 hours. Results are expressed as mean ± SD. Results were normalised to the house keeping 
gene HPRT1 and compared to the average of the mean of controls (MC). Two-tailed unpaired t test 
with Welch’s correction, N=3. 
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Figure 4-16: HS3ST3A HS3ST6 expression in HKC8 cells treated with TGFβ2 and IL1β 
(10ng/mL) 
HKC8 cells were seeded in 6-well plates with 2.4x105cells per well. Cells were incubated in 0.5% 
FBS medium for 24 hours and treated with 10ng/mL TGFβ2 and IL1β or only buffer (CTL) for 24 
and 48 hours. HS3ST3A expression is displayed in A, HS3ST6 expression is displayed in B. 
Results are expressed as mean ± SD. Results were normalised to the house keeping gene HPRT1 
and compared to the average of the mean of controls (MC). N≥2. 
 
 
4.3.4 HS3ST1 expression in renal fibroblast 
The study further addressed if the changes seen in HS3ST1 expression in the HK2 cells could be 
seen in other cell types such as NRK-49F a rat renal fibroblast line. Cells were gown and treated 
in T75 flasks to allow a sufficient quantity and quality RNA to be collected. NRK-49F were very 
sensitive to TGFβ1 (5ng/mL) and TGFβ2 and IL1β (10ng/mL) and showed a change in morphology 
after 24h. As observed Figure 4-17 they were elongated, and the cells had a needle myofibroblast 
like shape.  
 
Figure 4-17: NRK-49F cells morphology after TGFβ1 treatment 
NRK-49F cells were seeded in T75 flasks until 60-80% confluent. Cells were starved with 0.5% 
FBS media for 24h and were then treated with 5ng/mL of TGFβ1 for 24h. Magnification x200. 
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Figure 4-18: HS3ST1 expression in NRK-49F cells treated with TGFβ1 
NRK-49F cells were seeded in T75 flasks and were incubated in 0.5% FBS medium for 24 hours 
once they reached 60% confluence. Cells were incubated in 0.5% FBS medium for 24 hours and 
treated with 5ng/mL TGFβ1 or only buffer (CTL) for 3, 6, 24 hours. Results are expressed as mean 
± SD. Results were normalised to the house keeping gene HPRT1 and compared to the average of 
the mean of controls (MC). Two-tailed unpaired t test with Welch’s correction, p<0.05 (*) N=3.  
 
Figure 4-19: HS3ST1 expression in NRK-49F cells treated with TGFβ2 IL1β (10ng/mL) 
NRK-49F cells were seeded in T75 flasks and were incubated in 0.5% FBS medium for 24 hours 
once they reached 60% confluence. Cells were treated with 10ng/mL TGFβ2 IL1β or only buffer 
(CTL) for 3, 6, 24 hours. Results are expressed as mean ± SD. Results were normalised to the house 
keeping gene HPRT1 and compared to the average of the mean of controls (MC). Two-tailed 
unpaired t test with Welch’s correction, p<0.05 (*) and p<0.01 (**) N=3.  
 
 
4.3.5 Generating HKC8-HS3ST1 and HKC8-CTL stable transfectants  
In addition to the strong correlation between HS3ST1 and fibrosis in vivo, the modulation of 
HS3ST1 in HK2 and NRK-49F by pro-fibrotic factors in vitro increased interest regarding the role 
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of HS3ST1. As HS3ST1 expression was barely detectable in HKC8 cells, it was a suitable model 
for generating HS3ST1 overexpressing cells.  
 
4.3.5.1 HS3ST1 and empty plasmid amplification 
HS3ST1 plasmid (genecopoeia) was amplified in E. coli DH5α. Plasmid concentration, size and 
quality were assessed (Figure 4-20). Plasmid extraction resulted in a concentrated solution of 
466.2ng/µL. To analyse the plasmid, 1μg of isolated DNA was digested by SalI and 50ng, 100ng, 
250ng of the digested plasmid together with 200ng of the whole plasmid were analysed by agarose 
gel electrophoresis. HS3ST1 plasmid is 6346bp long and SalI cleaves at 2280bp and 4468bp and 
therefore produced two bands, one at 4158bp and one at 2188bp. Plasmid digestion showed 2 
bands, one around 2kb and one around 4kb as seen Figure 4-20. This result highlighted that the 
plasmid sequence correlated with what was expected. The plasmid was then sent for sequencing. 
 
Figure 4-20: HS3ST1 plasmid amplification and analysis 
Plasmid concentration following transformed bacteria lysis and purification (Qiagen mini-prep) 
was analysed by nanodrop DNA measurement (A). SalI restriction enzymes cleaves the plasmid in 
two sites, 2280bp and 4468bp (B) and generates two fractions, a 2188bp and 4158bp fragment (C). 
The digested and undigested plasmids were run into a 0.8% agarose gel together with a 1kb ladder 
and analysed under UV light (D). Digested plasmid lines (1= 50ng, 2=100ng, 3=250ng) showed 
the two expected band (4.158 kb and 2.188 kb). The fourth line is 200ng of undigested plasmid. 
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Plasmid sequencing by Source Bioscience showed 97% homology with the HS3ST1 sequence of 
the plasmid. The 3% difference was due to the analysing software being unable to identify some 
bases in the plasmid (N) (Figure 4-21). 
 
 
Figure 4-21: Blast alignment of the sequencing from the generated plasmid and HS3ST1 
sequence 
The generation of an empty plasmid was required to generate Mock cells in parallel with HS3ST1 
overexpressing cells for control purposes. The empty plasmid was generated by BsrGI digestion, a 
restrictive enzyme which cleaves at the extremity of HS3ST1 gene sequence. After the successful 
digestion of HS3ST1 plasmid for 3h at 37ºC, the empty linear plasmid and HS3ST1 sequence were 
observed by agarose gel as seen Figure 4-22. 
The empty plasmid was extracted from the gel and was ligated with T4 ligase 3 hours at room 
temperature. The empty circular plasmid was then transfected to competent bacteria E.coli DH5α. 
Out of five colonies, three were selected. Plasmid integrity and sequence were analysed by multiple 
restriction enzymes digestions. First to confirm that HS3ST1 sequence was not within the plasmid, 
the newly ligated plasmid was digested by KpnI, an enzyme cleaving exclusively within HS3ST1 
sequence. As seen Figure 4-23 C, digestion with KpnI linearised HS3ST1 plasmid but not the 
empty one as expected. Hence the presence of more than one band after digestion, representing 
nicked, linear and supercoiled forms of plasmids. Second, when digested with BsrGI, HS3ST1 
sequence could only be seen in the HS3ST1 plasmid and only linearised the empty one with the 
expected size of around 6Kb. 
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Figure 4-22: Generating empty plasmid by restrictive enzyme BsrGI digestion.  
BsrGI cleaves at the extremity of HS3ST1 sequence at 6342bp and 5391bp (A) and is expected to 
generate the empty plasmid of 5395bp (85% of the mass) and HS3ST sequence 951bp (15% of the 
mass) (B). BsrGI digestion of HS3ST1 plasmid was run into a 0.8% agarose gel together with a 
1kb ladder and analysed under UV showing the expected two bands in 200ng and 80ng of digested 
plasmid (C). The undigested product showed the nicked, linear and supercoiled forms of plasmids. 
The empty plasmid was excised from the gel using a sterile blade under UV light (D). 
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Figure 4-23: Assessing empty plasmid sequence 
Empty plasmid and HS3ST1 plasmid were digested with either KpnI or BsrGI restrictive enzymes 
3h at 37ºC. The digested plasmids were run into a 0.8% agarose gel together with a 1kb ladder and 
analysed under UV light. KpnI cleaves HS3ST1 plasmid within HS3ST1 gene sequence while 
BsrGI cleaves at the extremity of it. Line 1 is HS3ST1 plasmid (800ng) lines 2-4 are the empty 
plasmid from three different colonies (1µg). The empty plasmid was not digested by KpnI and 
therefore line 2-4 KpnI showed the nicked, linear and supercoiled forms of plasmids. 
 
 
4.3.5.2 Generating HKC8-HS3ST1 and HKC8-CTL  
HKC8 cells were grown in 10 cm petri dish until 90% confluent and were transfected with 2µg of 
linearised HS3ST1 plasmid. Forty-eight hours after transfection, cells were split 1:5 and grown in 
media supplemented with G418 to select stably transfected cells. Thirty-five clones (HKC8-
HS3ST1) were selected and cultured for several days. HS3ST1 expression in the 35 HKC8-
HS3ST1 clones was assessed by RT-qPCR. As seen Figure 4-24, all clones had different levels of 
expression and clone 3, 9, 10, 12 and 33 were selected to assess protein expression.  
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Figure 4-24: HS3ST1 expression in isolated clones  
Wild type HKC8 cells were transfected in 10cm petri dish with 2µg of HS3ST1 plasmid and 
effectene. Two days after transfection, cells were split 1:5 and grown in media supplemented with 
200µg/mL G418. Thirty-five clones were isolated by cloning ring and expanded. The clones’ 
HS3ST1 expression was analysed by qPCR. The amplification plot (A) shows heterogeneity in 
HS3ST1 expression between the different clones which is highlighted when compared arbitrary to 
clone 2 (B).  
HS3ST1 expression in the 5 selected clones was mirrored by their protein levels as seen Figure 
4-25. Clone 9 had the highest expression and protein level of HS3ST1 and was selected for future 
experiments. Additionally, clone 12 which had a lower expression was also selected to allow the 
study of two different clones. The HS3ST1 plasmid contains the HS3ST1 sequence with a flag tag 
at the C-term. Because most antibodies for HS3ST1 are unsuccessful or not trust worthy, the flag 
tag was used to allow western blot and immunofluorescence detection of the protein. The flag tag 
had to be added at the C-terminal of the protein due to the presence of a signal peptide at the N-
terminal.   
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Figure 4-25: HKC8-HS3ST1 clones protein levels 
Five HKC8-HS3ST1 clones were selected and their protein levels analysed by Western Blot. A 
quantity of 20µg of protein lysates were run into a 10% acrylamide gel for 1h30 at 110V and 
transferred onto a nitrocellulose cell membrane. The membrane was blocked 1h in 5% milk 0.1% 
TBST and incubated overnight at 4°C with flag tag antibody. The next day the membrane was 
washed with 0.1%TBST and incubated with secondary anti-rabbit antibody before detection. After 
a mild stripping and a blocking step, the membrane was probed for tubulin as a loading control. 
N=2 
Because generating stably transfected cells can have non-specific effects in cells, HKC8 control 
(HKC8-CTL) were generated as controls for future experiments. HKC8 cells were transfected in 
10cm petri dish with 2µg of empty plasmid. Three days after transfection, cells were grown in 
media supplemented with G418 to select stably transfected cells. Two clones were selected and 
HS3ST1 expression in the newly generated HKC8-CTL was analysed by RT-qPCR (Figure 4-26) 
and Western blot (Figure 4-27). HKC8-CTL cell HS3ST1 expression remained low. 
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Figure 4-26: HS3ST1 expression in HKC8-CTL and HKC8-HS3ST1 
Wild type HKC8 cells were transfected in 10cm petri dish with 2µg of empty plasmid and 
effectene. Three days after transfection, cells were split 1:5 and grown in media supplemented with 
200µg/mL G418. Cells mRNAs were extracted using Qiagen RNAeasy kit. Data were analysed by 
qPCR with HPRT1 as housekeeping gene. Two mock clones were selected for further studies. 
 
 
Figure 4-27: HKC8-CTL clones protein levels 
Two clones HKC8-CTL (clone C and clone E) were selected and their protein levels analysed by 
Western Blot. A quantity of 10µg of protein lysates were run into a 10% acrylamide gel for 20 
minutes at 180V and transferred onto a nitrocellulose cell membrane. The membrane was blocked 
1h in 5% milk 0.1% TBST and incubated overnight at 4°C with flag tag antibody. The next day the 
membrane was washed with 0.1%TBST and incubated with secondary anti-rabbit antibody before 
detection. After a mild stripping and a blocking step, the membrane was probed for tubulin as a 
loading control. 
 
To confirm that HS3ST1 was directed to the Golgi apparatus after synthesis, HKC8-HS3ST1 and 
HKC8-CTL were stained with a flag Tag antibody and GM130, a cis-Golgi marker (Figure 4-28). 
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HS3ST1-flag staining could be found colocalised with cis Golgi marker and around the nucleus. 
No detectable level of Flag tag protein was detected in the HKC8-CTL. 
 
Figure 4-28: immunofluorescence characterisation of HKC8-CTL and HKC8-HS3ST1 
HKC8-CTL (clone C and E) and HKC8-HS3ST1 (clone 9 and 12) cells were seeded in 8-well 
chamber slides and fixed 5-10 minutes in ice cold methanol at -20°C. Cells were incubated 1 hour 
at room temperature in 5% BSA to avoid unspecific binding and incubated with the primary 
antibodies overnight at 4°C. The next day slides were washed with PBS and incubated 2h at room 
temperature with the corresponding secondary antibody. Slides were mounted in Vectashield with 
DAPI. N≥2 
 
One popular hypothesis regarding HS is that the expression of one modifying enzymes can alter 
the expression of another (Esko and Selleck, 2002). Therefore HKC8-HS3ST1 and HKC8-CTL 
were screened for the other HS modifying enzyme expression (Figure 4-29). Firstly, there was no 
significant change in the other HS3ST expression even though HS3ST6 was downregulated in both 
clones but not significantly. HS3ST5 was not detectable. Secondly, HS6ST1 and SULF2 were 
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significantly decreased in HKC8-HS3ST1 compared to HKC8-CTL (p<0.05). It might be that the 
HKC8-HS3ST1 not only have a change in the 3-O-sulfation but also other sulfation patterns. 
 
Figure 4-29: HS modifying enzymes expression in HKC8-CTL and HKC8-HS3ST1 cells 
RNAs from HKC8-CTL and HKC8-HS3ST1 cells was extracted at different passage and analysed 
by qPCR with HPRT1 as housekeeping gene. Data were compared to the average of the mean of 
HKC8-CTL (MC). N=3 except HS3ST3B where N=1. One-way ANOVA, Bonferroni’s multiple 
comparison, p<0.05(*). 
The presence of HS3ST1 within cells does not provide information regarding enzyme activity. 
Additionally, the significant changes in expression of other enzymes could alter HS sulfation 
patterns on the surface of the transfected cells. Therefore, HS sulfation patterns on the cells was 
analysed to identify if HS3ST1 was active within the cells and if any other sulfation was affected 
by it. 
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4.3.6 Cell surface and ECM HS sequencing and imaging 
HKC8-CTL and HKC8-HS3ST1 disaccharide analysis showed five different types of sulfated 
disaccharides (Figure 4-30). GlcA-GlcNS3S6S represents a disaccharide with N, 3-O and 6-O 
sulfation. Interestingly HKC8-CTL had no detectable 3-O-sulfation even though they expressed 
other HS3ST isoforms. When analysing the total sulfated HS disaccharides, clone 9 had 1.6% of 
3-O-sulfation and clone 12 had 3.7%. These results show that the enzyme was active in the cells. 
However, it was surprising to observe half the amount of 3-O-sulfation in clone 9 compared to 
clone 12. The 3-O-sulfation being the last and rarely generated pattern on HS, it requires a specific 
HS chains structure. Clone 9 might have less 3-O-sulfation due to a lack of targeted sequence on 
HS. This clone also has a higher percentage of the 2-O sulfated disaccharide IdoA2S-aManR (61% 
for clone 9 against 36.5% for clone 12 of total sulfated disaccharide), a sulfation pattern known to 
prevent the activity of HS3ST1.  
Moreover, both clones showed less GlcA-GlcNS6S compared to HKC8-CTL. It was 6.5 times 
lower in clone 9 and 2.1 times lower in clone 12. Additionally, clone 9 displayed less trisulfated 
disaccharides while clone 12 showed more compared to HKC8-CTL. In contrast, clone 9 had more 
IdoA2S-GlcNS than clone 12 and HKC8-CTL. It could be possible that the activity of 6-O-
sulfatase on the trisulfated disaccharides on clone 9 led to a decrease in IdoA2S-GlcNS6S and an 
increase in IdoA2S-GlcNS on the cells. 
The changes in HS cell surface composition in HKC8-HS3ST1 could potentially lead to a change 
in growth factors binding, signalling and activity. Therefore, both cell types were screened for cell 
binding to FGF2 (flow cytometry), cell proliferation (WST-1 test), cell migration (wound healing) 
and cell signalling (Western blot) following treatment with 10ng/mL FGF2.  
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Figure 4-30: HKC8-CTL and HKC8-HS3ST1 HS disaccharides composition 
HKC8-CTL and HKC8-HS3ST1 cells were labelled with 35S. Cells were lysed, and GAGs were 
isolated from protein by alkali treatment. GAGs were isolated by DEAE column and desalted by 
PD10 column before being eluted with a G15 column. In collaboration with Prof Marion Kusche-
Gullberg, Bergen University. GlcA-GlcNS6S (GMS), IdoA-GlcNS6S (IMS), IdoA2S-GlcNS 
(ISM), IdoA2S-GlcNS6S (ISMS), GlcA-GlcNS3S6S (GMdiS, pointed by blue arrow).  
 
4.3.7 FGF2 and HS 3-O-sulfation 
4.3.7.1 FGF2 binding 
FGF2 binding to the clones was analysed by flow cytometry (Figure 4-31). The slight shift 
observed in HKC8-CTL fluorescence with FGF2 was not seen in HKC8-HS3ST1 cells (Figure 
4-31 A, B, C). The FGF2 kit to study cells binding comes with a negative control, a soya protein 
that should not bind to the cells. However, the negative control bound more to HKC8-HS3ST1 than 
HKC8-CTL (Figure 4-31, D, E). The reason for this was not known. Therefore, only the MFI values 
of single cells was analysed and as seen in Figure 4-31, there was no significant change in FGF2 
binding between clones. Nevertheless, these data were not conclusive considering the slight shift 
in fluorescence observed even with the CTL cells. The kit might have had some dysfunction in our 
experiment. Therefore, to further investigate the potential action of HS 3-O-sulfation in FGF2 
binding with its receptor, we decided to compare FGF2 signalling in HKC8-CTL and HKC8-
HS3ST1. 
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Figure 4-31: FGF2 binding to transfected cells 
HKC8-CTL (clone E) and HKC8-HS3ST1 (clone 9 and 12), 4x106cells/mL were incubated with 
biotinylated FGF2 or biotinylated soya protein control for 1h at 4°C and Avidin-FITC for 30 
minutes at 4°C. Cells fluorescence was analysed using Facs CantoII flow cytometer. Data were 
analysed by FlowJo. A-C clones binding to soya protein (red) or FGF2 (blue). D-E: Clone E 
binding to soya protein (red) compared to clone 12 (D) and clone 9 (E). F: Mean Fluorescence 
Intensity (MFI) of HKC8-CTL and HKC8-HS3ST1 binding to FGF2, each dot square and triangle 
represent one independent experiment. 
 
 
4.3.7.2 FGF2 signalling  
To determine if FGF2 signalling was modified with HS3ST1 overexpression, the phosphorylation 
of ERK pathway was assessed in the transfected cells.  HKC8-CTL displayed a strong signalling 
10 minutes after FGF2 treatment (10ng/mL). HKC8-HS3ST1 showed a similar signalling in both 
clones with an increase in ERK phosphorylation 10 minutes after stimulation (Figure 4-32). In 
conclusion, the phosphorylation of ERK following FGF2 treatment was not affected by HS3ST1 
overexpression. 
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Figure 4-32: FGF2 signalling in HKC8-CTL and HKC8-HS3ST1 
Representative images of FGF2 signalling studied by western blot. HKC8-CTL were incubated in 
0.5%FBS media for 24 hours and were then treated 2, 5 or 10 minutes at 37°C with 10ng/mL of 
FGF2 or buffer (untreated UT) (left panel). HKC8-HS3ST1 were incubated in 0.5% FBS media 
for 24 hours and were then treated 10 minutes at 37°C with 10ng/mL of FGF2 or buffer (untreated 
UT) (right panel). A quantity of 10-20µg of protein lysates were run into a 10% acrylamide gel and 
transferred onto a nitrocellulose cell membrane. The membrane was blocked 1h in 5% BSA 0.1% 
TBST and incubated overnight at 4°C with P-ERK antibody. The next day the membrane was 
washed with 0.1%TBST and incubated with secondary anti-rabbit antibody before revelation. After 
a mild stripping and a blocking step, the membrane was probed for tubulin as a loading control. 
N=3 
These data suggest that HS 3-O-sulfation is not implicated in FGF2 binding and signalling. 
However, it does not give any indication about other pathways activated by FGF2 and the changes 
in different biological activities and this could vary between HKC8-HS3ST1 and HKC8-CTL. 
 
 
4.3.7.3 FGF2, cell proliferation and migration 
One of the main action of FGF2 is to stimulate cell growth. HKC8-CTL and HKC8-HS3ST1 
proliferation and migration with and without treatment were analysed (Figure 4-33). There was no 
significant change in cell proliferation in 0.5% FBS media and with FGF2 treatment (10ng/mL). 
Additionally, cell front velocity with and without FGF2 treatment were assessed by wound healing 
assay (Figure 4-33). Once again FGF2 treatment did not have a significant effect. However, an 
increase in cell velocity in HKC8-CTL and HKC8-HS3ST1 (both clone 9 and 12) was observed 
with FGF2 stimulation.  
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Figure 4-33: HKC8-CTL and HKC8-HS3ST1 cells proliferation and migration after 48h 
treatment with FGF2 
A: HKC8-CTL and HKC8-HS3ST1 cells were seeded in 96-well plate and treated with 10ng/mL 
FGF2 for 48h. Cells viability was measured with WST-1 test, a tracker of metabolically active 
cells. Absorbance at 450 and 630 were measured.B: Cells were seeded in Ibidi inserts at 
3x105cells/mL. The next day, the inserts were removed, generating a wound within each well of 
12-well plates. Cells were incubated with 0.5% FBS media ± 10ng/mL FGF2 and wound closure 
was imaged every hour by Nikon Biostation. See methods section for cell velocity calculation. N=3 
for A and N=4 for B. 
Noteworthy HKC8-HS3ST1 clone 12 displayed a significantly higher cell front velocity (p<0.01) 
in complete media (Figure 4-34). As the increase in cell proliferation was only observed in one 
clone, more clones were screened for cell migration. Surprisingly the increase in cell migration was 
only seen in clone 12. When generating these cells, the clone selection might have selected a clone 
that has a higher capacity for migration. Secondly it is important to report that HS3ST1 is expressed 
differently in every clone and as mentioned above some clones have less 3-O-sulfation than others 
(clones 9 has 50% less than clone 12). However, it is possible that the difference observed in cell 
migration is due to more sulfated HS.  
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Figure 4-34: Cell velocity in complete media 
Cells were seeded in Ibidi inserts at 3x105cells/mL. The next day, the inserts were removed, 
generating a wound within each well of 12-well plate. Cells were incubated with 5%FBS media 
and wound closure was imaged every hour by Nikon Biostation. See methods section for cell 
velocity calculation. N=3. Statistical significance was calculated using a one-way ANOVA with 
Bonferroni’s multiple comparison test p<0.01(**), p<0.001 (***). 
 
 
All these data did not show any difference in FGF2 binding and its biological activity between 
HKC8-CTL and HKC8-HS3ST1. However, the increase in cell velocity with FBS in clone 12 
could indicate the presence of other growth factors in the serum that is affected by HS 3-O-
sulfation. In the previous chapter, HB-EGF was found decreased together with HS 3-O-sulfation 
in vivo. Therefore, HB-EGF signalling was analysed. 
 
4.3.8 HB-EGF and HS 3-O-sulfation 
HB-EGF is involved in cell proliferation and repair. It is also present in the blood circulation and 
was recently suggested as a potential biomarker of disease such as primary ovarian cancer (Miyata 
et al., 2017).  
HB-EGF signalling can be transient. Therefore, as preliminary data, WT HKC8 cells were serum 
starved for 16h and treated at different time points (5, 15, 30 minutes and 1 hour) with 1µm HB-
EGF to identify at what time STAT3 phosphorylation was detectable. As seen Figure 4-35, 
STAT3 was phosphorylated at 5 minutes and decreased until coming back to baseline at 1h. To 
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identify if HB-EGF binding was affected by the overexpression of HS3ST1, HKC8 clones were 
serum starved for 16 hours and stimulated with 1µm HB-EGF for 5 minutes and 1 hour. STAT3 
phosphorylation was studied by Western Blot Figure 4-36. 
 
Figure 4-35: Phospho-STAT3 induction by HB-EGF in WT HKC8 and HKC8-HS3ST1 
Serum starved Wild Type HKC8 (A) and HKC8-HS3ST1 (B) were treated for 5, 15, 30 minutes 
and 1 hour at 37°C with 1µM of HB-EGF or buffer (CTL). Protein lysates were run into a 10% 
acrylamide gel and transferred onto a nitrocellulose cell membrane. The membrane was blocked 
for 1h in 5% BSA 0.1% TBST and incubated overnight at 4°C with P-STAT3 antibody. The next 
day the membrane was washed with 0.1% TBST and incubated with secondary anti-rabbit antibody 
before visualisation. After a wash in 0.1% TBST, the membrane was probed for tubulin as a loading 
control.  
 
 
Figure 4-36: HB-EGF signalling in HKC8-CTL and HKC8-HS3ST1 
Representative images of HB-EGF signalling studied by western blot. Serum starved cells were 
treated for 5 minutes and 1hour at 37°C with 1µM of HB-EGF or buffer (CTL). A quantity of 10-
20µg of protein lysates were run into a 10% acrylamide gel and transferred onto a nitrocellulose 
cell membrane. The membrane was blocked for 1h in 5% BSA 0.1% TBST and incubated overnight 
at 4°C with P-STAT3 antibody. The next day the membrane was washed with 0.1% TBST and 
incubated with secondary anti-rabbit antibody before development. After a wash in 0.1% TBST, 
the membrane was probed for tubulin as a loading control.  
The signalling pattern of HB-EGF in HKC8-CTL showed a strong signalling at 5 minutes that 
returned to baseline at 1 hour. However, HKC8-HS3ST1 showed a strong signalling at 5 minutes 
that comes back after 1 hour treatment as seen Figure 4-35. The activation of STAT3 at 1h was 
observed in both clones of HKC8-HS3ST1 (Figure 4-36).  
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4.4 Discussion 
Three different cell lines were used for the first part of this work. Two human renal epithelial cells 
HK2, HKC8 and one rat renal fibroblasts NRK-49F. As expected HK2 and HKC8 cells were 
positive for E-cadherin, an epithelial marker while NRK-49F cells were negative. The 
heterogeneous staining observed in HK2 and HKC8 cells can be explained by the low confluency 
of the cells at the time of staining. Furthermore, proximal tubule cells do not express high level of 
E-cadherin compared to other renal cells such as distal tubule cells (Baer et al., 2006) or collecting 
duct (Nouwen et al., 1993; Prozialeck et al., 2004). Cytokeratin 18 could have been a better marker 
for these cells but was not available at the time of experiment.  
The second marker studied was fibronectin which is commonly known to be a marker of 
mesenchymal cells, but human tubular cells secrete fibronectin into their ECM (Burton et al., 1996) 
and is a positive marker of HK2 cells according to the ATCC. Therefore, the low level of staining 
of E-cadherin and strong staining of fibronectin in HK2 and HKC8 were good indications of the 
cells origin.  
The absence of E-cadherin staining and the positive staining of fibronectin were good indicators of 
the fibroblast characteristics of the NRK-49F cells. Surprisingly the α-SMA was weaker than 
expected, potentially because it is a marker of activated fibroblasts and the medium where the cells 
were grown did not stress or activate them enough to trigger expression of α-SMA.  
After characterising the cells, this work aimed to discover what growth factors regulate HS3STs 
expression. First TGFβ1 was used as it is a well-known pro-fibrotic factor (Leask and Abraham, 
2004). The data suggests that TGFβ1 is an important modulating factor of HS3ST3B and HS3ST1 
expression in renal epithelial and fibroblast cells. It upregulates HS3ST3B and downregulates 
HS3ST1. This correlates with previous studies showing a change in HS modifying enzymes 
following TGFβ1 treatment. In vitro, 24h treatment with TGFβ1 (0.05-5ng/mL) induced significant 
increase of SULF1 expression and a significant decrease in SULF2 at 1 and 5ng/mL in primary 
normal human lung fibroblasts (Yue et al., 2008). In vivo mice treated with adenovirus encoding 
active TGFβ1 via oropharyngeal aspiration showed an increase in pulmonary expression of SULF1 
and SULF2. Furthermore, TGFβ1 treated astrocytes (10ng/mL) showed an increase in HS2ST1 
(Properzi et al., 2008). 
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HS3ST3A and HS3ST6 expression did not vary with the treatment. However, the heterogeneity 
between samples might have hidden a possible effect of the treatment. Additional repeats could 
clarify this.  
Second, the combination of TGFβ2 and IL1β which has a role in fibrosis by promoting endothelial 
to mesenchymal transition (Maleszewska et al., 2013) was analysed in renal epithelial and 
fibroblast cells. The results were similar to what was found with TGFβ1 alone. There was a 
progressive decreased in HS3ST1 expression and an increase in HS3ST3B with no change in 
HS3ST3A and HS3ST6.  
Together these data show that TGFβ1, 2 and IL1β differentially regulate HS3STs in potentially an 
attempt to modify HS sulfation on the cell surface and ECM. Further disaccharides analysis of 
treated cells would enable us to assess if the change in RNAs expression is mirrored by a change 
in sulfation. However, due to time restriction and the lack of HS 3-O-sulfation standard, this could 
not be performed.  
The most dramatic change in HS3ST1 expression was seen in the NRK-49F which also showed a 
severe change in morphology. TGFβ1 and TGFβ2 were both shown to be pro fibrotic in the NRK-
49F cells (Yu et al., 2003) highlighting a possible role of HS3ST1 downregulation during fibroblast 
activation. 
These in vitro data identified growth factors that downregulate HS3ST1 expression. It is potentially 
these growth factors that triggered the decrease in HS 3-O-sulfation observed in the tubules of 
fibrotic kidneys in chapter 3. However, no treatment was found to upregulate HS3ST1 in vitro and 
therefore failed to explain the increase observed in total renal tissue seen in vivo. Fibrosis is 
triggered by more than two growth factors and it is highly possible that still unidentified growth 
factors or cytokines increase HS3ST1 expression in renal epithelial cells and fibroblasts. We could 
have potentially used IL-4 , IL-13 and FGF10 as they increased HS3ST1 in different cell lines 
(Takeda et al., 2010; Patel et al., 2014). Furthermore, the use of only two different cell types does 
not reflect exactly what is happening in vivo. Pro inflammatory factors can modulate HS3STs 
expression in endothelial cells and increase HS3ST1 expression in immune cells (Krenn et al., 
2008; Sikora et al., 2016). Macrophages can be found during the development of fibrosis and could 
be the origin of the increased expression. 
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The second part of this chapter was to analyse which growth factors would be affected by HS 3-O-
sulfation. Due to the very low expression of HS3ST1 in HKC8 cells, they were an excellent model 
to study the impact of HS3ST1 expression on growth factors binding, signalling and activity. 
To study HS3ST1 expression, both mock and HS3ST1 stable transfectants were successfully 
generated. No other HS3STs isoforms were altered in the stable cell lines. Surprisingly it did lead 
to a decrease in HS6ST1 expression in both clones of HKC8-HS3ST1 and a decrease in SULF2 
expression in clone 9 suggesting a potential decrease in HS 6-O-sulfation. Remarkably, the 
decrease in HS6ST1 was mirrored by a decrease in GlcA-GlcNS6S (GMS) in HKC8-HS3ST1 
compared to HKC8-CTL (6.5 times lower in clone 9 and 2.1 times lower in clone 12). The reason 
behind the differences between both clones could be the level of HS3ST1 expressed in the cells. 
Clone 9 has more HS3ST1 than clone 12 at both RNA and protein levels and even though SULF2 
only decreased significantly in clone 9, its expression decreases in clone 12 too but with p=0.08. 
Thus, HS3ST1 might decrease HS6ST1 expression and activity but more effectively in clone 9 
than clone 12. When looking at 3-O-sulfated disaccharides, the overexpression of HS3ST1 led to 
an increase in HS 3-O-sulfation between 1.6% (clone 9) and 3.7% (clone 12). This level of sulfation 
is similar to what was found in Chinese Hamster Ovarian cells transfected with HS3ST1 which 
displayed about 4% of HS with an AT binding site (Datta et al., 2013). Endothelial cells have 1% 
of HS-3-O sulfation (Marcum et al., 1986). Thus our in vitro data was in agreement with what was 
observed in vivo and in other in vitro studies of HS3ST1 activity. The lower amount of 3-O-
sulfation in clone 9 could be surprising considering that it was the clone with the most HS3ST1 
expression. However, as mentioned previously, this clone might have less substrate than clone 12. 
To summarise, the overexpression of HS3ST1 in HKC8 cells generates effectively more 3-O-
sulfation. Interestingly, it also changes other HS modifying enzymes expression. The cell might 
have a very well controlled system within the Golgi apparatus to balance the overexpression of one 
enzyme and prevent any damaging alteration of HS sulfation on the cell surface. 
In the last part of this chapter, the implication of FGF2 and HB-EGF with HS 3-O-sulfation were 
studied. FGF2 has been widely studied and its binding with HS 2-O, 6-O sulfation and HS-FGFR 
complex are well described (Pye et al., 1998). Because there have been conflicting results regarding 
the role of HS 3-O-sulfation and its implication in FGF2 binding we analysed its binding, signalling 
and biological activity on the transfected cells. There was no noticeable change between HKC8-
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HS3ST1 and HKC8-CTL. These results are in line with what Thacker et al. showed with CHO 
cells overexpressing HS3ST1 having no difference in FGF2 binding (Thacker et al., 2016a). We 
can conclude that HS 3-O-sulfation does not play a significant role in FGF2 activity in renal 
epithelial cells.  The increase of HS3ST1 expression seen in vivo might then not be related to 
increasing FGF2 activity.  
HB-EGF is a less studied growth factor and its structural binding to HS not very well documented. 
The increase in STAT3 phosphorylation at 5 minutes and 1h in HKC8-HS3ST1 cells showed a 
biphasic response of the cells to the treatment. This second signalling was not observed in HKC8-
CTL nor WT HKC8. The first explanation could be a retention of HB-EGF on the ECM of the cells 
which signals again when the EGF receptors are recycled at the cell surface. The second 
explanation could be a second messenger. In fact the biphasic signal observed in the HKC8-
HS3ST1 has been previously seen in vascular smooth muscle cells treated with HB-EGF (Lee et 
al., 2007). In this study, they identified the second signalling as interleukin 6 (IL-6) dependent. 
Treated cells showed an increase in IL-6 expression at 30 and 45 minutes after HB-EGF treatment 
(10ng/mL) and an increase in IL-6 secretion in the media at 60 minutes compared to untreated 
cells. The phosphorylation of STAT3 at 1h was decreased when using IL-6 neutralising antibody. 
Additional studies showed that the biphasic phosphorylation of STAT3 was caused by IL-6 related 
cytokines in cardiomycoytes after angiotensin II treatment  (Sano et al., 2000) and in mouse cardiac 
fibroblast after isoproterenol treatment (Yin et al., 2003). IL-6 can bind heparin and heparan sulfate 
which confers protection to degradation by endoproteinase Lys-C. Furthermore, this binding did 
not seem to require 2-O-sulfation, a sulfation that prevent HS3ST1 action (Mummery and Rider, 
2004). An ELISA assay using conditioned media from the treated/untreated HKC8-CTL and 
HKC8-HS3ST1 cells could answer whether or not IL6 is secreted in response to HB-EGF in our 
model.  
In conclusion, this chapter showed that the TGFβ growth factors together with IL1β are regulators 
of HS3STs enzymes. HS3ST1 overexpression is capable of generating HS 3-O-sulfation in renal 
epithelial cells but induced a decrease in HS6ST1 and SULF2 expression. This highlights a possible 
intra cellular regulation of HS modifying enzymes by the cell itself. Finally, HB-EGF signalling 
was identified as being potentially enhanced by HS 3-O-sulfation.   
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 Synthesis of potential inhibitors of FGF2 binding 
to heparan sulfate 
 
5.1 Introduction 
The current knowledge on HS interaction with growth factors, cytokines and their receptors make 
it an excellent target for drug development. X-ray crystallography, isothermal titration calorimetry 
(ITC) and sequencing, to just name a few techniques have allowed us to identify the specific motifs/ 
functional groups within a molecule that binds to HS. In fact, crystallography can identify the 
atomic details of protein-ligand interaction, ITC gives more precision about the type of binding 
(exothermic, endothermic), the strength of the binding (Kd) and sequencing gives the amino acid 
sequence of the protein. Therefore, recent technology has enabled the synthesis of recombinant and 
mutated protein to increase binding to HS, to receptors or to decrease affinity. All approaches are 
excellent tools to understand the role of HS in scavenging, binding, protecting or enhancing protein 
activity. 
For example, chemokines and HS interaction can be targeted by preparing mutant chemokine 
lacking HS binding which can compete for receptor binding and inhibit chemotactic gradient  
formation and cell migration (Cripps et al., 2005; Anders et al., 2006; O’Boyle et al., 2009). A 
mutant form of the chemokine CXCL12, where three basic residues at sequence positions 24, 25, 
and 27, were replaced by serine, showed inhibition of peripheral blood mononuclear cells 
transendothelial migration in vitro and decreased leukocyte recruitment in vivo (O’Boyle et al., 
2009). Similar results were found with a mutant CCL7 where two lysine (position 44, 46) and one 
arginine (position 49) were changed to alanine residues. The mutant inhibited leukocyte infiltration 
in a mouse isograft skin transplant model (Ali et al., 2010). Occasionally, targeting HS binding 
sequence does not significantly inhibit cell migration in vitro but does in vivo as seen in CXCL11 
mutants (Severin et al., 2010). This highlights the complexity of HS and protein interactions. 
Generating HS based antagonist chemokine can also be beneficial. Basic amino acid residues 
(termed “B” e.g. lysine and arginine) are important due to their positive charges interaction with 
HS negative charges. For example, the motif BBXB has been found important for binding CCL5 
to HS (Proudfoot et al., 2001), hence mutant chemokines with more basic residues increase binding 
(Brandner et al., 2009). A CXCL8 mutant with a higher affinity for HS and a lower affinity for the 
HS binding peptides and peptoids 
 
132 
G protein-coupled receptor (GPCR) showed no neutrophil chemotactic activity in vitro. This 
dominant negative mutant had additional lysine residues and lacked the ELR motif (glutamic acid-
leucine-arginine), important for GPCR binding. In vivo, after ischemia reperfusion injury in rat 
kidneys, the administration of mutant CXCL8 diminished tubulointerstitial damage and 
granulocyte infiltration (Bedke et al., 2010). Furthermore, in a model of acute rejection, the daily 
injection of the mutant CXCL8 decreased inflammation, tubulitis, the number of ED1 positive cells 
(equivalent to the CD68 human monocyte marker) and CD8 ( T-cells) cells in glomerular cross 
sections (Bedke et al., 2010). This mutant CXCL8 was found beneficial in other diseases such as 
cystic fibrosis (McElvaney et al., 2015) and in murine models of pulmonary fibrosis and urinary 
tract infection (Gschwandtner et al., 2017). 
Further work showed that small compounds based on the HS binding sequence can modify 
inflammatory responses.  Peptides from the C-term sequence of CXCL9 (74-103) with high affinity 
to HS decreased CXCL8-induced neutrophil extravasation (Vanheule et al., 2015). IFNγ C-
terminal sequence, hypothesised to be HS binding sequence, was used to generate a synthetic 
octapeptide (MC-2, LRKRLRSR). When used in a rat allograft skin transplant model, the peptide 
demonstrated delayed graft rejection (Fernandez-Botran et al., 1999, 2002) The same peptide was 
found to decrease liver injury in mice following hemorrhagic shock (Matheson et al., 2016).  
Synthetic peptides based on FGF2 sequence have previously been used to inhibit FGF2 mediated 
vascular endothelial cell proliferation (Yayon et al., 1993). Inhibiting FGF2-HS interaction might 
reduce fibroblast proliferation and ECM deposit and therefore limit fibrosis. Li et al. studied the 
interaction between FGF-2 and multiple disaccharides that HS can be theoretically composed of 
(Li et al., 2014). They found two main sites essential for the binding, the Asn27 and an 
electropositive pocket formed by residues 119-135. Depending on the sulfation pattern, the affinity 
of the disaccharide for FGF-2 changes. A disaccharide, GlcNS3S, IdoA2S with N-, 3-O and 2-O-
sulfation had the highest affinity (Kd= 1.73±0.31µM). This finding shows that the 3-O-sulfation 
might be implicated in the binding process. However, we previously showed that HS 3-O-sulfation 
did not alter FGF2 signalling. One possible explanation could be that FGF2 can bind to HS 3-O-
sulfation but does not require it for its biological activity. In this chapter, FGF2 was studied for the 
competition work assay as its structure and binding sequence are well characterised and 
documented. 
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The aims of this chapter are: 
-To identify a peptide that could compete with FGF2 binding to HS. The electropositive pocket 
described previously was used to inform the first peptide sequence synthesised 
“KRTGQYKLGSKTGPGQKAI”.  
-To show the importance of positively charged amino acids on HS binding by synthesising a 
modified peptide KRTGQYALGSKTGPGQKAI.  
 
5.2 Specific material and methods 
Peptides synthesis and characterisation were carried out in collaboration with Durham University 
under the supervision of Dr Steven Cobb and Dr Ehmke Pohl.   
 
5.2.1 Solid Phase Peptide Synthesis 
The use of Solid Phase Peptide Synthesis (SPPS) was preferable to liquid phase as it uses a larger 
excess of reagents at high concentration, which allows completion of coupling reactions. 
Furthermore, filtration and washings can be performed in the same vessel. This also provides a 
faster method for peptide synthesis (Amblard et al., 2006).   
In principle, with the strategy used, the first N-protected-side chain protected-C terminal amino 
acid is bound via its carboxyl group to a resin (in my case an amino resin: amine-linked peptide). 
The peptide sequence is linked from C to N terminus. Consequently, for the FGF2 peptide 
KRTGQYKLGSKTGPGQKAI, the synthesis starts with isoleucine and alanine. It starts with a N-
term deprotection followed by a coupling reaction that is repeated n times. During the synthesis, 
side chains of the amino acid are always protected with a protecting group to prevent mislinking. 
The amino group is temporarily protected and is unprotected before coupling. The procedure is 
illustrated Figure 5-1. 
HS binding peptides and peptoids 
 
134 
 
Figure 5-1: First steps of FGF2 peptide synthesis 
The Fmoc-Ile-OH amino acid was anchored to Rink amide resin. Elongation was performed with 
Nterm deprotection and next amino acid activation Fmoc-Ala-OH. DIC: Diisopropylcarbodiimide, 
HOBt: 1-hydroxybenzotriazole, DMF; Dimethylformamide. 
 
 
5.2.1.1 Experimental details  
The synthesis was carried out using a 30 mL polytetrafluoroethylene (PTFE) reaction vessel. 0.1 
mmol of rink resin was incubated for 1h with Dimethylformamide (DMF) to permit its swelling. 
A 5-fold excess of Fmoc-protected amino acid, piperidine (20% in DMF), 0.8 M of DIC in DMSO 
and 0.5 M of 1-hydroxybenzotriazole (HOBt) in DMF were used. Coupling was generated with a 
60 minutes room temperature following by 10 minutes microwave couplings at 0.10mmol scale, 
the temperature was set at 75 °C and power at 25W. Fmoc groups were removed at room 
temperature by treatment with 20% piperidine in DMF.  
Reagents used were from Sigma-Aldrich unless specified. The Rink amide resin was purchased 
from Novabiochem. DMF was purchased from AGTC Bioproducts (Hessle, UK). DMF is an 
organic solvent that facilitates the amino acid coupling reaction as it swells the resin. As 99% of 
coupling sites are situated inside the resin beads, the swelling allows an optimal permeation of 
activated amino acids. DMF will turn the resin from a shrunken state to a swollen state, it is the 
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reaction solvent. Amino acid derivatives were purchased from CEM, Novabiochem (Merck) or 
AGTC.  
Side chains of the different amino used were protected as follow:  
Fmoc-Arg(Pbf)-OH, Fmoc-Gln(Trt)-OH, Fmoc-Glu(tBu)-OH, Fmoc-Lys(Boc)-OH, Fmoc-
Ser(tBu)-OH, Fmoc-Thr(tBu)-OH and Fmoc-Tyr(tBu)-OH.  
To resume, each amino acid will have a base-labile N-Fmoc group on the alpha amino function, an 
acid-labile protecting group on side chains if necessary, and an acid labile linker on the C terminus. 
The Boc/Bzl protection was not chosen as it implicates the use of the highly toxic hydrofluoric acid 
and strong acidic conditions can be deleterious for structural integrity of the peptide. The Fmoc 
strategy permits a mild acidic condition for both peptide deprotection and cleavage from the resin.  
A base, piperidine was used to expose the amino acid in order to react with the next activated amino 
acid. This is the Fmoc deprotection step and was carried out using a 20% (v/v) solution of 
piperidine in DMF. Diisopropylcarbodiimide (DIC) and HOBt were used to activate peptide bond 
formation. DIC activates the carboxyl function. HOBt prevents racemisation to occur. They are 
activators for coupling. 
 
5.2.1.2 Acetylation and cleavage 
Following the 30 hour-synthesis, the peptide-resin was washed with DMF. The peptide needed to 
be acetylated to prevent any undesired reaction with the N-terminus of the last amino acid. Briefly, 
the peptide-resin was incubated twice with a 25% solution of acetic anhydride in DMF for 20 
minutes under agitation. It was then drained and washed 5 times with DMF and 2 times with 
diethylether (Et2O). The last wash removed the DMF and thus allow a better cleavage reaction. 
Peptide cleavage was carried out with a solution of 95:5:5 (v/v/v) Trifluoroacetic acid, 
Triisopropylsilane (TIPS) and water for 3 hours under agitation. Water and TIPS scavenge the 
protecting groups. The peptide resin mixture was filtered in order to collect the peptide. The filtrate 
was then concentrated with a rotary evaporator followed by ether wash. The solid peptide was 
dissolved in deionised water and acetonitrile (acetonitrile helps hydrophobic molecules to dissolve 
in solution). The crude peptide was analysed by mass spectrometry and lyophilised overnight for 
storage. 
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5.2.2 Peptoid synthesis 
Peptoid structure differs from peptides as the side chains are on nitrogen atoms. Their backbones 
are achiral (Figure 5-2). Peptoids were synthesised by Hannah Bolt (Cobb research group Durham 
University) using an Aapptec Apex 396 synthesiser as described before (Bolt, Williams, et al., 
2017). All experiments were done at room temperature unless specified. Briefly, about 0.1mmol 
of Fmoc-protected Rink Amide resin was swollen in 2 mL of DMF during 2 min shaking at 475 
rpm. The resin was deprotected with 1 mL of 20% 4-methylpiperidine solution in DMF for 1 min, 
475 rpm and then with 2 ml of solution for 12 min, 475 rpm. The acylation step was done by 
treating the resin with 1 mL of a 0.6 M haloacetic acid solution (either bromo- or chloroacetic acid 
diluted in DMF) for 20 min at 475 rpm. Five washing steps using 2 mL of DMF for 1 min at 475 
rpm were carried out before adding the amine sub-monomer. This was performed by incubating 1 
mL of 1.5M amine sub monomer in DMF for 60 mins with shaking at 475 rpm. The 5 washing 
steps were done once again following by acetylation and amine displacement steps until the 
sequence was complete. The crude peptoid was shrunk in diethyl ether and peptoid cleavage was 
carried out with 4 mL of a 95:5:5 (v/v/v) mixture of TFA:TIPS:water for 30 min on an orbital 
shaker at 250 rpm. The cleavage mixture was filtered and evaporated in vacuuo.  The resulting 
residue was precipitated in about 20mL of diethyl ether. The crude peptoid was obtained via 
centrifugation (15 mins, 4,000 rpm, 5 ˚C) and the ether layer decanted to yield the crude product 
as a white/yellow powder.  
 
 
Figure 5-2: Structure of an α-Peptide and α-Peptoid structure 
Adapted from (Bolt, Eggimann, et al., 2017) 
 
5.2.3 Compounds used in the study 
This study aimed to synthesise a peptide that could compete with FGF2 binding, as this growth 
factor is implicated in fibrosis (WT peptide). The sequence of interest was designed considering 
the FGF2 residues involved in Heparan Sulfate binding (Li et al., 2014). The importance of a lysine 
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residue in binding sulfation patterns was studied by synthesising a modified peptide (MD peptide) 
where the lysine was substituted by an alanine. The peptides have 19 amino acid residues as it is 
representative of the electropositive pocket of FGF2 (Li et al., 2014), a longer peptide could have 
been designed but the longer the peptide the harder the synthesis. Two peptides were synthesised 
by Fmoc-SPPS and four peptoids were kindly given by Hannah Bolt. Peptoids were first used as 
positive control for the ITC experiment as it has been shown that peptoids can have high binding 
affinity with HS (Ford et al., 2013). One peptoid used was based on earlier publication (HLB03-
50) and Dr Steven Cobb helped in designing 3 others peptoids that are positively charged (HLB03-
39, HLB03-41, HLB04-01). Characteristics and structures of the six compounds are summarised 
Figure 5-3. 
 
 
HS binding peptides and peptoids 
 
138 
 
 
 
 
 
 
 
 
Figure 5-3: Peptides and Peptoids characteristics 
Sequences, Molecular composition and weight are given for each compound. Abbreviations used: NSpe, N-((S)-1-phenylethyl) glycine; 
NLys, N-(4-aminobutyl)glycine);  Nbut, N-butylglycine
WT Peptide 
KRTGQYKLGSKTGPGQKAI, C90H155N29O26, 2058 g/mol 
 
HLB03-39 
(NLysNLysNspe)4, C88H143N21O12, 1686 g/mol 
 
MD Peptide 
KRTGQYALGSKTGPGQKAI, C87H148N28O26, 2001 g/mol 
 
 
HLB03-41 
(NaeNaeNspe)4, C88H143N21O12, 1463 g/mol 
 
HLB03-50 
(NLysNbutNspe)4, C88H139N17O12, 1626 g/mol 
 
HLB04-01 
(NaeNbutNspe)4, C80H123N17O12, 1515 g/mol 
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5.2.4 Mass spectrometry analyses 
Mass spectrometry (MS) is a very common technique to analyse both crude and purified peptides. 
Each peptide was dissolved in a mixture of deionised water and MeCN to a concentration of 
approximately 1mg/mL. The Matrix-Assisted laser desorption/ionization (MALDI) service in 
Durham performed all experiments using an Autoflex II ToF/ToF mass spectrometer (Bruker 
Daltonik GmBH). In principle, the matrix is composed of the sample and molecules α-cyano-4-
hydroxy-cinnamic acid (50 mg/mL) in a ratio of 1:9. A 337nm nitrogen laser is directed onto the 
matrix where energy is absorbed, and the matrix is ionised. The ionisation protects the samples 
from the laser and ionises them. Then samples are submitted to an electrical field, where all 
molecules are separated, and a detector analyses their time of flight. The speed at which the 
compound reaches the detector gives information about its weight. Results are therefore given as 
mass/charges written m/z. 
 
5.2.5 Purification and analytical HPLC 
High performance Liquid Chromatography was carried out using an Acquity HPLC system (Waters 
Ltd, UK) equipped with a 200 LC pump, and Waters 486 UV tunable absorbance detector, set to 
280 nm for peptides and 250 nm for peptoids. Chromatography purifies compounds according to 
their hydrophobic properties. Samples are injected onto a column where they interact with the 
hydrophobic ligands coated onto the column. The running buffer gradually changes from water to 
a non-polar organic solvent that weakens the interaction and therefore free the previously bound 
compound. A UV detector records absorbance and samples are collected based on their time of 
elution which correlates with the solvent concentration at point when the interaction with 
hydrophobic ligand is reversed.  In this work, 1-2mL of samples were injected onto an SB 
Analytical C8 column and the running buffer was from 95% H2O, 5%MeCN, and 0.1% TFA to 
95%MeCN, 5%H2O, and 0.1% TFA. Each fraction was collected and lyophilised. 
 
5.2.6 Circular Dichroism spectra 
Dichroism reflects light absorption differences depending on direction. Plane polarised light is 
composed of a right and left circularly polarised lights. Plane polarised light can become circulatory 
when passing through a birefringent surface. Circular Dichroism is based on the effect of circular 
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polarised light on a molecule. Left and right handed circularly polarised light are absorbed 
differently when directed onto the compound. CD spectropolarimeter measures the far UV 
absorbance of left and right handed light. It measures the difference in absorption between the right 
and left-handed light components. This difference in absorption leads to an ellipticity. The angle 
of polarisation defined by the eclipse is measured in degrees (deg). This angle gives information 
about the secondary structure of a molecule. All samples were analysed with a Jasco J-810 
spectropolarimeter.  
 
5.2.7 Isothermal Titration Calorimetry (ITC) 
ITC measures the heat released or absorbed upon the binding of two components. As seen in Figure 
5-4 two cells are used for this purpose. One reference cell containing the buffer only and one cell 
where one of the compounds of interest is added. A power unit maintains the same temperature in 
the two cells. A syringe is inserted on top of the sample cell and filled with a solution containing 
the second compound of interest diluted in the same buffer as compound 1. Gradually the syringe 
injects small volumes of compound 2 into the sample cells leading to an interaction between the 
two molecules (Figure 5-4). The power unit detects the temperature variations due to this 
interaction and provides the power needed to keep isothermal conditions. The calibrated power 
units between the reference cell and the sample cell are recorded. As an example, an exothermic 
reaction will release heat and therefore gives a negative differential power and inversely for 
endothermic reaction (Figure 5-5). The final graph gives a curve where affinity, stoichiometry and 
enthalpy of the binding can be determined (Figure 5-5).   
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Figure 5-4: Isothermal Titration Calorimetry apparatus 
ITC apparatus (A) is composed of a power unit, a reference cell, a sample cell and a syringe. To 
study the binding of two compounds, the syringe is filled with one compound and the sample cell 
with the other one. The syringe injects the compound of interest into the sample cell (B). 
 
 
Figure 5-5: Isothermal Titration Calorimetry principles 
The syringe injects the compound of interest into the sample cell and the change in temperature 
following the binding of the 2 compounds inside the sample cell is detected by the power unit (left 
panel). An endothermic reaction will decrease the temperature in the sample cell leading to a 
positive difference between the reference cell temperature and the sample one (REF-SAMPLE). 
This will be display on the screen as a peak (green graph). On the contrary, an exothermic reaction 
within the sample cell will increase the temperature generating a negative REF-SAMPLE 
temperature and therefore a drop on the analytical graph (red graph). Plotting all experimental data 
(right panel) allows the calculation of affinity, enthalpy and stoichiometry characteristics of the 
binding. 
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5.2.7.1 Samples preparation 
All samples were diluted in 50mM sodium phosphate buffer pH 7.4, filtered with 0.22µm filter and 
degassed prior to each experiment. For heparin solution, 5mL of 1mM Heparin was dialysed 
overnight with magnetic stirring at 4°C using a Maxi Geba Flextube Dialysis Kit MWCO 8kDa 
against 800 mL of the sodium phosphate buffer. Final heparin concentration used for peptoids 
experiments was 0.11mM and 0.1mM for peptides. Peptoids solutions were at a concentration 
around 0.1mM (it was not possible to use UV technique to control concentration precisely). 
Peptides solutions were at a concentration between 0.1-0.3mM and concentrations were checked 
using a nanodrop before each experiment.  
 
5.2.7.2 Instrument and experiment settings 
ITC measurements were carried out using a VP-ITC isothermal titration calorimeter (MicroCal, 
Inc). Reference power was set at 15 µcal/sec, initial delay 60 seconds and the stirring speed at 
307rpm. Cells temperature was set at 25°C. A volume of 1.8mL of peptide/peptoid was loaded to 
the sample cell when 300µL of heparin was charged into the syringe (see specific concentrations 
below). 
For peptoids experiments, 30 injections of 6µL of 0.11mM heparin solution were titrated into a 
0.1mM peptoid solution. Each injection lasted 60 seconds with a spacing time of 300 seconds and 
a filter period of 2 seconds. 
For peptides experiments, 19 injections of 15µL of 0.1mM heparin solution were titrated into a 
0.1-0.3mM peptide solution. Each injection lasted 60 seconds with a spacing time of 300 seconds 
and a filter period of 2 seconds. 
 
5.2.8 Data analysis 
Dilution effect was corrected by subtracting samples data for control experiment (i.e. heparin 
titration into phosphate buffer). Once corrected, titration data were integrated and analysed using 
Origin 7.0 software (MicroCal Inc). Results were fit with the one-set-of-sites model with Ligand 
in syringe parameters. Dissociation constant (Kd), binding stoichiometry (N), enthalpy, energy 
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change (ΔH) and change in entropy (ΔS) were determined by ITC software. The free energy (ΔG) 
was calculated with the formula: 
 𝚫𝐒 =
𝚫𝐇−𝚫𝐆
𝑻
. 
 
5.3 Results 
First, the two peptides sequences from FGF2 were synthesised by SPPS. After synthesis, each 
compound was subjected to HPLC and MALDI-TOF.  Evaluation of crude peptides by MALDI 
shows whether the peptide is present in the crude preparation or not. Other unwanted peptides can 
be detected at higher and lower m/z value. For some figures, a table with the main m/z value and 
their meaning was created. 
 
5.3.1 WT peptide synthesis: run 1 
As seen in Figure 5-3, the expected molecular weight of WT peptide was 2058.17 g/mol. MALDI 
spectrum from crude peptide in Figure 5-6 had a peak at 2060 m/z which was the target peptide 
(M+H+). The peak at 1926 m/z was the peptide minus Arginine (Arg or R) (+Na). The peak at 2312 
m/z is likely to be the target peptide plus a Pbf protecting group (Pbf = 2, 2, 4, 6, 7-
pentamethyldihydrobenzofuran-5-sulfonyl), on the Arg side chain. 
 
Figure 5-6: MALDI Mass Spectrum from first crude WT peptide  
The target peptide was 2060 m/z (red arrow). Peaks that are on the right side of the target peptide 
show unwanted peptide with additional amino acid/ protecting group. Peaks that are on the left side 
are unwanted peptides with one or several amino acid deletions. 
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 A second cleavage was done to try to remove the Pbf group and therefore increase the yield of the 
target peptide. Results are shown Figure 5-7. The additional cleavage did not cleave all the arginine 
protecting groups as the 2312 m/z peak was still present.  
 
Figure 5-7: MALDI Mass Spectrum after an additional cleavage  
The WT peptide was 2060 m/z (in red). The peptide+ Pbf group was still present (2312 m/z peak). 
Table: m/z values from first FGF2 peptide synthesis and their respective interpretation. 
In order to purify our peptide, samples were purified by Reverse Phase High Performance Liquid 
Chromatography (RP-HPLC). The RP-HPLC trace is displayed Figure 5-8. Six main peaks were 
observed. After an overnight lyophilisation, samples from fractions 1 and 6 were found empty. 
They might have been only buffer. Samples 2, 3, 4 and 5 were analysed by MALDI.  
 
Figure 5-8: RP-HPLC trace of first WT peptide  
HPLC gradient: 0-100% B over 45min (A=5:95:0.1 Acetonitrile/H2O/TFA; B=95:5:0.1). 
Absorbance was recorded at 280nm. Fractions 1-6 were collected and lyophilised overnight. 
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Surprisingly the MALDI spectra from RP-HPLC fractions were similar to the crude one (Figure 
5-9). The separation was not successful. However, fraction 2 contained the most WT peptide. All 
fractions contained the peptide minus arginine. The 2166 m/z peak was only seen in fraction 4 and 
5. The peak 2060 m/z of the FGF2 peptide was weakly seen in fraction 4 analysis. 
 
Figure 5-9: MALDI mass spectrum after RP-HPLC  
Fraction 2 is shown on top left, fraction 3 on top right, fraction 4 on left bottom and fraction 5 on 
right bottom. Fraction 2 had one major peak of m/z= 2060.5= WT peptide. In the 3 other fractions, 
there was a peptides mixture. FGF2 peptide m/z peak is indicated by red square or red arrow. 
 
5.3.2 WT peptide synthesis: run 2 
Because the first synthesis did not lead to a fully purified peptide, a second synthesis was 
performed. The procedure used was the same as explained previously except that a double coupling 
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was used for Arginine (2 x 60 mins) and a longer TFA cleavage time was used (5h) to help avoid 
Arginine deletions and to ensure full deprotection of all Pbf groups. The MALDI of the crude 
peptide from the second synthesis is shown Figure 5-10. The WT peptide (2060.1m/z) was present 
but again so were the target peptide –Arginine (1904m/z) and the target peptide + a Pbf group 
(2312m/z). 
 
Figure 5-10: MALDI Mass Spectrum of the second WT peptide synthesis  
In red is the target peptide. The crude also had the peptide minus an Arginine (1904 m/z) and with 
Pbf group (2312 m/z). 
The crude peptide was subjected to RP-HPLC where 3 fractions were collected (see Figure 5-11). 
Fraction 1 mainly had the WT peptide (see Figure 5-12) compared to other fractions (data not 
shown). 
The second synthesis and RT-HPLC provided a clearer HPLC graph, showing a successful 
synthesis. Fraction 1 was chosen for ITC experiments. From 130mg of crude peptide, 
approximately 15mg was purified. The yield was around 11.5%, which is low but better than the 
first synthesis where all fractions had arginine deletions. The low yield was mainly due to the fact 
that a lot of fractions contained the peptide with arginine deletion. 
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Figure 5-11: RP-HPLC trace of second WT peptide 
HPLC gradient: 0-100% B over 45min (A=5:95:0.1 Acetonitrile/H2O/TFA; B=95:5:0.1). 
Absorbance was recorded at 280nm. Fractions 1-3 were collected and lyophilised overnight. R: 
Arginine, T: Threonine, G: Glycine. 
 
Figure 5-12: LC-MS of fraction 1-second WT peptide 
Major peak in LC (1.7 min) had masses at 687, 515 and 412 that correspond to the desired product 
(M+3H, M+4H, M+5H). M/z values of the target peptide are highlighted in red.  
 
HS binding peptides and peptoids 
 
148 
5.3.3 Modified peptide synthesis 
In the modified peptide as seen Figure 5-3, the 7th amino acid from WT peptide (lysine) was 
substituted by an alanine. As observed Figure 5-3, the expected molecular weight of modified 
peptide (MD pep) was 2001 g/mol. In Figure 5-13, the peak at 2003 m/z was the target peptide 
(M+H+). The peak at 1847 was the peptide minus Arginine (+Na) and the peak at 2255 could be 
the peptide plus a Pbf group, the Arginine side chain protecting group.  
 
Figure 5-13: MALDI Mass Spectrum of modified peptide 
The target peptide is 2003 m/z (in red). The crude has the peptide, peptide + Pbf group (2255m/z 
peak), peptide-Arginine (1847m/z) and peptide with multiple deletions and additions (2109 m/z). 
Table:  m/z values from MALDI crude modified peptide synthesis spectrum and their respective 
interpretation. 
RP-HPLC trace following synthesis is represented Figure 5-14. The purification was successful, 
all MALDI data are not displayed, only the one from the fraction with the highest purification. 
Fraction 1 was selected for ITC experiments. From 120 mg of crude peptide, approximately 36 mg 
has been purified (yield=30%). 
Peak  Deletion  Adduct  
1847 R 
 
2003 - - 
2109 A, P Na+, Pbf 
2255 
 
Pbf 
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Figure 5-14: RP-HPLC trace of modified peptide and fraction 1 mass spectrometry analysis  
HPLC gradient: 0-100% B over 45min (A=5:95:0.1 Acetonitrile/H2O/ TFA; B=95:5:0.1). 
Absorbance was recorded at 280nm (left image). Fractions 1-4 were collected and lyophilised 
overnight. MALDI analyses of all fractions showed that fraction 1 was the most purified fraction 
for the target peptide (right figure). R: Arginine, A: Alanine, P: Proline. 
 
5.3.4 Peptoid purification  
The four peptoids were synthesised by Hannah Bolt and purified in Durham. RP-HPLC traces and 
MALDI spectra from the best fractions are represented Figure 5-15. The purification of the four 
peptoids did not give high yield (see Table 5-1). This might be explained by a poor synthesis. Only 
HLB03-50 and HLB04-01 peptoids had a final mass above 5mg. These two peptoids were later 
used for CD analysis and ITC experiments. 
 
 Initial mass (mg) 
crude peptoid 
Final mass (mg) 
purified peptoid 
Yield 
HLB 03-39 195 <2mg around 1% 
HLB 03-41 90 <2mg around 2% 
HLB 03-50 80 12 15% 
HLB 04-01 80 6 7.5% 
Table 5-1: Peptoids yield and purified mass
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Figure 5-15: RP-HPLC traces of the four peptoids 
HPLC gradient: 0-60% B over 60min (A=5:95:0.1 Acetonitrile/H2O/TFA; B=95:5:0.1). Absorbance was recorded at 250nm. All 
fractions were collected, lyophilised overnight and analysed with mass spectrometry the next day. (P) represents the fraction were most 
purified peptoids were collected. Highlighted m/z peaks represent the target peptoid peak. 
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5.3.5 Analytical HPLC 
All compounds used for ITC experiments were subjected to analytical HPLC (Figure 5-16). WT 
peptide had a purity around 90%, MD peptide 95%, HLB04-01 around 86% and HLB03-50 around 
96%. These levels of purity were satisfactory and no more HPLC was necessary for these 
compounds. 
 
Figure 5-16: Analytical HPLC graphs  
Purified WT Peptide (A) and modified peptide (B) and peptoid HLB03-50 (C) and HLB04-01 (D). 
 
5.3.6 Circular Dichroism analyses 
CD provides secondary structure for peptides and peptoids of interest. Helical structures are 
characterised by negative bands at 222 and 208 nm and with a positive band at 193nm. β-sheets 
are characterised by a negative band at 218nm and positive at 195 nm while unfolded molecules 
have low ellipticity over 210nm and negative trace around 195 nm (Figure 5-17) (Greenfield, 
2006). Peptides showed a random coil while peptoid displayed a helical structure with two 
negatives bands between 227 and 197nm and a last positive band around 195nm. Only WT peptide 
and HLB03-50 graphs are represented, MD peptide was similar to WT peptide and HLB04-01 to 
HLB03-50 (data not shown).  
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Figure 5-17: CD spectra analyses  
Samples were diluted in PBS 10µM peptide and 100µM peptoid and analysed at 20°C with 
wavelength ranging from 180nm to 260nm. WT peptide (top left image) showed a curve typical of 
random coil structure. HLB03-50 (bottom left image) displayed an alpha helix structure. Right 
image from (Greenfield, 2006). 
 
5.3.7 Isothermal titration calorimetry experiments  
Isothermal titration calorimetry (ITC) was performed for all four compounds described before. All 
data are summed up in Table 5-2 and Figure 5-18, Figure 5-19. Surprisingly the peptides did not 
bind strongly to Heparin with a Kd between 100 and 1 000µM for WT peptide and MD peptide 
respectively. The lack of secondary structure as seen in Figure 5-17 might explain this. The 
dissociation constant of HLB03-50 peptoid was considerably lower than both peptides and had 
more binding sites, once again the helicoidal structure of the peptoid might favour stronger binding. 
However, the WT peptide bound with a Kd almost ten times lower than MD but with less binding 
sites (N=7 for WT vs N=17 for MD). This result confirmed that positively charged amino acids 
influence peptide binding to HS but the difference was not significant. It is noticeable that peptoid 
and peptides did not bind heparin the same way (Figure 5-18), while peptide titration indicated an 
exothermic binding (ΔH<0), peptoid binding displayed an endothermic reaction (ΔH>0).  
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HLB03-50 Kd (µM) Kd SD (µM) N 
ΔH 
(cal/mole) 
ΔH SD 
ΔS 
(cal/mole/deg) 
ΔG 
(cal/mole) 
exp 1 1.19 0.33 23 1906 43.31 33.5 1068.5 
exp 2 1.07 0.26 21 1905 37.33 33.7 1062.5 
exp 3 1.29 0.28 23 1574 28.67 32.2 769 
Average 1.18   22 1795   33.1 966.7 
WT peptide Kd (µM) Kd SD (µM) N ΔH ΔH SD ΔS ΔG 
exp 1 120 10 9 -720.5 4.66 15.5 -1108 
exp 2 130 10 6 -912.3 6.89 14.7 -1279.8 
exp 3 140 10 7 -834.2 5.27 14.9 -1206.7 
Average 130   7 -822.33   15 -1198.2 
MD peptide Kd (µM) Kd SD (µM) N ΔH ΔH SD ΔS ΔG 
exp 1 1450 750 24 -577.9 14.97 11.1 -855.4 
exp 2 550 150 8 -586.2 18.59 12.9 -908.7 
exp 3 420 40 15 -579.5 4.96 13.5 -917 
exp 4 1300 1170 21 -607.2 28.93 11.2 -887.2 
Average 930   17 -587.7   12.2 -892.1 
 
Table 5-2: ITC data for HLB03-50, WT peptide and MD peptide  
Dissociation constant (Kd), binding stoichiometry (N), enthalpy, energy change (ΔH) and change 
in entropy (ΔS) were determined by ITC software. The free energy (ΔG) was calculated with the 
formula 𝚫𝐆 =  𝚫𝐇 − 𝑇𝚫𝐒. Exp= experiment. N was given as integer and without SD considering 
that a binding site cannot be less than 1.  
As seen Figure 5-19, HLB04-01 did not fit to a one binding site model but to a model with two 
binding sites. The first two experiments displayed two binding sites. The third time, all instruments, 
syringes, cells were cleaned and new buffer, new heparin prepared but once again, the binding of 
HLB04-01 to heparin displayed two binding sites. Another fraction from a different RT-HPLC 
(data not shown) was used and again two binding sites appeared. It could be that the purification 
of the peptoid was not good and that two different molecules were in the cells. However, the 
analytical HPLC did not indicate impurity. No data can be given for the two binding sites constants 
as the software could not analyse a two binding site model when ligand is in the syringe.  
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Figure 5-18: Representative ITC titrations of WT peptide, MD peptide and HLB03-50 
Samples were diluted in 50mM sodium phosphate buffer pH 7.4, filtered with 0.22µm filter and 
degassed prior to each experiment. Peptides and peptoids concentrations were checked using a 
nanodrop before each experiment. ITC measurements were carried out using a VP-ITC isothermal 
titration calorimeter (MicroCal, Inc). Reference power was set at 15 µcal/sec, initial delay 60 
seconds and the stirring speed at 307rpm. Cells temperatures were set at 25°C. A volume of 1.8mL 
of peptide/peptoid was loaded to the sample cell when 300µL of heparin was charged into the 
syringe. For peptoids experiments, 30 injections of 6µL of 0.11mM overnight dialysed heparin 
solution were titrated into a 0.1mM peptoid solution. Each injection lasted 60 seconds with a 
spacing time of 300 seconds and a filter period of 2 seconds. For peptides experiments, 19 
injections of 15µL of 0.1mM heparin solution were titrated into a 0.1-0.3mM peptide solution. 
Each injection lasted 60 seconds with a spacing time of 300 seconds and a filter period of 2 seconds. 
Dilution effect was corrected by subtracting samples data for control experiment (i.e. heparin 
titration into phosphate buffer). Once corrected, titration data were integrated and analysed using 
Origin 7.0 software (MicroCal Inc). Results were fit with the one-set-of-sites model with Ligand 
in syringe parameters. A: WT peptide (N=3), B: MD peptide (N=4), C: HLB03-50 (N=3) 
 
B C 
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Figure 5-19: Representative ITC titrations of HLB04-01 
Samples were diluted in 50mM sodium phosphate buffer pH 7.4, filtered with 0.22µm filter and 
degassed prior to each experiment. Peptoid concentration were checked using a nanodrop before 
each experiment. ITC measurements were carried out using a VP-ITC isothermal titration 
calorimeter (MicroCal, Inc). Reference power was set at 15 µcal/sec, initial delay 60 seconds and 
the stirring speed at 307rpm. Cells temperatures were set at 25°C. A volume of 1.8mL of peptoid 
was loaded to the sample cell when 300µL of heparin was charged into the syringe. For each 
experiment, 30 injections of 6µL of 0.11mM overnight dialysed Heparin solution were titrated into 
a 0.1mM peptoid solution. Each injection lasted 60 seconds with a spacing time of 300 seconds 
and a filter period of 2 seconds. Dilution effect was corrected by subtracting samples data for 
control experiment (i.e. heparin titration into phosphate buffer). Once corrected, titration data were 
integrated and analysed using Origin 7.0 software (MicroCal Inc). Results were fit with the one-
set-of-sites model with Ligand in syringe parameters. Left image: HLB04-01 (N=3). Right image: 
HLB04-01 from a new fraction (N=1). 
To investigate the potential use of the peptides and peptoids to prevent renal fibrosis, their ability 
to inhibit FGF2 binding to renal epithelial cells was analysed by flow cytometry.  
 
5.3.8 FGF2 binding to renal epithelial cells by flow cytometry 
The first experiment was to verify the functionality of the FGF2 binding kit and its detection by 
flow cytometry. HKC8 cells were incubated with biotinylated FGF2 for 1h at 4°C or in buffer 
followed by 30 minutes incubation with Avidin-FITC at 4°C. FGF2 binding was analysed by flow 
cytometry with Facs Canto II excitation at 488nm and emission 530nm. Cells incubated only with 
FGF2 and buffer showed the same profile while cells incubated with FGF2 and Avidin-FITC 
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showed an increase in FITC fluorescence and therefore a binding of FGF2 and Avidin-FITC to the 
cells (Figure 5-20 B). As a negative control, cells were incubated with heparin which inhibited 
FGF2 binding to the cells (Figure 5-20 C). Overall, the binding of FGF2 was successful in all 
conditions with heparin inhibiting FGF2 interaction with the cell surface (Figure 5-20 D) 
 
Figure 5-20: FGF2 binding to HKC8 cells 
HKC8 cells grown in T75 flask were detached with warm accutase at 37°C and were suspended in 
3.2% BSA in PBS. FGF2 binding to cells was carried out with R&D kit NFFB0 following 
manufacturer’s instructions. About 100 000 cells were incubated with biotinylated FGF2 or 
biotinylated Soya protein (negative CTL) or buffer for 1h at 4°C. As a negative control, cells were 
incubated with 10µL of 500µg/mL of heparin with biotinylated FGF2 for 1h at 4°C. Then cells 
were incubated with Avidin conjugated FITC or buffer for 30 minutes at 4°C. Cells were washed 
two times and resuspended in wash buffer before analysis with FACS Canto II recording 10 000 
events with excitation at 488nm and emission at 530nm. The binding of FGF2 is associated with 
an increase in the cells fluorescence intensity and therefore a shift to the right of the population. 
N=1 
 
HS binding peptides and peptoids 
 
157 
In order to test the competition activity of the peptoids with FGF2 binding, three different 
concentrations of peptoids were used and cells were incubated 30 minutes at 4°C with each 
compound prior to FGF2 treatment. As observed in Figure 5-21 both HLB03-50 and HLB04-01 
inhibited FGF2 binding in a dose dependent manner with the concentration of 370µM showing an 
MFI value similar to the negative control. 
 
 
 
Figure 5-21: Increased concentration of peptoids treatment decrease FGF2 binding 
HKC8 cells grown in T75 flask were detached with warm accutase at 37°C and were suspended in 
3.2% BSA in PBS. FGF2 binding to cells was carried out with R&D kit NFFB0 following 
manufacturer’s instructions. About 100 000 cells were incubated with PBS or peptoid treatment 
with HLB03-50 (3.7µm, 37µM, 370µM) or HLB04-01 (3.7µm, 37µM, 370µM) for 30 minutes at 
4°C. Cells were then incubated 1h with biotinylated FGF2 or biotinylated soya protein (negative 
CTL) for 1h at 4°C. Then cells were incubated with Avidin conjugated FITC or H2O for 30 minutes 
at 4°C. Cells were washed two times and resuspended in wash buffer before analysis with FACS 
Canto II recording 10 000 events with excitation at 488nm and emission at 530nm. N=1 
 
However, when recording the cells fluorescence by flow cytometry, a new population of cells was 
observed when treated with peptoid concentrations of 37µM and 370 µM (Figure 5-22). Peptoids 
are known for permeabilising membranes. The compounds used might have been be toxic for the 
cells at high concentration. Therefore, cell death was analysed in HKC8 cells with peptoid 
treatments. The nuclear dye DAPI was used to detect cells integrity in treated cells (Figure 5-23).  
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Figure 5-22: Example of the switch in cell morphology with FGF2 treatment and peptoid 
HLB03-50 
HKC8 cells grown in T75 flask were detached with warm accutase at 37°C and were suspended in 
3.2% BSA in PBS. FGF2 binding to cells was carried out with R&D kit NFFB0 following 
manufacturer’s instructions. About 100 000 cells were incubated with PBS (D) or peptoid treatment 
with HLB03-50 (370µM, 37µM, 3.7µm) for 30 minutes at 4°C (A-C respectively). Cells were then 
incubated 1h with biotinylated FGF2 or PBS for 1h at 4°C. Then cells were incubated with Avidin 
conjugated FITC or PBS for 30 minutes at 4°C. Cells were washed two times and resuspended in 
wash buffer before analysis with FACS Canto II recording 10 000 events with excitation at 488nm 
and emission at 530nm. Live cells are circled in red while debris are seen in black. N=1 
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Figure 5-23: DAPI staining with peptoids treatment 
HKC8 cells grown in T75 flask were detached with warm accutase at 37°C and were suspended in 
3.2% BSA in PBS. FGF2 binding to cells was carried out with R&D kit NFFB0 following 
manufacturer’s instructions. About 100 000 cells were incubated with PBS or peptoid treatment 
with 03-50 and peptoid HLB 04-01 (370µM, 3.7µm, 37µM) for 30 minutes at 4°C. Cells were then 
incubated 1h with biotinylated FGF2 or PBS for 1h at 4°C. Then cells were incubated with Avidin 
conjugated FITC or PBS for 30 minutes at 4°C. Cells were washed two times and resuspended in 
wash buffer containing DAPI before analysis with FACS Canto II recording 10 000 events with 
excitation at 488nm and emission at 530nm. DAPI positive cells represent dead cells with a shift 
of the cell population to the right of the graph. 
As observed Figure 5-23, the peptoids treatments increased cell death especially at 370µM. For 
this reason only a low dose of 4µM was used for the study. Peptides treatment did not show any 
cell death and therefore the highest dose of 370µM was used in all experiments. 
Unfortunately, both peptides and peptoids did not show inhibition of FGF2 binding as seen Figure 
5-24. Even though the WT peptide caused a reduction in FGF2 binding, the decrease was not 
significant. The strong binding of FGF2 to HS with a Kd of about 10-9M could explain the 
difficulties to compete with binding.  
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Figure 5-24: FGF2 binding with peptides and peptoids treatment  
HKC8 cells grown in T75 flask were detached with warm accutase at 37°C and were suspended in 
3.2% BSA in PBS. FGF2 binding to cells was carried out with R&D kit NFFB0 following 
manufacturer’s instructions. About 100 000 cells were incubated with PBS or peptide treatment 
(370µM) and peptoid treatment (4 µM) for 30 minutes at 4°C. Cells were then incubated 1h with 
biotinylated FGF2 or soya protein (negative CTL) for 1h at 4°C. Then cells were incubated with 
Avidin conjugated FITC or PBS for 30 minutes at 4°C. Cells were washed two times and 
resuspended in wash buffer before analysis with FACS Canto II recording 10 000 events with 
excitation at 405nm and emission at 450nm. FGF2 binding to the cells resulted in an increase in 
the Mean Fluorescence Intensity. All peptides and peptoids treatment did not successfully inhibit 
FGF2 binding. N≥3. 
 
 
5.4 Discussion 
Peptides based therapies are very attractive. Compared to larger molecules, they are less 
immunogenic, often more active, quicker to generate and cheaper. However, it does have 
challenges. Their degradation and clearance can be fast (sometimes within minutes), they often 
have a poor solubility and therefore often need to be delivered intravenously (Vlieghe et al., 2010). 
However, in cancer research, FGF2 based peptides had already been developed in order to inhibit 
proliferation (Terada et al., 2006; Fan et al., 2015). Peptides binding to HS have been shown to 
inhibit herpes virus entry in vitro (Dogra et al., 2015) and for amyloid deposit in vitro and in vivo 
(Wall et al., 2011; Martin et al., 2013). This highlights the potential of synthesising a peptide with 
high affinity to HS. Additionally, studying peptoids gives a lot of advantages as they are resistant 
to proteases, not immunogenic and have a better cell permeability compared to peptides (Simon et 
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al., 1992; Kwon and Kodadek, 2007; Astle et al., 2008). Their helical structure is an advantage for 
HS binding as the positive charges are displayed in a different manner than linear peptides. 
It was somewhat surprising to observe dissociation constants above 100µM for both synthesised 
peptides. These results are likely to be related to their unfolded structure as a strong relationship 
between spatial arrangement of positive charge and a peptide’s ability to bind HS has been reported 
in the literature (Rullo and Nitz, 2010). A 3-10 helix was expected for the peptides as the sequence 
chosen generates this pattern within FGF2. The unfolded structure could be explained by a lack of 
hydrogen bonding on the peptides. The α-chiral side chain on every third residue of the peptoid 
generates the helical secondary structure and was expected (Ford et al., 2013). In fact, peptoid 
HLB03-50 displayed a helicoidal repartition of the positive charges and had a stronger binding, 
almost ten times higher than the peptide and a higher binding stoichiometry. Peptide binding to 
heparin showed an exothermic reaction while peptoid was endothermic. Furthermore, this study 
did not find a significant difference between MD peptide and WT peptide. The replacement of only 
one positively charged amino acid could explain this. Additionally, it is possible that if both 
peptides were helical, the difference in binding would be increased.  
The body already has some molecules that modulate FGF2 availability and bioactivity. In future 
studies, a peptide sequence based on known proteins that compete or inhibit FGF2 binding should 
be used. For example, thrombospondin 1 was shown to reduce the binding of FGF2 to the 
endothelium (Margosio et al., 2003).  In vitro, the anti-proliferative activity of endostatin has been 
hypothesised to be due to its binding to HS FGF2 binding patterns (Ricard-Blum et al., 2004). The 
pentraxin-related protein PTX3 naturally inhibits FGF2 stimulated angiogenesis and specific 
peptides from the binding pattern of PTX3 were successful at showing similar effects (Leali et al., 
2010). Within the circulation, the plasma protein α2-macroglobulin can bind to FGF2 and diminish 
fetal bovine heart endothelial proliferation in vitro (Asplin et al., 2001). Furthermore, FGF2 
activity can be diminished by Platelet factor 4 which supposedly inhibit FGF2 dimerisation and 
therefore binding to the receptor (Perollet et al., 1998). Platelet derived growth factor abolished 
bovine aorta endothelial cells proliferation and  migration in response to FGF2 (de Marchis et al., 
2002). CXCL13 can display FGF2 from cells and decreased FGF2 induced proliferation of 
HUVEC (Spinetti et al., 2001). This shows that there are other possible peptides that could be more 
effective in competing FGF2 binding.  
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Another strategy to target growth factor binding to HS would be the use of HS mimetics which are 
chemically modified heparin derivatives. These compounds have shown promising results in 
muscle satellite cells where FGF2 activation of ERK signalling was decreased with treatment 
(Ghadiali et al., 2017). Our laboratory has just started a collaboration with the University of 
Liverpool and the first results of HS mimetics treatment with renal epithelial cells HKC8 showed 
a decrease in FGF2 biological activity as seen Figure 5-25. 
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Figure 5-25: HS mimetic on HKC8 proliferation 
HS mimetics were kindly given by Prof. Jeremy Turnbull the University of Liverpool. HKC8 cells 
were seeded in 24 well plate and counted at 24h, 48h and 72h with a haemocytometer. Control cells 
were incubated with 0.5%FBS media supplemented with dilution buffer only. Treated cells were 
incubated with 0.5%FBS media supplemented with FGF2 10ng/mL ± HS mimetic 1µg/mL. A 
positive control with 5%FBS media was used to assess maximum growth rate. These data were 
generated by MRes student Hanna Lane supervised by Laura Ferreras. 
 
HKC8 growth was increased with FGF2 treatment and the addition of HS mimetic reduced the 
growth to basal level as seen with starvation media only. HS mimetics can be specifically 
desulfated. The one used in Figure 5-25 is specifically 6-O-desulfated but does have N and 2-O-
sulfation, the latter being important for HS binding to FGF2. Therefore, it could be hypothesised 
that this HS mimetic binds to FGF2 but does not allow the growth factor to bind its receptor due to 
the lack of 6-O-sulfation and therefore inhibit its biological activity. The use of HS mimetic is very 
promising and will further be explored in our laboratory. 
HS binding peptides and peptoids 
 
163 
In conclusion, results presented in this chapter showed that positive charge organisation on a 
molecule can affect HS binding, with a helicoidal molecule having a stronger affinity. Additionally, 
peptide and peptoids synthesised did not significantly change FGF2 binding to renal epithelial cells. 
The use of peptoids at high concentration was found to be toxic for the cells and therefore could 
not be developed further. New peptide sequences inspired by competitive protein for FGF2 binding 
should be further explored together with HS mimetics. 
 General discussion 
 
164 
 General discussion 
 
Heparan Sulfate plays a central role in development, homeostasis and disease progression as it is 
present on the cells membrane and ECM. HS sulfation is essential for HS function. The sulfated 
patterns regulate HS interaction with proteins including cytokines and growth factors, hence, 
modulating cell signalling and behaviour. To date, there is very little literature about HS and renal 
diseases even though some HS modifying enzymes are overexpressed during fibrosis and therefore 
promising biomarkers (Einecke et al., 2010; Tátrai et al., 2010; Yue et al., 2013; Lu et al., 2014; 
DePianto et al., 2015). Renal fibrosis is incurable, and every avenue should be explored to 
understand and develop new therapeutics. This project had the ambition to analyse the modulation 
of HS during fibrosis, understand the biological significance of it and finally to develop potential 
inhibitors of HS growth factors binding. 
 
6.1 Findings arising from this study 
6.1.1 HS modulation in vivo: results and implications 
The first aim of this work was to determine if HS sulfation and HS modifying enzymes changed 
during the development of renal fibrosis. 
In chapter 3, HS sulfation was analysed in an in vivo model of renal fibrosis. GAGs sequencing 
showed an increase in HS N- and 2-O-sulfation together with a decrease in 6-O-sulfation at D5 and 
D10 of unilateral ureteral obstruction (UUO). Total HS 3-O-sulfation staining was decreased at D5 
and D10 UUO. Specific staining of HS3ST1 generating HS 3-O-sulfation showed similar results. 
These results showed that renal fibrosis progression triggered HS N- and 2-O-sulfation increase 
and HS 3-O and 6-O-sulfation diminution. It can be speculated that this change in cells and matrices 
surfaces modulates growth factors binding. Potentially these alterations are promoting fibrosis. In 
accordance with the present results, previous studies have demonstrated that N-sulfation was 
increased in pulmonary fibrosis (Lu et al., 2014; Westergren-Thorsson et al., 2017) and N-
sulfated/acetylated/sulfated patterns were important in attracting immune cells by modulating 
cytokines presented by the cells (Lortat-Jacob et al., 1995; Spillmann et al., 1998). Hence 
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decreasing N-sulfation can be a promising target for limiting pro fibrotic growth factors activities. 
However, as N-sulfation is often required for other sulfated pattern, the inhibition of HS 2-O-
sulfation might be more specific for targeting renal fibrosis. The somehow surprising decrease in 
HS 6-O-sulfation was conflicting with the increase observed in lung fibrosis (Lu et al., 2014; 
Westergren-Thorsson et al., 2017). However, this result supports evidence from previous 
observations from Tatrai et al. who showed a decrease in 6-O-sulfation with liver fibrosis  (Tátrai 
et al., 2010). The modulation of HS 6-O-sulfation might be organ specific. In fact, HS 2-O-sulfation 
seems more important than 6-O-sulfation in kidneys as HS2ST1 -/- mice but not HS6STs -/- mice 
developed renal agenesis (Bullock et al., 1998; Habuchi et al., 2007; Habuchi and Kimata, 2010). 
Therefore, HS 2-O-sulfation in kidney should be further studied as it has good potential as a marker 
of renal function. Another therapeutic approach would be to increase the amount of HS 3-O-
sulfation. The decrease in HS 3-O-sulfation seen in our model was also observed in liver fibrosis  
(Tátrai et al., 2010). Restoring HS 3-O-sulfation could enhance binding and signalling of potent 
cytoprotective growth factors including HB-EGF. 
Additionally, HS modifying enzymes expression were detected by RT-qPCR. HS2ST1, SULF1 
and HS3ST1 were increased and significantly correlated to collagen deposition. In contrast, 
HS3ST3A was decreased but also significantly correlated to collagen deposition. These results are 
in line with those of previous studies. HS6STs and HS3ST1 were overexpressed in pulmonary 
fibrosis (Lu et al., 2014; DePianto et al., 2015) and heparanase, SULF1, SULF2, HS3ST1 were 
overexpressed in liver fibrosis (Tátrai et al., 2010). 
These findings highlight the potential of HS modifying enzymes as biomarkers. Remarkably, 
HS3ST1 enzymes stands out by having the best correlation in our and other studies (Tátrai et al., 
2010). Additionally, HS3ST1 correlates with glomerular filtration rate and graft survival (Bunnag 
et al., 2009; Einecke et al., 2010; Sagoo et al., 2010).  
There are several explanations for the inconsistency between HS3ST1 increase and HS 3-O-
sulfation decrease. First, the increase in expression can originate from endothelial cells considering 
that blood vessels staining were not decreased with the days of UUO. Second, infiltrating cells 
could have an increased expression of HS3ST1 as interstitial staining was observed at D5 UUO. In 
fact, activated macrophages M2 have high level of HS3ST1 mRNA level (Martinez et al., 2015). 
Another potential explanation could be the lack of HS precursor for HS3ST1 activity. Finally, HS 
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3-O-sulfation was analysed by immunofluorescence and there is a possibility that the sulfation 
pattern is masked by proteins bound to it. Further work is required to confirm these findings and 
hypothesis. 
 
6.1.2 Modulation of Heparan sulfate 3-O-sulfotransferases expression: results and 
implication 
The first aim of chapter 4 was to investigate what modulates HS3STs expression. TGFβ1 is one of 
the most studied pro-fibrotic growth factors. Additionally, research has shown that TGFβ1 
increased SULF1 expression in vitro and in vivo (Properzi et al., 2008; Yue et al., 2008). However, 
the impact of TGFβ1 on HS3STs expression has never been explored before. This study showed 
for the first time that TGFβ1 is involved in regulating HS3STs expression in renal epithelial cells 
and fibroblasts. In renal epithelial cells, while HS3ST1 was generally decreased, HS3ST3B was 
increased with treatment. Furthermore, renal fibroblasts showed the highest decrease in HS3ST1 
expression accompanied with a change in cells morphology.  
IL1β is a cytokine involved in inflammation and tissue repair. Additionally, the combination of 
TGFβ2 and IL1β has pro-fibrotic properties by promoting endothelial to mesenchymal transition 
(Maleszewska et al., 2013). This treatment showed similar results to TGFβ1. HS3ST1 was 
decreased in renal epithelial cells and fibroblasts while HS3ST3B was increased in renal epithelial 
cells.  
Together these results provide important insights into HS3STs regulation by TGFβs and IL1β 
stimulation. Considering the results seen in vivo in chapter 3, it can be suggested that these factors 
are contributing to the decrease in HS 3-O-sulfation observed on the tubules basement membrane 
of UUO samples. However, none of the treatments used increased HS3ST1 expression as seen in 
vivo. This increase could potential come from endothelial cells or macrophages which express high 
levels of HS3ST1 (Martinez et al., 2015). To develop a full picture of HS3ST1 expression in renal 
fibrosis, additional studies will be needed that analyse different cell lines and different growth 
factors. 
The generation of HS3ST1 overexpressing tubular epithelial cells led to the decrease of HS6ST1 
expression. This observation may support the hypothesis of a GAGosome within the cells where 
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HS modifying enzymes interact with each other. It can thus be suggested that the increase in 
HS3ST1 within the Golgi inhibits HS6ST1 expression by a yet to be determined mechanism. The 
decrease in HS6ST1 was mirrored by a decrease in the disulfated disaccharide GlcA-GlcNS6S. 
The same disaccharide was found decreased in vivo. Therefore, these data suggest that the decrease 
in HS 6-O-sulfation and the increase in HS3ST1 expression could be correlated. 
HKC8-HS3ST1 cells binding and signalling of FGF2 was similar to HKC8-CTL. The 3-O-
sulfation does not seem to be involved in FGF2 binding. These data correlate with previous studies 
on HS3ST1 transfected CHO cells which showed no difference in FGF2 binding compared to 
control (Thacker et al., 2016b). However, HKC8-HS3ST1 showed a biphasic response to HB-EGF 
treatment seen by a phosphorylation of STAT3 at 5 minutes and 1 hour. Whether this second 
signalling is from HB-EGF potentially retained in the ECM or a second messenger is to be 
determined. The association of HS3ST1 expression and HB-EGF signalling could explain the 
decrease observed in both HS 3-O-sulfation and HB-EGF staining in vivo. Hence, it could 
conceivably be hypothesised that HB-EGF requires HS 3-O-sulfation to bind to tubular epithelial 
cells. 
HB-EGF has both protective and healing properties. Following intestinal ischemia reperfusion, 
HB-EGF -/- mice are more susceptible to intestinal ischemia reperfusion injuries (El-Assal et al., 
2008) and HB-EGF administration accelerated intestinal recovery after ischemia reperfusion (El-
Assal and Besner, 2005). Furthermore, HB-EGF is important for tubular cells repair (Sakai et al., 
1997) and protective in liver fibrosis (Huang et al., 2012; Takemura et al., 2013). Therefore, the 
modulation of HS 3-O-sulfation and to some extend HB-EGF binding should be further explored 
to potentially create new therapeutics. 
A summary of chapter 3 and chapter 4 findings on HS3STs and HS 3-O-sulfation modulation in 
fibroblasts and epithelial tubular cells/ tubular staining is displayed Figure 6-1. 
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Figure 6-1: Summary of HS 3-O-sulfation modulation by growth factors in vitro and by 
interstitial fibrosis progression in vivo 
 
6.1.3 Synthesis of potential inhibitors of FGF2 binding to heparan sulfate: results and 
implication 
Peptides and peptoids synthesis offer a large range of new compounds and potential drugs. HS, 
FGF2 and FGFR have been crystalised and FGF2 binding to HS extensively studied. The aim of 
section 5 was to assess the binding of peptides and peptoids to heparin and investigate their 
potential binding competition with FGF2 to renal tubular epithelial cells. The peptides were 
designed based on FGF2 binding region with HS. 
The WT peptide with more positive charged displayed a stronger binding than the MD peptide. 
However, peptoids had the best constant binding dissociation compared to peptides. These results 
provide two indications on HS binding to protein. First that positive charge is important for binding 
and second, that their structural organisation has a significant impact on the binding strength. 
Interestingly, FGF2 WT and MD peptides did not significantly decrease FGF2 binding to the cells 
at high concentration. Peptoids at high concentration showed a promising inhibition of binding. 
However, due to the toxicity of the peptoids, they could not be used at high concentration and low 
dose were not as effective. 
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FGF2 peptides have been generated previously and successfully decreased proliferation and 
migration in endothelial cells stimulated with FGF2 in vitro and angiogenesis in vivo (Facchiano 
et al., 2003). However, in this study, the sequence used DPHIKLQLQAE is predicted to be required 
for FGF2 dimerisation. Hence, the authors targeted FGF2 dimerisation and not its interaction with 
HS. The strong binding between HS and FGF2 (Kd= 32nM) could explain the incapacity of the 
compounds to inhibit or displace FGF2 to HS (Ibrahimi et al., 2004).  
The dosage of peptoids is important due to their potential toxicity. However they are very 
promising and are nowadays being developed and used in vivo as antimicrobial agents (Czyzewski 
et al., 2016). 
 
6.2 Limitations and future work 
There are several questions that remain unanswered from the in vivo results. First, the cells 
overexpressing HS3ST1 during fibrosis have not been identified. The isolation of different cell 
types from fibrotic kidneys would provide insights into what cells trigger the change in HS3ST1 
expression. Furthermore, the staining of renal tissue with the labelled AT generated in our 
laboratory should give thought-provoking questions regarding the clinical relevance of what was 
found in vivo. 
The analyses of HS 3-O-sulfation for the in vivo work was only assessed by fluorescence staining 
due to the lack of standard for the HPLC. Fluorescence is a great tool for localising molecule but 
is not the best technique for quantification. Staining techniques have several limitations with 
technical and interpretation bias including fixation technique, peptide retrieval, types and clones of 
antibodies and the observer accuracy (Matos et al., 2010). GAGs composition can be analysed by 
mass spectrometry (Staples and Zaia, 2011), a technique that could have been better. Only few 
groups are capable of doing it and my collaborators could not do it. 
Additionally, only one model of renal interstitial fibrosis was used. An ischemia reperfusion injury 
model could have been used to reinforce the data on the correlation between HS modifying 
enzymes and the development of fibrosis.  
 General discussion 
 
170 
HS modifying enzymes expression was only analysed on a gene level. In the current market, the 
antibodies generated for these enzymes are of poor quality and not very specific. I did try to use an 
antibody for HS3ST1 by using the HKC8-HS3ST1 cells as positive control, but it was unsuccessful.  
Regarding the in vitro work, only two cell types, renal epithelial cells and fibroblasts were used. It 
would have been interesting to use endothelial cells and leukocytes with the different treatments 
used in my study. This could potential specify which cells were responsible for the increase of 
HS3ST1 in the kidney.  Additionally, the cell lines were immortalised cells and primary cells could 
have further validated our in vitro data. 
The two treatments of TGFβ1, TGFβ2 IL1β were used as they were widely used in my laboratory. 
The treatments concentration had been optimised by previous students. However, other growth 
factors and cytokines such as TNFα, LPS could have been used to screen their effect on renal 
epithelial and fibroblast cells. 
The generation of overexpressing cells can influence the cell activity, behaviour and response to 
treatment. However, I tried to avoid any bias by generating mock cells and by using different 
clones. Additionally, the use of HS3ST1-/- mice would have been ideal to study. However, 
considering the time frame of my project it was not feasible. The interaction between HS 3-O-
sulfation and HB-EGF has only been studied by cell signalling. Further studies looking at HB-EGF 
binding to HS should be required to determine the exact sequence essential for binding and 
signalling. 
The use of peptides and peptoids in only one cell type can explain the lack of competition observed. 
FGF2 being important for fibroblast, it would have been interesting to screen the peptides and 
peptoids inhibition on them. However, the NRK-49F cells only became available during the last 
months of my project. 
Initially, the peptoids were used as positive control for ITC but due to their strong binding to 
heparin, were further studied. However, they were only used for FGF2 binding competition assay. 
As they are not specific to FGF2, it would have been interesting to use these compounds in other 
models with different growth factors.  
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6.3 New avenues 
This work highlighted for the first time the significance of several HS modifying enzymes 
correlation to renal fibrosis. The panel of these enzymes should be further studied in human renal 
fibrosis as they could potentially be biomarkers of disease progression. Furthermore, as seen in 
Figure 6-2, the changes in HS modifying enzymes do not seem to be only specific to renal fibrosis 
and a wider study on multiple fibrotic tissues could investigate if HS sulfotransferase and sulfates 
expression have a specific signature during fibrosis. 
In line with the data on HS3ST1 expression, Einecke et al. found that HS3ST1 was overexpressed 
in rejected renal graft (Einecke et al., 2010).Therefore, it would be interesting to see if HS3ST1 is 
correlated with renal allograft pathologies. Furthermore, HS3ST1 is found overexpressed in renal, 
liver and lung fibrosis (Figure 6-2). There is a huge potential in HS3ST1 studies to discover a 
potential biomarker or target for treating fibrosis. 
 
 
Figure 6-2: HS modifying enzymes in fibrosis 
Summary of several research on HS in fibrotic diseases. A “+” means an increase of mRNA level 
in the tissue and a “-“a decrease. (Einecke et al., 2010; Tátrai et al., 2010; Yue et al., 2013; Lu et 
al., 2014; DePianto et al., 2015). 
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To further explore the potential of HS as biomarker, recent studies have measured HS in urine 
samples of patients with septic shock by mass spectrometry. The authors found that HS was 
elevated in patients with sepsis and was correlated with renal dysfunction. Furthermore, the amount 
of HS was predictive of patients mortality (Schmidt et al., 2016). Even though the analysis of HS 
levels and HS sulfation are attractive predictive tools, the use of mass spectrometry is costly. 
Therefore, there is a need to develop further the techniques currently used for GAGs analysis to 
make them easier and cheaper.  
Most studies about HS sulfation in diseases have not studied HS 3-O-sulfation. This is mainly due 
to its rare prevalence and because it is technically difficult to analyse. However, the work presented 
in this thesis emphasises the need to explore the relevance of HS 3-O-sulfation in disease 
progression and the necessity to develop HS 3-O-sulfated standards for HPLC analysis.  
 
In conclusion, this project demonstrated that HS 3-O-sulfotransferases expression is modulated by 
pro-inflammatory and pro-fibrotic growth factors and are correlated with the development of 
fibrosis. These may affect HS pattern on the cell surface and ECM to enhance or diminish the 
binding of growth factors. Furthermore, HS 3-O-sulfation is implicated in HB-EGF signalling in a 
potentially protective mechanism. Finally, the generation of peptides and peptoids to inhibit HS 
binding to growth factors should have specific secondary structure to allow strong binding. The 
use of peptoids is promising but more optimisation on their toxicity vs efficacy dose should be 
performed.  
A better understanding of the role of HS3STs in growth factor signalling and fibrosis will allow 
the development of novel biomarkers and potential therapeutics that could prevent fibrosis and 
organ loss. 
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Abstract 
One of the main feature of chronic kidney disease is the development of renal fibrosis. Heparan 
Sulfate (HS) is involved in disease development by modifying the function of growth factors and 
cytokines and creating chemokine gradients. In this context, we aimed to understand the function 
of HS sulfation in renal fibrosis. Using a mouse model of renal fibrosis, we found that total HS 2-
O-sulfation was increased in damaged kidneys, whilst, tubular staining of HS 3-O-sulfation was 
decreased. The expression of HS modifying enzymes significantly correlated with the development 
of fibrosis with HS3ST1 demonstrating the strongest correlation. The pro-fibrotic factors TGF1 
and TGF2/IL1 significantly downregulated HS3ST1 expression in both renal epithelial cells and 
renal fibroblasts. To determine the implication of HS3ST1 in growth factor binding and signaling, 
we generated an in vitro model of renal epithelial cells overexpressing HS3ST1 (HKC8-HS3ST1). 
Heparin Binding EGF like growth factor (HB-EGF) induced rapid, transient STAT3 
phosphorylation in control HKC8 cells. In contrast, a prolonged response was demonstrated in 
HKC8-HS3ST1 cells. Finally, we showed that both HS 3-O-sulfation and HB-EGF tubular staining 
were decreased with the development of fibrosis. Taken together, these data suggest that HS 3-O-
sulfation is modified in fibrosis and highlight HS3ST1 as an attractive biomarker of fibrosis 
progression with a potential role in HB-EGF signaling. 
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1. Introduction 
Chronic kidney disease (CKD) is a worldwide health problem affecting 8-16% of the world’s 
population [1]. CKD is characterised by glomerulosclerosis and interstitial fibrosis and is caused 
by a wide range of pathologies including metabolic disease, inflammation and vascular damage 
which finally lead to the accumulation of extracellular matrix [2]. There is currently no treatment 
that can reverse renal fibrosis, therefore finding new biomarkers and treatments is one of the major 
challenges in medicine [2,3].  
Heparan Sulfate (HS) is a sulfated polysaccharide with a structure consisting of repeating units of 
uronic acid (UA) linked to a N-acetyl- or N-sulfo-D-glucosamine (GlcNAc, GlcNS), which can 
vary in length and degree of sulfation. HS is an abundant component of extracellular matrices and 
cell surfaces, where it is found covalently bound to the core protein of HS proteoglycans (HSPG) 
[4]. HSPGs regulate the function of growth factors and chemokines by preventing their proteolysis, 
regulating receptor activation and anchoring them to the extracellular matrix and to the cell surface 
[5–7]. Due to its role in leukocyte recruitment and in the binding and modulation of pro-fibrotic 
factors such as TGF [8], HS plays a crucial role in the development of fibrosis [9,10]. 
Furthermore, HS has been associated with renal tissue remodelling as expression of HSPGs 
including Collagen XVIII and perlecan is increased in interstitial fibrosis of kidney isografts and 
allografts in rats [11]. In addition, we have previously shown increased HS sulfation on the tubular 
epithelial cell membranes and in the interstitium of kidneys in patients with chronic rejection [12].  
HS can be sulfated at the N, 2-O, 3-O and 6-O position. These modifications are key to its function, 
as the negative charge provided by the sulfation modulates HS binding to proteins. HS sulfation in 
the glomerular basement membrane (GBM) has been extensively studied but the role of HS in the 
glomerular filtration is still not fully understood [13,14]. However, it is evident that there is a 
fundamental change in HS composition in pathological conditions [14,15]. In diabetic patients, 
disaccharide analysis of the glomerular basement membrane revealed a decrease in 3-O-sulfation 
[16]. Biopsies from patients with glomerulopathies such as lupus nephritis, membranous 
glomerulonephritis, minimal change disease and diabetic nephropathy showed a decrease in HS by 
indirect immunofluorescence staining [15]. In contrast, patients with proliferative lupus nephritis 
had a significant increase of N- and 2-O-sulfated HS in their glomeruli [17]. 
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Several enzymes are responsible for the biosynthesis and sulfation of HS. The exostosin (EXT) 
enzymes EXT1 and EXT2 are involved in HS polymerisation [18], while the sulfotransferases add 
sulfate groups to the carbohydrate backbone. There are four isoforms of N-deacetylase/N-
sulfotransferase (NDST), one 2-O-sulfotransferase (HS2ST), seven isoforms of 3-O 
sulfotransferase (HS3ST) and three isoforms of 6-O sulfotransferase (HS6ST) [19–21].  
Additionally, HS can be 6-O-desulfated by two endogenous sulfatases (SULF) [22]. Changes in 
the expression of enzymes involved in HS biosynthesis are associated with the development of 
renal dysfunction [23]. Podocyte specific NDST1 knockout led to the development of glomerular 
hypertrophy together with an increase in mesangial area at 6 months [24]. Additionally, podocyte 
specific EXT1 knockout mice showed hypertrophic glomeruli and a decrease in highly sulfated HS 
on the glomerular capillary endothelium [25]. Furthermore, heparanase, an enzyme that cleaves 
HS from HSPG and releases biologically active oligosaccharide fragments, is also important in the 
development of renal diseases [26,27]. Heparanase expression is increased in rats with Adriamycin 
nephropathy [28] and in patients with overt diabetic nephropathy [29]. Heparanase KO mice were 
protected against the development of diabetic nephropathy [30]. 
Although HS 3-O sulfation composition and localisation in the kidney have been previously studied  
[31,32], very little is known about its biological role and possible effects on growth factor function 
[33]. HS3STs are known to generate the binding motif for antithrombin III and HS herpes simplex 
virus 1 gD protein, but their activity and substrate specificity are still being studied [34]. These 
enzymes are not homogeneously expressed in the body and there is increasing evidence that their 
expression changes during the development of disease. HS3ST2 and HS3ST4 are mainly expressed 
in the brain [35,36] and there has been interest in HS3ST2 in tauopathies, with its expression 
increasing in the hippocampus of patients with Alzheimer’s disease [37]. HS3ST3 and HS3ST1 
are more widely expressed with HS3ST1 mostly expressed in the brain, heart, lung, spleen, 
stomach, small intestine, colon, testis and the kidney [35,36]. HS3ST1 expression is regulated by 
a number of factors, with LPS and TNF reducing its expression in human microvascular 
endothelial cells [38],  whereas expression is increased by IL-4 and IL-13 treatment of intestinal 
epithelial cells [39] and FGF10 treatment of salivary gland epithelia [40]. Reports describing the 
expression of HS3ST1 during renal transplantation show that it is overexpressed in tolerant patients 
[41] and in failing grafts [42]. While the first study examined blood samples, the latter analysed 
tissue expression, which may explain the discrepant findings. These studies did not investigate the 
mechanism underlying the changes in HS3ST1 expression.   
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In this study, we have investigated changes in HS sulfation during the development of renal 
interstitial fibrosis in vivo and determined whether these changes were mirrored by the expression 
of HS modifying enzymes. Furthermore, we identified factors that modulate the expression of 
HS3ST1 in renal cells in vitro. Finally, we analysed the implications of the changes in HS3ST1 
expression on HB-EGF signalling, a growth factor known to stimulate tubular epithelial cells repair 
[43], cell motility [44] and is expressed in renal transplants [45,46]. 
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2. Materials and Methods 
2.1. Animal work 
All experiments were carried out under UK Home Office regulations (PPL60/4521) at the 
Comparative Biology Centre (CBC) in Newcastle University. C57BL/6 mice aged 8-10 weeks 
were subjected to Unilateral Ureteral Obstruction (UUO). The non-ligated kidney was used as 
control. Mice kidneys were harvested at 5 and 10 days post-UUO with 6 animals per group. Each 
kidney collected was dissected for paraffin embedded sections, frozen sections, RNA extraction 
and HS disaccharide analysis. 
2.2. Cells culture and treatments 
All media were supplemented with 2 mM L-Glutamine, 100 U/mL Penicillin, 100 μg/mL 
Streptomycin (Sigma). The immortalised renal tubular epithelial cell line HK2 (ATCC) was grown 
in Dulbecco’s Modified Eagle Medium (DMEM, Sigma, D5671) supplemented with 10% heat 
inactivated Fetal Bovine Serum (FBS). The second cell line of immortalised renal epithelial cells 
studied was HKC8 [47]. They were cultured in DMEM-F12 (Sigma, D6421) supplemented with 
5% FBS. NKR-49F were cultured in DMEM supplemented with 5% FBS. All cells were grown in 
a humidified incubator with 5% CO2 at 37°C. 
Cell were seeded in complete media until 80% confluent then in starving medium supplemented 
with 0.5% FBS for 16-24 hours. For Western Blot studies, cells were treated with 10 ng/mL HB-
EGF (Sigma E4643).  For HS3ST1 expression study, all recombinant human cytokines were 
purchased from PeproTech and were active in both human and rats. Cells were treated with either 
5 ng/mL TGFβ1 (100-21C), 10 ng/mL TGFβ2 (100-35B) + 10 ng/mL IL1β (200-01B). 
Human kidney primary proximal tubular epithelial cells (primary PTECs) were isolated from 
macroscopically normal parts of nephrectomy specimens removed for oncological indications 
(ethical approval 13/EM/0311). The resected kidney tissue was collected in sterile RPMI 1640 
media (Sigma-Aldrich) supplemented with 5% FBS and Penicillin (100U/mL) / Streptomycin (100 
µg/ml), and was immediately transferred to 4°C for subsequent cell isolation procedure. Primary 
PTECs were isolated using Percoll gradient centrifugation protocol as previously reported [48]. 
Briefly, samples were enzymatically digested with collagenase, mechanically sieved and 
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centrifuged with two discontinuous Percoll gradients (1.04 gram/mL and 1.07 gram/mL). This 
method yielded 1.5 to 2 million cells/gram wet weight of tissue specimen. Primary PTECs were 
maintained in DMEM/HAM F-12 media (Lonza) supplemented with insulin, hydrocortisone, GA-
1000, adrenaline, T3, transferrin, foetal bovine serum, and human epithelial growth factor. 
Preliminary experiments to characterise the isolated cells showed positive staining of epithelial cell 
markers, such as ZO-1, E-cadherin, K-cadherin and Cytokeratin. The isolated cells did not express 
mesenchymal markers, such as -SMA, Vimentin or Collagen type-1. Under light microscope, the 
cells were hexagonal in shape, and showed “cobblestone-like” appearance with the occasional 
presence of hemicysts or “dome” formation when grown to form a confluent monolayer. Moreover, 
scanning electron microscope images of the isolated cells revealed the presence of brush borders, 
which is a typical feature of kidney tubular epithelial cells. These epithelial characteristics were 
evident up to the first three passages. Only cells in passage two were used in our experiments. 
2.3. RNAs extraction and quantitative RT-PCR 
In this study, two methods of RNA extraction were used. A column-based method using the Qiagen 
RNeasy Plus Mini Kit for cells following manufacturer’s instructions and a Trizol/Chloroform 
method for mouse tissue. Briefly, mouse kidney tissue was homogenised in TRI reagent (Ambion) 
using the Tissue Lyser II by Qiagen. RNA was isolated separated from the protein by adding 
chloroform (AnalaR) and mixed by inversion. Samples were centrifuged, and the aqueous phase 
mixed with isopropanol. The RNAs pellet was suspended in 1mL of 70% ethanol and air dried 
before being suspended in 30μL of RNAse free water (Ambion). To avoid gDNA contamination 1 
μg of sample was treated with RQ1 DNAse (Promega) for 30 minutes at 37°C. Next, samples were 
treated with DNase stop solution (Promega) 10 minutes 65°C. Complementary DNA (cDNA) was 
generated using Tetro cDNA synthesis kit (Bioline, BIO-65043) following the manufacturer’s 
instruction. TaqMan probes (Thermofisher) were used to amplify cDNA (see supplementary data, 
table 1). HPRT was used as housekeeping gene to normalize CT values. Samples were analysed 
using the comparative ΔΔCT method. 
2.4. HS disaccharide analysis from cells 
Subconfluent HKC8 cells were cultured with 200 µCi/ml Na235SO4 (Perkin Elmer) for 24 hrs at 
37°C. After incubation, the culture medium was removed and frozen at –20 °C for further use. The 
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cell layer was washed twice with cold PBS and solubilized at 4°C for 60 min in 1% Triton TX-
100, 50 mM Tris/HCl pH (7.4), 0,15 M NaCl and proteinase inhibitors. After centrifugation, the 
supernatant was collected and an aliquot (100µl) was removed for protein determination using the 
BCA protein determination kit (Pierce). The remaining supernatant was used for purification of the 
35S-labeled polysaccharides. Polysaccharide chains were released from the core protein by 
treatment with 0.5 M NaOH over night at 4°C. After completed ß-elimination, the samples were 
neutralized with 4 M HCl. Samples were adjusted to 0.15 M NaCl and applied to a 0.5 ml DEAE-
Sephacel column equilibrated in 0.15 M NaCl, 0.05 M Tris-HCl pH 7.4, 0.1% Triton X-100. The 
column was washed with the equilibration buffer, followed by 0.15 M NaCl, 0.05 M acetate buffer 
pH 4.0, 0.1% Triton X-100 and 0.05 M Tris/HCl pH 7.5. Finally, the labeled GAG chains were 
eluted with 1.5 M NaCl and desalted by gel chromatography using PD-10 columns (Sephadex G-
25, Amersham Biosciences) in H2O.  Purified 35S-labeled HS chains were cleaved at N-sulfated 
GlcN residues by deamination with nitrous acid at pH 1.5 followed by reduction with NaBH4. 
Labeled deamination products were fractionated by gel chromatography on Sephadex G-15 (1 cm 
x 180 cm) in 0.2 M NH4HCO3. Fractions corresponding to oligo- and disaccharides were collected 
and desalted by lyophilization. HS disaccharides analysis was performed with HPLC using a 
Whatman Partisil 10-SAX column eluted with aqueous KH2PO4 of stepwise increasing 
concentration at a rate of 1 ml/min. 
2.5. HS disaccharide analysis from renal samples 
Pooled frozen kidney tissue were collected to generate four groups (D5 Control, D5 UUO, D10 
Control, D10 UUO) with each group containing between 35 to 62 mg of frozen tissue. Samples 
were lysed, digested, purified and analysed as previously described [49]. Briefly, all samples were 
mechanically lysed in 50 mM Tris Buffered Saline, 2 mM EDTA, 6 M Urea and dialysed against 
25 mM Tris, 5 mM EDTA pH 7.8. Following protein degradation in 2 mg/ml of pronase 24h at 
37°C and two treatments with 5% v/v trichloroacetic acid, supernatants were washed with 50% v/v 
diethylether and run onto a DEAE-Sephacel column equilibrated in 20 mM phosphate pH 6.5. 
Samples were eluted in 20 mM phosphate, 1 M NaCl pH 6.5 and desalted with a PD-10 column. 
Finally, GAG chains were digested with 10 mU of heparinase I (Grampian enzymes) overnight at 
30°C, then with 10 mU heparinase II and 10 mU heparinase III (Grampian enzymes) for 24h at 
37°C. Disaccharides analysis was performed by reverse-phase ion-pair high-performance liquid 
chromatograph [49] in triplicate. 
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2.6. Stable transfectants 
Plasmid EX-TO223-M13 containing flag tagged HS3ST1 enzyme sequence was purchased from 
GeneCopoeia. Bacterial transformation of E.coli DH5α (Invitrogen) was performed using the heat 
shock method. Bacterial cells lysis and plasmid purification were performed using Plasmid Mini 
Kits (Qiagen). To generate an empty plasmid (plasmid without HS3ST1 sequence), 3 μg of plasmid 
were digested with 30U of BsrGI (Bsp 1407I, ThermoFisher). The digested plasmid was extracted 
using QIAquick Gel Extraction Kit Plasmid extraction. The final plasmid was ligated 3h at room 
temperature using T4 DNA ligase.  
Cells transfections were performed using Effectene Reagent (Qiagen) in combination with an 
enhancer and a DNA-condensation buffer. The following day, fresh media containing 200 µg/mL 
of selective antibiotic G418 was added to the transfected cells. Colonies were isolated using cloning 
cylinders.  
2.7. Western Blotting 
Cellular proteins were extracted using CelLytic M (Sigma) complemented with protease (Complete 
Mini Protease Inhibitor Cocktail, Roche) and phosphatase (Roche) inhibitors. Between 10 to 50 μg 
of protein extract samples were denaturated and electrophoretically separated by Sodium Dodecyl 
Sulfate (SDS) Polyacrylamide gel electrophoresis, then transferred by semi dry transfer (BioRad) 
to nitrocellulose membranes (BioRad). Membranes were blocked for 1h at room temperature in 
0.1% Tween Tris-buffered saline (TBS) with 5% fat free milk or 5% Bovine Serum Albumin (BSA) 
when looking at phosphorylated proteins and probed overnight at 4°C using the following primary 
antibodies diluted in blocking buffer (STAT3 Y705 ab76315 Abcam 1:20 000, alpha tubulin T6074 
Sigma 1:4000). Following overnight incubation, membranes were washed in TBS 0.1% Tween and 
incubated with the corresponding secondary antibodies conjugated with HorseRadish Peroxidase 
(R&D 1:1000), for 1 hour at room temperature. Finally, membranes were washed again, and bands 
were visualized by enhanced chemiluminescence and exposed to X-ray films.      
2.8. Staining 
Cells were fixed in ice-cold methanol for 5 minutes at -20°C, gradually rehydrated with PBS, 
blocked with 5% BSA in PBS for 2 hours at room temperature and incubated overnight with 
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primary antibodies (Flag Tag 2368 Cell Signalling 1:3000, GM130 Abcam 1:70). Slides were 
washed with PBS, then incubated for 2h at room temperature with the corresponding secondary 
antibody (anti-mouse Alexa fluor 488 ThermoFisher 1:100, anti-rabbit Dylight550, 
Immunoreagents 1:100). Finally, slides were washed in PBS and mounted with liquid mounting 
medium containing DAPI (Vectashield). 
The use of fluorescently labeled Antithrombin III (AT) for detecting HS 3-O-sufation has been 
previously described [31]. Fluorescently labeled AT with Alexa fluor 647 was generated following 
manufacturer’s instructions (ThermoFisher Scientific, A20173). Staining specificity was assessed 
with heparin competition. Cryosections of 7 m thickness were fixed in acetone and blocked with 
1% BSA in PBS for 20 minutes at room temperature. Slides were incubated for 1 hour with labeled 
antithrombin III and washed three times with blocking buffer. Slides were mounted using Diamond 
antifade with Dapi. 
Mouse kidneys were dissected and fixed in 10% formalin solution and embedded in paraffin. Serial 
tissue sections of 4 µm thickness were cut and mounted onto slides. Peptide retrieval was performed 
by microwaving the slides in EDTA buffer. Sections were blocked 10 minutes with 2% FBS in 
PBS and incubated overnight at 4°C with primary antibody (HB-EGF ab192545 Abcam 1:200, 
HS4C3 1:5 given by Toin van Kuppevelt, Radboud University, Netherlands). The next day, 
sections were washed in PBS, then incubated with secondary antibody (anti VSV C7706 sigma, 
Dylight 550 Immunoreagent) diluted in PBS for 1-2 hours at room temperature. Sections were then 
washed in PBS, incubated with Sudan Black for 20 minutes in the dark at room temperature and 
finally washed in PBS before mounting with VECTA shield DAPI liquid mounting medium.  
Sirius red and Haematoxylin Eosin staining were performed following standard procedures. 
All images were analysed using Fiji software.  Fluorescent imaging was performed using Leica 
LCM microscope, Zeiss Axioimager, Nicon A1R confocal microscope.  For Sirius red 
quantification, images were analysed using LeicaQWin analysis software with 10 cortex fields 
analysed per section for each kidney. 
2.9. Software 
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Graphs were created using Microsoft Excel and GraphPad Prism 6.0. Diagrams were generated 
using Servier Medical Art images (http://servier.com/Powerpoint-image-bank).  
2.10. Statistical Analysis 
Results are expressed as mean ± Standard Deviation. Statistical evaluations were performed using 
GraphPad Prism 6.0. Significant results were considered when P<0.05 (*), P<0.01 (**) and 
P<0.001 (***). P values were calculated using two tailed unpaired student’s t-test with Welch’s 
correction. 
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3. Results 
3.1. Unilateral Ureteral Obstruction induces interstitial fibrosis and modulates HS sulfation 
To assess the structural changes and fibrosis development in the UUO model, kidney sections were 
stained with H&E and Sirius red. Sections from day 5 (D5) and 10 (D10) showed tubular dilatation 
and tubulointerstitial expansion (figure 1A). Additionally, there was a significant increase in 
interstitial fibrosis as assessed by Sirius red staining when compared with control kidneys at D5 
and D10 UUO (p<0.05 and p<0.001 respectively) (figure 1B-C). To further address the relevance 
of the UUO model for HS studies, HS sulfation was evaluated. As shown in figure 1D total HS O-
sulfation, measured by reverse-phase ion-pair HPLC, increased in UUO by 13.7% at D5 and 6.5% 
at D10. Assessment of the pattern of HS sulfation showed an increase of total 2-O-sulfation by 
45.3% at D5 and 19.2% at D10 (figure 1E). HS disaccharide composition (supplementary data, 
figure 1) revealed an increase of the disulfated disaccharides ΔUA.2S-GlcNS but a decrease in the 
monosulfated disaccharides ΔUA-GlcNAc.6S and in the disulfated disaccharides ΔUA-GlcNS.6S 
at D5 and D10 UUO. Overall, these results show that UUO-induced renal fibrosis results in changes 
in HS disaccharide sulfation patterns which could potentially translate in altered protein binding.  
3.2. HS sulfotransferases and sulfatases mRNA expressions are altered in UUO 
In order to investigate whether the increase in HS sulfation was mirrored by a change in the levels 
of HS sulfotransferases and sulfatases, their expression levels in control and UUO kidneys was 
analysed by real time qPCR. RNA expression analysis was chosen over protein analysis as 
endogenous protein levels can be difficult to measure with the antibodies currently available [50]. 
The increase of HS 2-O-sulfation was reflected by a significant increase of HS2ST1 expression at 
D10 of UUO (p<0.01) (figure 2A). Additionally, there was an increase of SULF1 at D5 (p<0.05) 
(figure 2B). The level of HS3ST3A expression shown in figure 2C decreased at D5 and D10 but 
only significantly at D5 (p<0.05). There was a significant increase in expression of HS3ST1 at both 
D5 and D10 UUO (figure 2D) (p<0.001). Furthermore, HS3ST1 expression correlated significantly 
with the degree of fibrosis assessed by Sirius red staining, Pearson correlation coefficient r=0.7881 
with p<0.001 (figure 2E). The other enzymes, HS2ST1, HS3ST3A and SULF1 also showed a 
correlation with Sirius red staining (supplementary data, figure 2). Taken together, these results 
suggest that there is an association between the level of fibrosis and the expression of HS modifying 
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enzymes. Because of the highest correlation between HS3ST1 and fibrosis, we then explored the 
functional implication of this change. 
 
Figure 1. The development of interstitial fibrosis at D5 and D10 of UUO is accompanied by a 
change in HS sulfation. Representative images of Haematoxylin and Eosin staining (A) and Sirius 
red staining (B) of cortex from control unobstructed kidney, D5 UUO and D10 UUO. Scale bars 
represent 100 µm. Interstitial fibrosis was assessed by Sirius red staining (C). N=6 with 10 cortex 
fields analysed per section for each kidney, two-tailed unpaired t test, p<0.05 (*), p<0.001 (***). 
HS sulfation of 6 pooled control unobstructed kidney, D5 UUO and D10 UUO is represented as 
percentage of total disaccharides with error bars from technical replicates. Total O-sulfation (D) 
and total 2-O-sulfation (E). Results are represented as mean ±SD. 
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Figure 2. HS sulfotransferases are modulated at D5 and D10 UUO. Expression was adjusted to 
HPRT1 expression and normalised to the mean of controls (MC) N=6. Two-tailed unpaired t test 
with Welch’s correction with p<0.05 (*), p<0.01 (**) p<0.001 (***). The Pearson’s correlation 
coefficient was generated with the data from HS3ST1 expression and results from Sirius red 
staining. 
3.3. Localisation of antithrombin binding HS within control and fibrotic kidneys 
The purpose of analysing antithrombin III binding to the kidney was to localise HS 3-O-sulfation 
specifically resulting from HS3ST1 and HS3ST5 activity. As HS3ST5 is expressed at very low 
levels in the kidney, AT binding can be used as a surrogate marker of HS3ST1 activity. AT binding 
was seen in the luminal surface of blood vessels, on tubules, around Bowman’s capsule and at the 
vascular pole of the glomerulus (figure 3). In D5 UUO kidney AT binding was not changed in 
blood vessels and could be observed within the expanded tubulointerstitium (figure 3D). The 
overall tubular staining decreased. The specificity of AT binding was assessed by competition with 
soluble heparin, which blocked AT binding to tissue sections (supplementary data, figure 3). The 
reduced tubular binding of AT, and by implication reduced 3-O sulfated HS, is despite the 
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increased expression of HS3ST1 seen in UUO kidneys. The increase of HS3ST1 expression might 
originate from other cells within the kidney including endothelial that produce AT binding HS [51] 
or M2 macrophages that express high levels of HS3ST1 [52,53] and are prominent in the UUO 
model [54]. However, the decrease in HS 3-O-sulfation observed in the tubular compartment was 
unexpected and further studied. 
 
Figure 3. HSPG staining in control and fibrotic renal sections. Representative images of 
antithrombin III (AT) staining on cryosections from control kidney (A, C) and D5 UUO (B, D). 
AT was labelled with Alexa fluor 647. AT binding was detectable around Bowman’s capsule (⤏), 
on blood vessels (❍), on the tubular basement membrane (➝), at the vascular pole of the 
glomerulus (△) and in the expanded interstitium at D5 UUO (✩). N=6 with at least 5 cortex fields 
analysed per section for each kidney. Scale bars represent 100 and 50 µm. 
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3.4. Modulation of HS3ST1 expression by TGF1, TGF2/IL1 in renal epithelial cells and 
renal fibroblasts 
To better understand the role of HS3ST1 in the development of fibrosis, we studied factors 
influencing HS3ST1 expression in the kidney. Primary human tubular epithelial cells screened for 
expression of HS3ST-family members by real time qPCR showed that HS3ST1 was the 
predominant enzyme, followed by HS3ST3A. HS3ST6 and HS3ST3B were expressed at low levels 
(figure 4A). To understand what modulates HS3ST1 expression in renal tubular epithelial cells, 
HK2 cells were treated with 5ng/mL TGF1. HS3ST1 expression was downregulated after 6 hours 
(p<0.05) and 48 hours (p<0.05) of treatment. HK2 cells treated with a  pro-fibrotic combination of 
TGF2 (10 ng/mL) and IL1 (10 ng/mL) [55], also showed significant downregulation of HS3ST1 
after 6 hours (p<0.05) and 24 hours (p<0.01) of treatment. This downregulation in the expression 
of HS3ST1 in tubular cells in response to pro-fibrotic stimuli is consistent with the reduced AT 
binding evident within the tubular compartment during the development of fibrotic disease. The 
down regulation of HS3ST1 expression was more pronounced in the renal fibroblast cell line NRK-
49F (figure 5), with a significant decrease at 6 hours and 24 hours with both TGF1 and combined 
TGF2/IL1 (p<0.05 and p<0.01 respectively).  In view of the reduction in tubular H3ST1 
expression and the reduction in 3-O sulfation that is likely to result from this change, we next 
explored the function of 3-O sulfated HS in tubular cells. 
 
Figure 4. HS3ST1 expression in primary tubular epithelial cells isolated from human kidneys and 
immortalised renal epithelial cells HK2. Primary tubular epithelial cells were isolated from 
macroscopically healthy parts of the kidney N≥2. Results are displayed as log 2 of HS3ST1 fold 
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change normalised to HPRT1 (A). HK2 cells were incubated 24h in 0.5% FBS and treated for 3, 6 
24 and 48 hours with 5 ng/mL TGFβ1 (B) and 10 ng/mL TGFβ2 IL1β (C) or maintained in media 
alone (CTL). Results are expressed by mean ±SD N=3 and were normalised to the mean of controls 
(MC). Two-tailed unpaired t test with Welch’s correction with p<0.05 (*), p<0.01 (**). 
 
Figure 5. HS3ST1 expression is decreased in immortalised rat fibroblast NRK-49F cells following 
profibrotic treatments. Cells were incubated 24 hours in 0.5% FBS and treated for 3, 6 and 24 hours 
with 5 ng/mL TGFβ1 (A) and 10 ng/mL TGFβ2 IL1β (B) or maintained in media alone (CTL). 
Results are expressed by mean ±SD N=3 and were normalised to the mean of controls (MC). Two-
tailed unpaired t test with Welch’s correction with p<0.05 (*), p<0.01 (**). 
3.5. Identification of HB-EGF as a potential growth factor modulated by HS 3-O-sulfation 
The renal epithelial cell line HKC8 was stably transfected with either an empty plasmid (HKC8-
CTL) or with a plasmid containing the HS3ST1 sequence (HKC8-HS3ST1). HKC8-CTL and 
HKC8-HS3ST1 were screened for protein expression and localisation by immunofluorescence 
(figure 6A). HS3ST1-flag co-localised with the cis Golgi and around the nucleus. To address the 
functionality of the HS3ST1 present in the HKC8-HS3ST1 cells, HS disaccharide analysis was 
performed after metabolic labeling of HKC8-CTL and HKC8-HS3ST1 (figure 6B). There was no 
detectable HS 3-O-sulfation in the HKC8-CTL but 3.7% (figure 6B) and 1.6% (supplementary 
data, figure 4) HS 3-O-sulfation in two clones of HKC8-HS3ST1. HB-EGF is known to bind to 
HSPG and can signal through STAT3. The signalling pattern was studied by assessing the 
phosphorylation of STAT3 (Y705). HB-EGF induced phosphorylation of STAT3 after 5 minutes 
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of stimulation, which then diminished by 1 hour in HKC8-CTL. However, HKC8-HS3ST1 showed 
a strong signal at 5 minutes, with continued phosphorylation at 1 hour in two clones (figure 6C). 
Taken together, these data show that the overexpression of HS3ST1 can affect HB-EGF signalling. 
The relevance of this finding in vivo was further studied using the UUO model.  
 
Figure 6. HS3ST1 overexpressing cells have more HS 3-O-sulfation and a different HB-EGF 
signalling. In stably transfected HKC8 cells, HS3ST1 expression was assessed by 
immunofluorescence (A) HS3ST1-FLAG is shown in red and GM130, a cis Golgi membrane 
marker, in green. Scale bar represents 50 µm. HS disaccharide analysis (B) showed no 3-O-
sulfation in the mock (HKC8-CTL) and a small amount in the transfected cells HKC8-HS3ST1 (
➔). HB-EGF signalling via P-STAT3 was analysed at 5 minutes and 1 hour in transfected cells 
HKC8-CTL and HKC8-HS3ST1 at 5 minutes and 1 hour, N=3 (C). 
3.6. Total HS 3-O-sulfation and HB-EGF staining in renal fibrosis 
HB-EGF staining was predominantly found on the basement membranes of tubules. The staining 
was not uniform, with some cortical tubules, most likely proximal tubules, staining more strongly 
than others (figure 7). A similar staining was observed at D5 and D10 UUO, but with a noticeable 
decrease in intensity (figure 7). Total HS 3-O-sulfation was analysed using the phage display 
antibody HS4C3, which recognises highly sulfated HS when 3-O-sulfation is present. The staining 
was similar to the AT staining but with a more intense staining in the glomerulus. Furthermore, 
and in agreement with the results from the AT staining (figure 3), the staining for HS 3-O-sulfation 
decreased during the development of fibrosis. In conclusion, both HB-EGF and HS 3-O-sulfation 
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are present on the tubular basement membrane and both are decreased during the development of 
fibrosis. 
 
Figure 7. Staining of HB-EGF and total HS 3-O-sulfation. Representative images of HB-EGF and 
HS4C3 staining on paraffin embedded sections of control tissues, D5 UUO and D10 UUO. HB-
EGF staining was mainly present on the tubular basement membrane. The HS4C3 antibody, which 
stains heavily sulfated HS, showed glomerular, vascular and tubular staining. N=6 with 10 cortex 
fields analysed per section for each kidney. Scale bars represent 100 µm. 
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4. Discussion 
We hypothesise that, changes in HS O-sulfation in diseased kidneys alters growth factor binding 
and activity, potentially promoting either repair or fibrosis. We have shown here that there are 
changes in the pattern of HS sulfation during the development of renal fibrosis. Total HS O-
sulfation was increased mainly due to an increase in 2-O-sulfation. Our results are consistent with 
the increase of HS 2-O-sulfation observed in tissue from patients with idiopathic pulmonary 
fibrosis [56] in which its role during tissue remodelling was proposed. 2-O-sulfation is known to 
be important for binding multiple growth factors for example members of the FGF family [57,58]. 
Due to the lack of HS 3-O-sulfation standards for the tissue disaccharides analysis, we could not 
analyse 3-O-sulfation during the evolution of UUO.  Altered HS expression may be an attempt to 
increase growth factor activity and promote repair. However, in the context of persistent or repeated 
injury, the outcome may be fibrosis and loss of function. 
The increase in HS 2-O-sulfation was mirrored by an increase in HS2ST1 expression. Surprisingly 
the HS sulfatase SULF1, that removes 6-O-sulfate groups, was also increased in UUO tissue. The 
increase in SULF1 expression can be explained by the presence of TGF1 in fibrotic tissue, a 
growth factor known to induce SULF1 expression [59]. Furthermore, HS3ST3A expression was 
decreased in renal fibrosis while HS3ST1 expression was increased and showed a strong 
correlation with the amount of fibrosis. SULF1 and HS3ST1 expression were previously found to 
be increased in fibrotic liver and in patients with hepatocellular carcinoma [60]. Taken together, 
these data highlight the potential of HS enzymes as markers of disease development.  
Recently, there has been an increased interest in the function of HS 3-O-sulfation. In mouse 
embryos, HS 3-O-sulfation supported stem cell differentiation [61]. In the brain, HS3STs were 
found to regulate axonal growth cone collapse in mice [62] and neuronal development in 
Caenorhabditis elegans [63]. Furthermore, HS3STs have been extensively studied in cancer [64–
66]. The impact of the increase of HS3ST1 expression was analysed with staining for 3-O-sulfation. 
There was an overall decrease in HS 3-O-sulfation in UUO tissue, particularly in the tubular 
compartment. There are several potential explanations for this decrease. First, the decrease in 3-O-
sulfation might be explained by the presence of highly 2-O sulfated disaccharides that prevent 
HS3ST1 action and therefore by a low level of suitable HS precursor disaccharides as has been 
described in glomerular epithelial cells [31]. The increase of HS3ST1 mRNA might be an 
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unsuccessful attempt to increase the level of HS 3-O-sulfation. Second, HS 3-O-sulfation was only 
analysed by immunofluorescence and potentially the 3-O-sulfation was masked by growth factors 
bound to it. Lastly, an increase in HS3ST1 expression may occur in endothelial or infiltrating 
immune cells such as macrophages, masking a reduction in tubular cell HS3ST1 expression. 
HS3ST1 expression could be increased in some cells but decreased in others.  
This study also aimed to identify regulators of HS3ST1 expression. TGF1 is known to be a pro-
fibrotic factor [67] and TGF2/IL1 are implicated in endothelial to mesenchymal transition, a 
mechanism that contributes to fibrosis [55]. Both treatments downregulated HS3ST1 expression in 
renal fibroblasts and renal epithelial cells. Other enzymes such as SULF1 and SULF2 have been 
shown to be modulated by TGF1 [59] and heparanase is implicated in the regulation of TGF1 
expression in tubular cells [68]. Taken together, these data show a relationship between TGF 
signalling and the expression of HS modifying enzymes. HS sulfation is known to influence protein 
binding and it is not surprising that pro fibrotic factors would be implicated in its regulation. 
Although we have looked at two different cell types, expression in tissues will be influenced by 
other cell types as well. Indeed, previous studies have shown that HS3ST enzyme expression by 
endothelial cells [38] and immune cells [69] is controlled by pro-inflammatory factors.  
In order to study the effect of HS3ST1 expression on growth factor binding, we developed an in 
vitro model of renal epithelial cells overexpressing HS3ST1. Overexpression of HS3ST1 had an 
effect on HS disaccharide composition including an increase in HS 3-O-sulfation (up to 3.7%). 
This level of sulfation might seem low, but HS 3-O sulfation is a rare modification. In previous 
work on anticoagulant HS chains, 3-O sulfated glucosamine residues represented around 1% in 
porcine endothelial cells [51] and 6% in follicular fluid [70]. In CHO cells overexpressing HS3ST1, 
HS containing AT binding site represented 4% of the total HS [71].  
Very little is known about the effect of 3-O-sulfated HS on growth factor function. HB-EGF can 
bind EGF receptor and induce STAT phosphorylation [72]. This happens rapidly and in control 
cells the response diminishes by 1 hour. In contrast, in cells overexpressing HS3ST1 the STAT 
phosphorylation is evident at 1 hour, suggesting that the cellular response to HB-EGF is altered by 
the presence of HS 3-O-sulfation. The mechanism of this delayed response remains to be 
elucidated, but a previous paper suggested that a delayed response to HB-EGF could be mediated 
by a second messenger such as IL-6 [73]. HB-EGF plays a role in cellular repair [43] and was 
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found to be protective in the development of liver fibrosis [74,75]. A decrease in tubular 3-O-
sulfated HS staining was seen together with a decrease in HB-EGF during UUO. This could affect 
the capacity for tubular repair and worsen the severity of injury. It is also possible that in addition 
to reduced 3-O-sulfation, other structural changes in HS such as the increase in 2-O-sulfation are 
affecting HB-EGF binding. Further studies are required to elucidate precisely which HS structures 
can modify HB-EGF binding. 
 
Figure 8. The complex regulation of HS3ST1 in fibrosis. HS3ST1 expression is strongly modulated 
in fibrosis. While in vivo data showed a strong correlation between HS3ST1 expression and the 
development of fibrosis, in vitro data showed a decreased expression following TGFβ1 and 
TGFβ2/IL1β treatment. Graphical illustrations were produced using Servier Medical Art 
(www.servier.com). 
In conclusion, we believe this study has highlighted the complexity of the regulation of HS 3-O-
sulfation and its potential role in renal fibrosis (figure 8). The strong correlation between the 
increase of HS3ST1 expression and the development of fibrosis, the changes in sulfation patterns 
during disease and the functional consequences of these changes all highlight the importance of 
studying HS 3-O- sulfation. A better understanding of HS biology may lead to more effective 
strategies to measure or modify sulfation for diagnostic or therapeutic benefit. 
 
 
Appendices 
 
255 
Acknowledgements 
This work was funded by the European Commission FP7 in the framework of the Prolong Organ 
Survival After Transplantation, Initial Training Networks, 606979, by the Northern Counties 
Kidney Research Fund and by the French National Agency for Research (ANR-12-BSV8-0023). 
The Research was also supported by NIHR Newcastle Biomedical Research Centre. The authors 
would like to thank Dr Jeremy Palmer, Newcastle University, for the AT labeling help and the 
Bioimaging facility, Newcastle University for their support in imaging. The authors are grateful to 
Mona Gronning, University of Bergen for HS compositional analyses of cells and Toin van 
Kuppevelt, Radboud University Medical Center for providing the HS4C3 antibody. 
 
Declarations of interest: none. 
 
 
Appendices 
 
256 
References 
1 Jha V, Garcia-Garcia G, Iseki K, et al. Chronic kidney disease: Global dimension and 
perspectives. Lancet 2013;382:260–272. 
2 Breyer MD, Susztak K. The next generation of therapeutics for chronic kidney disease. Nat 
Rev Drug Discov 2016;15:568–588. 
3 Genovese F, Manresa AA, Leeming DJ, et al. The extracellular matrix in the kidney: a 
source of novel non-invasive biomarkers of kidney fibrosis? Fibrogenesis Tissue Repair 
2014;7:4. 
4 Bishop JR, Schuksz M, Esko JD. Heparan sulphate proteoglycans fine-tune mammalian 
physiology. Nature 2007;446:1030–1037. 
5 Ferreras L, Sheerin NS, Kirby JA, et al. Mechanisms of Renal Graft Chronic Injury and 
Progression to Interstitial Fibrosis. Curr Transplant Reports 2015;2:259–268. 
6 Iozzo R V, Schaefer L. Proteoglycan form and function: A comprehensive nomenclature of 
proteoglycans. Matrix Biol 2015;42:11–55. 
7 Iozzo R V. Heparan sulfate proteoglycans: intricate molecules with intriguing functions. J 
Clin Invest 2001;108:165–167. 
8 Lyon M, Rushton G, Gallagher JT. The Interaction of the Transforming Growth Factor- s 
with Heparin/Heparan Sulfate Is Isoform-specific. J Biol Chem 1997;272:18000–18006. 
9 Ali S, Hardy L, Kirby J. Transplant immunobiology: a crucial role for heparan sulfate 
glycosaminoglycans? Transplantation 2003;75:1773–1782. 
10 Massena S, Christoffersson G, Hjertström E, et al. A chemotactic gradient sequestered on 
endothelial heparan sulfate induces directional intraluminal crawling of neutrophils. Blood 
2010;116:1924–1931. 
11 Rienstra H, Katta K, Celie JW a M, et al. Differential expression of proteoglycans in tissue 
remodeling and lymphangiogenesis after experimental renal transplantation in rats. PLoS 
One 2010;5:e9095. 
12 Alhasan AA, Spielhofer J, Kusche-Gullberg M, et al. Role of 6-O-sulfated heparan sulfate 
in chronic renal fibrosis. J Biol Chem 2014;289:20295–20306. 
13 Goldberg S, Harvey SJ, Cunningham J, et al. Glomerular filtration is normal in the absence 
of both agrin and perlecan-heparan sulfate from the glomerular basement membrane. 
Nephrol Dial Transplant 2009;24:2044–2051. 
14 Borza DB. Glomerular basement membrane heparan sulfate in health and disease: A 
regulator of local complement activation. Matrix Biol 2017;57–58:299–310. 
15 Van Den Born J, Van Den Heuvel LPWJ, Bakker MA, et al. Distribution of GBM heparan 
sulfate proteoglycan core protein and side chains in human glomerular diseases. Kidney Int 
Appendices 
 
257 
1993;43:454–463. 
16 Edge AS, Spiro RG. A specific structural alteration in the heparan sulphate of human 
glomerular basement membrane in diabetes. Diabetologia 2000;43:1056–1059. 
17 Rops AL, van den Hoven MJ, Bakker MA, et al. Expression of glomerular heparan sulphate 
domains in murine and human lupus nephritis. Nephrol Dial Transplant 2007;22:1891–
1902. 
18 Busse M, Feta A, Presto J, et al. Contribution of EXT1, EXT2, and EXTL3 to heparan sulfate 
chain elongation. J Biol Chem 2007;282:32802–32810. 
19 Rabenstein DL. Heparin and heparan sulfate: structure and function. Nat Prod Rep 
2002;19:312–331. 
20 El Masri R, Seffouh A, Lortat-Jacob H, et al. The “in and out” of glucosamine 6-O-sulfation: 
the 6th sense of heparan sulfate. Glycoconj J 2017;34:285–298. 
21 Li JP, Kusche-Gullberg M. Heparan Sulfate: Biosynthesis, Structure, and Function. Int Rev 
Cell Mol Biol 2016;325:215–273. 
22 Vivès RR, Seffouh A, Lortat-Jacob H. Post-Synthetic Regulation of HS Structure: The Yin 
and Yang of the Sulfs in Cancer. Front Oncol 2014;3:331. 
23 Talsma DT, Katta K, Ettema MAB, et al. Endothelial heparan sulfate deficiency reduces 
inflammation and fibrosis in murine diabetic nephropathy. Lab Invest 2018;98:427–438. 
24 Sugar T, Wassenhove-Mccarthy DJ, Esko JD, et al. Podocyte-specific deletion of NDST1, 
a key enzyme in the sulfation of heparan sulfate glycosaminoglycans, leads to abnormalities 
in podocyte organization in vivo. Kidney Int 2014;85:307–318. 
25 Chen S, Wassenhove-McCarthy DJ, Yamaguchi Y, et al. Loss of heparan sulfate 
glycosaminoglycan assembly in podocytes does not lead to proteinuria. Kidney Int 
2008;74:289–299. 
26 Van Den Hoven MJ, Rops AL, Vlodavsky I, et al. Heparanase in glomerular diseases. 
Kidney Int 2007;72:543–548. 
27 Masola V, Zaza G, Onisto M, et al. Impact of heparanase on renal fibrosis. J Transl Med 
2015;13:181. 
28 Kramer A. Induction of Glomerular Heparanase Expression in Rats with Adriamycin 
Nephropathy Is Regulated by Reactive Oxygen Species and the Renin-Angiotensin System. 
J Am Soc Nephrol 2006;17:2513–2520. 
29 Van Den Hoven MJ, Rops AL, Bakker MA, et al. Increased expression of heparanase in 
overt diabetic nephropathy. Kidney Int 2006;70:2100–2108. 
30 Gil N, Goldberg R, Neuman T, et al. Heparanase is essential for the development of diabetic 
nephropathy in mice. Diabetes 2012;61:208–216. 
Appendices 
 
258 
31 Girardin EP, HajMohammadi S, Birmele B, et al. Synthesis of anticoagulantly active 
heparan sulfate proteoglycans by glomerular epithelial cells involves multiple 3-O-
sulfotransferase isoforms and a limiting precursor pool. J Biol Chem 2005;280:38059–
38070. 
32 Edge ASB, Spiro RG. Characterization of novel sequences containing 3-O-sulfated 
glucosamine in glomerular basement membrane heparan sulfate and localization of sulfated 
disaccharides to a peripheral domain. J Biol Chem 1990;265:15874–15881. 
33 Thacker BE, Xu D, Lawrence R, et al. Heparan sulfate 3-O-sulfation: a rare modification in 
search of a function. Matrix Biol 2014;35:60–72. 
34 Wang Z, Hsieh PH, Xu Y, et al. Synthesis of 3-O-Sulfated Oligosaccharides to Understand 
the Relationship between Structures and Functions of Heparan Sulfate. J Am Chem Soc 
2017;139:5249–5256. 
35 Mochizuki H, Yoshida K, Shibata Y, et al. Tetrasulfated disaccharide unit in heparan sulfate: 
Enzymatic formation and tissue distribution. J Biol Chem 2008;283:31237–31245. 
36 Shworak NW, Liu J, Petros LM, et al. Multiple isoforms of heparan sulfate D-glucosaminyl 
3-O-sulfotransferase. Isolation, characterization, and expression of human cdnas and 
identification of distinct genomic loci. J Biol Chem 1999;274:5170–5184. 
37 Sepulveda-Diaz JE, Alavi Naini SM, Huynh MB, et al. HS3ST2 expression is critical for 
the abnormal phosphorylation of tau in Alzheimer’s disease-related tau pathology. Brain 
2015;138:1339–1354. 
38 Krenn EC, Wille I, Gesslbauer B, et al. Glycanogenomics: a qPCR-approach to investigate 
biological glycan function. Biochem Biophys Res Commun 2008;375:297–302. 
39 Takeda K, Hashimoto K, Uchikawa R, et al. Direct effects of IL-4/IL-13 and the nematode 
Nippostrongylus brasiliensis on intestinal epithelial cells in vitro. Parasite Immunol 
2010;32:420–429. 
40 Patel VN, Lombaert IMA, Cowherd SN, et al. Hs3st3-Modified Heparan Sulfate Controls 
KIT+ Progenitor Expansion by Regulating 3-O-Sulfotransferases. Dev Cell 2014;29:662–
673. 
41 Sagoo P, Perucha E, Sawitzki B, et al. Development of a cross-platform biomarker signature 
to detect renal transplant tolerance in humans. J Clin Invest 2010;120:1848–1861. 
42 Einecke G, Reeve J, Sis B, et al. A molecular classifier for predicting future graft loss in late 
kidney transplant biopsies. J Clin Invest 2010;120:1862–1872. 
43 Sakai M, Zhang MZ, Homma T, et al. Production of heparin binding epidermal growth 
factor-like growth factor in the early phase of regeneration after acute renal injury: Isolation 
and localization of bioactive molecules. J Clin Invest 1997;99:2128–2138. 
44 Takemura T, Hino S, Okada M, et al. Role of membrane-bound heparin-binding epidermal 
growth factor-like growth factor (HB-EGF) in renal epithelial cell branching. Kidney Int 
Appendices 
 
259 
2002;61:1968–1979. 
45 Celie JWAM, Katta KK, Adepu S, et al. Tubular epithelial syndecan-1 maintains renal 
function in murine ischemia/reperfusion and human transplantation. Kidney Int 
2012;81:651–661. 
46 Talsma DT, Daha MR, Van Den Born J. The bittersweet taste of tubulo-interstitial glycans. 
Nephrol Dial Transplant 2017;32:611–619. 
47 Racusen LC, Monteil C, Sgrignoli A, et al. Cell lines with extended in vitro growth potential 
from human renal proximal tubule: Characterization, response to inducers, and comparison 
with established cell lines. J Lab Clin Med 1997;129:318–329. 
48 Brown CDA, Sayer R, Windass AS, et al. Characterisation of human tubular cell monolayers 
as a model of proximal tubular xenobiotic handling. Toxicol Appl Pharmacol 
2008;233:428–438. 
49 Hijmans RS, Shrestha P, Sarpong KA, et al. High sodium diet converts renal proteoglycans 
into pro-inflammatory mediators in rats. PLoS One 2017;12:e0178940. 
50 Sembajwe LF, Katta K, Grønning M, et al. The exostosin family of glycosyltransferases: 
mRNA expression profiles and heparan sulphate structure in human breast carcinoma cell 
lines. Biosci Rep 2018;38. 
51 Marcum JA, Atha DH, Fritze LMS, et al. Cloned bovine aortic endothelial cells synthesize 
anticoagulantly active heparan sulfate proteoglycan. J Biol Chem 1986;261:7507–7517. 
52 Martinez P, Denys A, Delos M, et al. Macrophage polarization alters the expression and 
sulfation pattern of glycosaminoglycans. Glycobiology 2015;25:502–513. 
53 Martinez FO, Gordon S, Locati M, et al. Transcriptional profiling of the human monocyte-
to-macrophage differentiation and polarization: new molecules and patterns of gene 
expression. J Immunol 2006;177:7303–7311. 
54 Pan B, Liu G, Jiang Z, et al. Regulation of renal fibrosis by macrophage polarization. Cell 
Physiol Biochem 2015;35:1062–1069. 
55 Maleszewska M, Moonen J-RAJ, Huijkman N, et al. IL-1β and TGFβ2 synergistically 
induce endothelial to mesenchymal transition in an NFκB-dependent manner. 
Immunobiology 2013;218:443–454. 
56 Westergren-Thorsson G, Hedström U, Nybom A, et al. Increased deposition of 
glycosaminoglycans and altered structure of heparan sulfate in idiopathic pulmonary 
fibrosis. Int J Biochem Cell Biol 2017;83:27–38. 
57 Ashikari-Hada S, Habuchi H, Kariya Y, et al. Characterization of Growth Factor-binding 
Structures in Heparin/Heparan Sulfate Using an Octasaccharide Library. J Biol Chem 
2004;279:12346–12354. 
58 Turnbull JE, Fernig DG, Ke Y, et al. Identification of the basic fibroblast growth factor 
Appendices 
 
260 
binding sequence in fibroblast heparan sulfate. J Biol Chem 1992;267:10337–10341. 
59 Yue X, Li X, Nguyen HT, et al. Transforming growth factor-beta1 induces heparan sulfate 
6-O-endosulfatase 1 expression in vitro and in vivo. J Biol Chem 2008;283:20397–20407. 
60 Tátrai P, Egedi K, Somorácz Á, et al. Quantitative and qualitative alterations of heparan 
sulfate in fibrogenic liver diseases and hepatocellular cancer. J Histochem Cytochem 
2010;58:429–441. 
61 Hirano K, Sasaki N, Ichimiya T, et al. 3-O-sulfated heparan sulfate recognized by the 
antibody HS4C3 contribute to the differentiation of mouse embryonic stem cells via fas 
signaling. PLoS One 2012;7:e43440. 
62 Thacker BE, Seamen E, Lawrence R, et al. Expanding the 3-O-Sulfate Proteome - Enhanced 
Binding of Neuropilin-1 to 3-O-Sulfated Heparan Sulfate Modulates Its Activity. ACS 
Chem Biol 2016;11:971–980. 
63 Tecle E, Diaz-Balzac CA, Bülow HE. Distinct 3-O-sulfated heparan sulfate modification 
patterns are required for kal-1-dependent neurite branching in a context-dependent manner 
in Caenorhabditis elegans. G3 (Bethesda) 2013;3:541–552. 
64 Kumar AV, Gassar ES, Spillmann D, et al. HS3ST2 modulates breast cancer cell 
invasiveness via MAP kinase-and Tcf4 (Tcf7l2)-dependent regulation of protease and 
cadherin expression. Int J Cancer 2014;135:2579–2592. 
65 Hellec C, Delos M, Carpentier M, et al. The heparan sulfate 3-O-sulfotransferases (HS3ST) 
2, 3B and 4 enhance proliferation and survival in breast cancer MDA-MB-231 cells. PLoS 
One 2018;13:e0194676. 
66 Mao X, Gauche C, Coughtrie MWH, et al. The heparan sulfate sulfotransferase 3-OST3A 
(HS3ST3A) is a novel tumor regulator and a prognostic marker in breast cancer. Oncogene 
2016;35:5043–5055. 
67 Leask A, Abraham DJ. TGF-beta signaling and the fibrotic response. FASEB J 
2004;18:816–827. 
68 Masola V, Zaza G, Secchi MF, et al. Heparanase is a key player in renal fibrosis by 
regulating TGF-β expression and activity. Biochim Biophys Acta 2014;1843:2122–2128. 
69 Sikora AS, Delos M, Martinez P, et al. Regulation of the Expression of Heparan Sulfate 3-
O-Sulfotransferase 3B (HS3ST3B) by Inflammatory Stimuli in Human Monocytes. J Cell 
Biochem 2016;117:1529–1542. 
70 De Agostini AI, Dong JC, Arrighi CDV, et al. Human follicular fluid heparan sulfate 
contains abundant 3-O-sulfated chains with anticoagulant activity. J Biol Chem 
2008;283:28115–28124. 
71 Datta P, Li G, Yang B, et al. Bioengineered chinese hamster ovary cells with golgi-targeted 
3-O-sulfotransferase-1 biosynthesize heparan sulfate with an antithrombin-binding site. J 
Biol Chem 2013;288:37308–37318. 
Appendices 
 
261 
72 Knudsen SLJ, Wai Mac AS, Henriksen L, et al. EGFR signaling patterns are regulated by 
its different ligands. Growth Factors 2014;32:155–163. 
73 Lee KS, Park JH, Lee S, et al. HB-EGF induces delayed STAT3 activation via NF-κB 
mediated IL-6 secretion in vascular smooth muscle cell. Biochim Biophys Acta - Mol Cell 
Res 2007;1773:1637–1644. 
74 Takemura T, Yoshida Y, Kiso S, et al. Conditional knockout of heparin-binding epidermal 
growth factor-like growth factor in the liver accelerates carbon tetrachloride-induced liver 
injury in mice. Hepatol Res 2013;43:384–393. 
75 Huang G, Besner GE, Brigstock DR. Heparin-binding epidermal growth factor-like growth 
factor suppresses experimental liver fibrosis in mice. Lab Investig 2012;92:703–712. 
 Supplementary data 
Supplementary figure 1. HS sulfation of 6 pooled control unobstructed kidney, D5 UUO and D10 
UUO is represented as percentage of total disaccharides with error bars from technical replicates. 
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Supplementary figure 2. HS modifying enzymes correlation to Sirius red staining.  
 
Supplementary figure 3. Antithrombin III staining specificity was assessed on mouse kidney tissue 
by incubating 1 hour with labelled ATIII or with ATIII and 20 µM heparin. The ATIII staining was 
abolished by incubating with 20 µM of heparin. Scale bars represent 100 µm. 
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Supplementary figure 4. HS disaccharide analysis of a different overexpressing cellular clone than 
shown in figure 6B showed 1.6% HS 3-O-sulfation (➔) 
Species Gene name Gene Symbol Reference
Human Heparan sulfate-glucosamine 3-O-sulfotransferase 3B1 HS3ST3B1 Hs01391447_m1
Human Heparan sulfate-glucosamine 3-O-sulfotransferase 1 HS3ST1 Hs00245421_s1
Human Heparan sulfate-glucosamine 3-O-sulfotransferase 3A1 HS3ST3A Hs00925624_s1
Human Hypoxanthine guanine phosphoribosyl transferase HPRT1 Hs02800695_m1
Human Heparan sulfate-glucosamine 3-O-sulfotransferase 1 HS3ST1 (for plasmid) Hs01099196_m1 
Human Heparan sulfate-glucosamine 3-O-sulfotransferase 6 HS3ST6 Hs03007244_m1
Mouse Heparan sulfate (glucosamine) 3-O-sulfotransferase 1 HS3ST1 Mm01964038_s1
Mouse Heparan sulfate (glucosamine) 3-O-sulfotransferase 3A HS3ST3A1 Mm000780907_s1
Mouse Hypoxanthine guanine phosphoribosyl transferase HPRT Mm03024075_m1
Mouse Sulfatase 1 SULF1 Mm00552283_m1
Mouse Heparan Sulfate 2-O-sulfotransferase 1 HS2ST1 Mm00478684_m1  
Supplementary table 1. Gene expression was determined using TaqMan probes from 
ThermoFisher. Hs: Homo sapiens, Mm: Mus musculus. Suffix m indicates probes that are designed 
between two exons whereas s defines probes that bind within a single exon. 
 
 
